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Summary 
Rheumatoid arthritis (RA) is characterised by chronic joint inflammation, which is 
generally associated with destruction of articular cartilage and bone. Inflammatory 
cytokines, such as tumour necrosis factor (TNF), promote the up-regulation of proteases 
that degrade components of the extracellular matrix in cartilage and bone. Chronic joint 
inflammation results in reduced concentrations of oxygen (hypoxia). Hypoxic conditions 
cause anaerobic respiration and lactic acid build-up in synoviocytes, which are the cells 
that line articular joints. Acid-sensing proteins respond to these acidic conditions in the 
extracellular space of joints. We hypothesized that acid-sensing proteins play a critical 
role in the development and pathology of RA through diverse signalling and cellular 
functional responses. Identification of the exact signalling mechanisms and expression of 
acid-sensing proteins may facilitate development of effective management options for 
patients with RA.  
In this study, by using immunohistochemistry paraffin protocol (IHC-P) and real-time 
polymerase chain reaction, we demonstrated that four acid-sensing proteins were 
expressed at variable levels in synovial biopsies from RA patients and at the messenger 
ribonucleic acid (mRNA) level in RA fibroblast-like synoviocytes (FLS). Expression 
levels of these proteins were slightly induced at the mRNA level by the inflammatory 
cytokine TNF. Importantly, acidic conditions that mimicked the inflamed synovial joint 
in RA also resulted in a significant increase in matrix metalloproteinase (MMP)-1 and 
MMP-9, whereas migration activity of RA FLS was reduced. Furthermore, ASIC3 and 
TRPV1 inhibition resulted in a significant down-regulation of MMP-1 and -9 at mRNA 
level in RA-FLS under low pH. 
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RA progression. This diagram illustrates the progression of RA starting from immune 
response to acid build-up in the inflamed joint. The aim of this project is to understand 
the function and role of acid-sensing proteins expressed by FLS obtained from the RA 
tissue. FLS, fibroblast-like synoviocytes; RA, rheumatoid arthritis. 
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1 Chapter 1:  Rheumatoid arthritis 
1.1 Introduction 
RA is a symmetrically distributed and chronic autoimmune disorder that primarily affects 
the joints of the feet and hands (Gomez et al., 2011). The global incidence of RA is 
approximately 0.5%–1.5% according to Kobelt and Johnson (2008). Nonetheless, it most 
commonly occurs in people older than 50 years, although it can affect people at any age 
(Oliver and Silman, 2009).  
  
1.2 Aetiology of rheumatoid arthritis 
The aetiology of RA remains unknown; however, various risk factors for RA have been 
investigated. In the 1970s, a link between human leukocyte antigen – D related (HLA-
DR) and RA was found. Researchers found that about 70% of RA patients had the 
HDLA-DR4 serotype, whereas only 30% of controls did, suggesting that individuals with 
HDLA-DR4 have a higher risk of RA (McMichael et al., 1977). Moreover, three times 
more females develop RA than males, which suggests that hormonal and sex-related 
genetic factors may be involved in RA initiation (Weyand et al., 1998). Age may also be 
a risk factor for RA, as reported in a study by Karlson et al. (Karlson et al., 2004), which 
showed that the risk of RA is elevated in women between 50 and 64 years of age as 
compared to women younger than 50 years of age. Furthermore, researchers have 
considered infectious agents, such as the Epstein-Barr virus, parvoviruses, retroviruses, 
bacteria, and their products as agents that may initiate RA. Bacterial products activate 
innate immunity through Toll-like receptors, which can lead to rapid inflammatory 
responses. Moreover, antigen presentation by dendritic cells (DCs) in the lymphoid 
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system will activate T and B cells to produce pathogenic antibodies or migrate to the joint 
and enhance the production of cytokines, such as interleukins (ILs), which in turn recruit 
other cells to the joint and activate other cells such as macrophages and FLS (Figure 1.1) 
(Firestein and Zvaifler, 1990). However, this hypothesis remains unproven (Firestein and 
Zvaifler, 1990, Wilder and Crofford, 1991). RA patients are classified into seropositive 
and seronegative (according to the serological status). Seropositive RA refers to RA 
patients with positive rheumatoid factor (RF) and/or anticitrullinated protein antibody 
(ACPA), seronegative RA refers to patients with negative serological test result for both 
RF and ACPA. It has been concluded that the majority of RA patients are seropositive, 
with approximately 79% RF and 70% ACPA positivity (Balsa et al., 2001, Sapir-Koren 
and Livshits, 2016). Seropositive RA patients tend to develop a sever course of disease 
progression, subcutaneous nodules (37.5%) and vasculitis (6.3%) (Alarcon et al., 1982).  
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Figure ‎1.1 Schematic diagram of disease mechanisms that likely occur in RA 
DC, dendritic cell; M, macrophage; OC, osteoclast; FLS, fibroblast-like synoviocytes; 
RA, rheumatoid arthritis. 
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1.3 Extra-articular manifestations of RA 
1.3.1 Rheumatoid vasculitides  
Rheumatoid vasculitis is considered to be the major cause of extra-articular 
complications in RA. These complications are rare (affecting 1%–5% of RA patients) and 
mainly affect patients who are rheumatoid factor (RF)-positive. Rheumatoid vasculitides 
can affect any organ (e.g., skin, heart, eyes, nerves, and kidneys) and have no specific 
signs or symptoms. However, histopathological analysis of affected organs may help to 
identify vasculitides (Prete et al., 2011). Identification of acute necrotizing arteritis in 
small vessels of the affected organs will help in the treatment of RA Treatment of 
rheumatoid vasculitides is based mainly on cytotoxic drugs or steroids. 
 
1.3.2 Skin manifestations 
The skin is considered the most common target of RA (Cojocaru et al., 2010). 
Subcutaneous nodules occur in about 30% of RA patients and exist mainly in RF-positive 
patients (Prete et al., 2011). These nodules form during the progression of RA, but some 
may develop in early RA (before the involvement of joints). Other skin manifestations 
include Raynaud’s phenomenon (triphasic colour change of the extremities), periungual 
infarcts (tiny black dots close to the corner where the distal nail touches the skin), leg 
ulcers, splinter haemorrhages (fingernail haemorrhage), digital gangrene (finger and toe 
gangrene), and sharply demarcated painful ulcerations as a result of small vessel 
vasculitides (Cojocaru et al., 2010, Prete et al., 2011). Most skin manifestations in RA 
localize in areas that are exposed to external pressure or repetitive irritation, such as the 
24 
 
surfaces of the forearms, fingers, and heels. Rheumatoid nodules are sometimes 
alleviated with standard treatment, but they may also worsen with therapy (Patatanian 
and Thompson, 2002). 
1.3.3 Accelerated rheumatoid nodulosis 
Accelerated nodulosis (AN) occurs in 8%–11% of long-term methotrexate-treated RA 
patients (Combe et al., 1993). There is a clear association between AN and the use of 
methotrexate. Reducing or replacing methotrexate with another treatment such as 
hydroxychloroquine or sulphasalazine suppresses the development of AN (Combe et al., 
1993). However, the pathogenic mechanism behind methotrexate activity and AN 
remains elusive. Cases of AN have also been reported in RA patients treated with anti-
tumour necrosis factor (TNF) and/or leflunomide (Cunnane et al., 2002), suggesting that 
pathogenetic mechanisms of RA are essential inducers of AN. 
1.3.4 Pulmonary complications 
Although pulmonary manifestations are detected in about 5%–10% RA patients, autopsy 
studies showed that pleural involvement affects about 50% of patients and is thus a 
significant contributor to morbidity and mortality (Bharadwaj and Haroon, 2005, 
Sahatciu-Meka et al., 2010). Pulmonary manifestations associated with RA include small 
airway disease, rheumatoid nodules, pleural effusion, and pulmonary vasculitides. The 
most common pulmonary manifestation is interstitial lung disease (ILD), which occurs in 
25% of RA patients (McDonagh et al., 1994, Dawson et al., 2001). ILD is rarely 
symptomatic in the early stages of RA; only 10% of RA patients showed clinical 
symptoms of ILD when they were evaluated by high-resolution computed tomography. 
Chronic obstructive pulmonary disease is also reported more frequently in RA patients 
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(Nannini et al., 2013). Treatment pulmonary disease in RA patients is based mainly on 
systemic steroids and cyclophosphamide. Moreover, it has been reported that anti-CD20 
therapy has a beneficial effect on patients with pulmonary involvement related to primary 
vasculitis or other connective tissue disease (Prete et al., 2011). 
1.3.5 Cardiac disease 
RA patients are susceptible to cardiac conditions such as pericarditis, myocarditis, 
valvular disease, arrhythmias, and ischemic heart disease (Sarzi-Puttini et al., 2010).  In 
addition, myocardial infarction (MI) is twice as prevalent in female RA patients than in 
women without RA (Maradit-Kremers et al., 2005). Pericarditis is described as the most 
common cardiac disease in RA patients. Symptomatic pericarditis is rare in RA patients 
(affecting 1%–4%), but echocardiography and/or autopsy has revealed histopathological 
abnormalities in about 50% of RA patients, and early detection of pericarditis in an 
asymptomatic stage is essential (Turiel et al., 2010). RA patients are also prone to 
valvular dysfunction due to endocarditis with formation of rheumatoid nodules in the 
aortic or mitral valves (Ristic et al., 2010). Non-steroidal anti-inflammatory drugs or 
steroids are a rapid solution for symptomatic pericardial disease (Kitas et al., 2001). 
Immunosuppressive treatment with cyclophosphamide may be necessary when 
pericardial effusion recurs. Emergency intervention is required for effusive pericarditis 
(Turesson and Matteson, 2004).  
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1.3.6 Renal manifestations 
Renal diseases are uncommon in RA patients. Mesangial glomerulonephritis is described 
as the most common renal disease, occurring in about 60% of cases of renal involvement 
in RA patients (Korpela et al., 1997). Secondary amyloidosis has been detected in about 
25% of patients with severe proteinuria and nephrotic syndrome, but interstitial nephritis 
is very rare in RA patients (Korpela et al., 1997). Renal abnormalities are 
frequently described as iatrogenic. 
 
1.3.7 Ophthalmic manifestations  
Ocular manifestations include secondary Sjögren’s syndrome, episcleritis, scleritis, 
keratitis, and retinopathy. Keratoconjunctivitis sicca, which is described as the most 
common ophthalmic manifestation of rheumatologic disease, is frequently observed with 
secondary Sjögren’s syndrome (xerostomia) and affects about 10% of RA patients 
(Cronstein, 2007). Episcleritis (i.e., inflammation of the layer superficial to the sclera) 
may lead to a severe form of scleritis known as necrotizing scleritis (scleromalacia 
perforans). Scleromalacia perforans is reported in <1% of patients and can lead to corneal 
melting and loss of vision (Wu et al., 2005). These complications can be managed with 
anti-inflammatory drugs or the disease-modifying antirheumatic drugs (DMARDs) anti-
TNF-α or anti-CD20 (rituximab) (Atchia et al., 2006, Iaccheri et al., 2010). 
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1.3.8 Haematologic abnormalities 
Haematologic manifestations include anaemia, which is considered the most common 
symptom of RA, along with thrombocytopenia, thrombocytosis, eosinophilia, and 
haematological malignancies (Bowman, 2002, Agrawal et al., 2006). Felty’s syndrome is 
a rare, severe condition reported in <1% of patients (Balint and Balint, 2004). This 
syndrome is characterised by chronic polyarthritis, neutropenia, and splenomegaly and 
usually develops in the late stages of RA. In these patients, susceptibility to bacterial 
infection is high because of the development of neutropenia, which can be managed by 
DMARDs, methotrexate, and rituximab (Newman and Akhtari, 2011). 
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1.4 Treatment of rheumatoid arthritis 
The pharmacological mainstays of treatment of RA and its complications include 
DMARDs, non-steroidal anti-inflammatory drugs (NSAIDs), and glucocorticoids. 
Moreover, when used in combination with pharmacological treatments, physical and 
occupational therapy may help patients cope with RA complications. In the mid-1990s, 
research revealed that biological treatments such as antibodies targeting TNF, IL-6, and 
IL-1 exhibited greater efficacy than previously used pharmacological compounds. 
However, the positive impact of these biological inhibitors occurred in only about 50% of 
the RA patients studied (Bartok and Firestein, 2010). 
1.4.1 Disease-modifying antirheumatic drugs (DMARDs) 
DMARDs are described as the mainstay of treatment for RA. All RA patients should 
receive one or more DMARDs once RA is diagnosed. It has been found that using of 
DMARDs within the first 3 months of RA has more beneficial effects in controlling 
disease activity and improves the long-term outcome (Demoruelle and Deane, 2012). 
Clinical response to DMARDs requires approximately 3 to 6 months for the full effect of 
treatment. DMARDs can be divided into non-biologic and biologic drugs. 
1.4.1.1 Non-biologic DMARDs 
1.4.1.1.1 Methotrexate 
Methotrexate is considered to be the first-line therapy (drug of choice) for RA patients. 
Methotrexate is a folic acid metabolism inhibitor that appears to exert its action by 
binding to dihydrofolate reductase (Lopez-Olivo et al., 2014). Supplementation with folic 
acid can decrease common side effects of methotrexate such as stomatitis, nausea, and 
diarrhoea. The main concern with using methotrexate is the potential hepatotoxicity, 
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which is increased by alcohol consumption and pre-existing liver disease, diabetes, and 
obesity (Brasington). Liver damage is very unlikely in patients who do not have liver 
disease and consume minimal amounts of alcohol. Regular liver function tests and 
complete blood counts should be performed after 1 month of therapy until the optimal 
dose is established. 
1.4.1.1.2 Sulfasalazine  
In the 1940s sulfasalazine was used as a treatment for rheumatic polyarthritis and 
established as a DMARD in the past two decades (Rains et al., 1995). Side effects of 
sulfasalazine include changes in blood counts, nausea or vomiting, dizziness, rash, and 
myelosuppression (Plosker and Croom, 2005). Bacterial azoreductases in the large 
intestine are thought to act on sulfasalazine and split it into sulphapyridine and 
mesalazine; however, the exact mode of sulfasalazine action remains uncertain (Rains et 
al., 1995). This drug should not be prescribed for patients with true sulpha allergy or 
glucose- 6-phosphate dehydrogenase deficiency. 
 
1.4.1.1.3 Leflunomide  
Leflunomide is a pyrimidine synthesis inhibitor that can be used as an add-on agent to 
methotrexate. This agent can improve all clinical outcomes of RA; however, toxicity and 
long-term efficacy need to be evaluated (Osiri et al., 2003). 
1.4.1.1.4 Hydroxychloroquine 
Hydroxychloroquine has shown the ability to slow the progression of RA compared with 
placebo in double-blind studies (Pavelka et al., 1989). The risk of retinal damage is 
increased when the agent is used long-term at a high dose (Brasington), so it is important 
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for RA patients receiving hydroxychloroquine to be monitored by an ophthalmologist 
every 6–12 months. Hydroxychloroquine can be used alone or as an add-on to 
methotrexate. 
1.4.1.2 Biologic DMARDs 
1.4.1.2.1 TNF inhibitors (anti-TNF) 
All biologic DMARDs are considered as second-line therapy for RA treatment. Among 
biologic DMARDs, the drugs of choice are TNF inhibitors (anti-TNF agents), which 
include etanercept and infliximab, then adalimumab and, most recently, certolizumab and 
golimumab. These agents improve RA treatment and can be used as monotherapy or in 
combination with non-biologic DMARDs (Kahlenberg and Fox, 2011). The clinical 
response to biologic DMARDs is more rapid than response to non-biologic drugs and 
requires approximately 3–4 weeks (Kahlenberg and Fox, 2011). TNF inhibitors block an 
overexpressed signalling protein in RA; however, they also inhibit an important 
signalling protein required for the normal immune response, thereby increasing the risk 
of opportunistic infections. For that reason it is essential for RA patients to receive 
pneumococcal and influenza vaccines prior to treatment with TNF inhibitors (Saag et al., 
2008). One study reported hepatitis B re-activation 1 month after the third dose of an 
anti-TNF drug in patients with chronic hepatitis B infection (Carroll and Bond, 2008). An 
elevated risk of lymphoma in RA remains a concern; however, Askling et al. (Askling et 
al., 2009) concluded that anti-TNF inhibitors do not increase the already elevated risk of 
lymphoma in RA. However, other rare diseases have been reported with anti-TNF 
therapy including new-onset multiple sclerosis, optic neuritis, and transverse myelitis 
(Sicotte and Voskuhl, 2001, Simsek et al., 2007, Mohan et al., 2001). 
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1.4.1.2.2 Rituximab 
Rituximab is a genetically modified chimeric IgG1 monoclonal antibody that targets 
CD20+ B cells and rapidly depletes circulating B lymphocytes (Reff et al., 1994). When 
used in conjunction with methotrexate and glucocorticoids, rituximab has shown 
significant clinical benefits for RA patients by inhibiting the progression of structural 
joint damage (Reff et al., 1994, Keystone et al., 2009). Rituximab is an alternative 
treatment for RA patients who show an inadequate response to anti-TNF therapies 
(Keystone et al., 2009). 
 
1.4.1.2.3 Abatacept (Orencia) 
Abatacept is a selective costimulation modulator that inhibits T-cell activation. The 
mechanism of action involves binding CD80 or CD86 on the antigen-presenting cell to 
inhibit the interaction with CD28 on the T cell, thus preventing T cell activation and the 
B cell immunological response (Herrero-Beaumont et al., 2012). 
 
1.5 Rheumatoid arthritis pathogenesis within the inflamed joint 
 RA is characterised by inflammation and destruction of the synovial cartilage and bone, 
which is mediated by uncontrolled and tumour-like growth of synovial fibroblasts, as 
shown in Figure 1.2. This process is referred to as pannus tissue expansion (Muller-
Ladner and Gay, 2002). This expansion of cells results in a depletion of the oxygen 
supplied to the joint, rendering the synovial microenvironments hypoxic (Stevens et al., 
1991).  
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1.5.1 Cartilage damage in RA and OA  
 Cartilage damage is a key feature of osteoarthritis (OA) and RA. In OA, the cartilage 
damage is caused by mechanical, cellular, and biochemical processes (Hinton et al., 
2002). The exact cause of OA is unknown; however, risk factors that may include age, 
sex, joint injuries, obesity, and bone deformities (Heidari, 2011). The loss of CXC 
chemokines containing the ELR motif (ELR-CXC chemokines) during cartilage 
breakdown in OA appears to be involved in the loss of phenotypic stability of articular 
chondrocytes (Sherwood et al., 2015). Chondrocyte hypertrophy-like changes have been 
described as contributing to OA progression (van der Kraan and van den Berg, 2012). 
The formation of osteophytes (new bone at joint margins) and subchondral plate 
thickening are two features associated with OA but not seen in RA (Pap and Korb-Pap, 
2015). Inflammation of the synovium, which is associated with OA, is characterised by 
cellular infiltrate composed largely of lymphocytes and monocytes (Haraoui et al., 1991). 
However, the formation of tumour-like pannus is considered to be the key difference 
between RA and OA synovitis (Pap and Korb-Pap, 2015). 
1.5.2 Joint damage and disability in RA 
Early diagnosis and treatment of RA (within 12 weeks of symptom onset) improves long-
term outcomes and reduces disability, joint damage, and complications. Three main signs 
of inflammatory arthritis that may progress to RA include early morning stiffness (>30 
minutes), swelling (clinical synovitis) of multiple joints, and tenderness of 
metacarpophalangeal (MCP) or metatarsophalangeal (MTP) joints (upon lateral 
squeezing). Early specialist referral is necessary for patients who are suffering from these 
symptoms (Wiesinger et al., 2013). 
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 Any joint can be affected in RA. The MCP, proximal interphalangeal (PIP), and MTP 
joints of the hands and feet are most commonly affected in RA, followed by large joints 
such as elbows, shoulders and knees (Jeffery). Juxta-articular erosion in early RA is 
considered to be the main sign of progressive damage (Scott et al., 2000). X-ray is the 
most commonly used method to clinically evaluate structural damage in RA joints (Ory, 
2003). A strong relationship exists between later disability and anatomical joint damage, 
which increases over time in RA patients (Ory, 2003, Scott et al., 2000). Joint damage in 
RA can be assessed by semi-quantitative scoring methods, such as those developed by 
Sharp and Larsen (Sharp et al., 1971, Larsen et al., 1979). In Sharp’s scoring system, 29 
areas in each hand and wrist are evaluated for erosion (scores range from 0 to 5 for each 
joint, and the total score ranges from 0 to 290), whereas 27 joints are evaluated for joint 
space narrowing (scores range from 0 to 4, and the total score ranges from 0 to 219). On 
the other hand, Larsen’s scoring system evaluates joint abnormalities of the hand, wrist, 
and foot as follows: stage 0 = normal, stage 1 = slight abnormalities, stage 2 = definite 
early abnormalities, stage 3 = medium destructive abnormalities, stage 4 = severe definite 
abnormalities, and stage 5 = mutilating abnormalities. Disability in RA is commonly 
assessed by using the Health Assessment Questionnaire (HAQ) (Scott et al., 2000). The 
HAQ scores functional ability from 0 to 3 as follows: 1–2 = moderate to severe disability, 
and 2–3 = severe to very severe disability (Bruce and Fries, 2003). In early RA there is 
no correlation between joint damage on X-rays and disability; however, once radiological 
scores exceed 33% of maximum joint damage, the relationship becomes more linear 
(Ory, 2003). In previous studies, 103–142 RA patients were evaluated for joint damage 
by using Larsen’s score in the first 2 years of RA and were followed up for 
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approximately 20 years. The mean Larsen’s score increased with the duration of the 
disease as follows: in the first 2 years of RA the score was 25, from 5–8 years of RA the 
score increased to 30–70, and after 20 years the score exceeded 75 (Egsmose et al., 1995, 
Mottonen et al., 1996, Paimela et al., 1997). A correlation between HAQ score and 
disease duration was also observed in various studies. Analysis of 725 RA patients 
showed a significant relationship between HAQ score and RA duration (Scott et al., 
2000). Another study of 400 RA cases reported a HAQ score of ≤1.0 for RA duration of 
7 years, and ≥2.0 for RA duration of 20 years (Wolfe et al., 1988). Furthermore, it has 
been found that the correlation between Larsen’s score and HAQ disability score was 
significant by 5 years of RA duration (Scott et al., 2000). The HAQ disability score can 
be influenced by other factors including demographic factors (age, sex), genetic factors 
including HLA-DR4, low socioeconomic and educational status, RF positivity, markers 
of active synovitis including erythrocyte sedimentation rate and C-reactive protein, and 
treatments such as DMARDs. Mortality can occur within first few years of the RA 
diagnosis, and the mortality rate may increase with disease duration. Other extra-articular 
manifestations of RA, such as cardiovascular disease, infections, and malignancy, are the 
main causes of death in RA patients (Dougados et al., 2014). RF positivity and the 
presence of nodules are associated with the tendency to develop severe cardiovascular 
disease, infections, osteoporotic fractures, lung disease, and functional disability (Naz et 
al., 2008, Dougados et al., 2014).  
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Figure ‎1.2 Inflamed joint in RA as compared to healthy joint. 
This figure illustrates the involvement of hyperplastic synovium, FLS, and other 
inflammatory cells, including macrophages, dendritic cells, B cells, T cells, and plasma 
cells, in bone and cartilage destruction within a RA joint. FLS, fibroblast-like 
synoviocytes; RA, rheumatoid arthritis. 
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1.5.3 Bone and cartilage destruction at the cellular level 
Inflammatory cytokines, such as IL-1, IL-6, IL-8, and TNF, and various chemokines play 
a vital role in RA by attracting other inflammatory cells to the inflamed joint. These 
cytokines also enhance the up-regulation of adhesion molecules. Moreover, cytokines 
such as vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) 
enhance the growth of new blood vessels, or angiogenesis. Thus, an influx of blood and 
inflammatory cells cause further inflammation of the synovial membrane. Hyperplasia of 
the intimal lining results from a marked rise in FLS and macrophage-like synoviocytes.  
Increased concentrations of inflammatory cytokines result in the up-regulation of 
multiple enzymes that degrade components of the extracellular matrix in RA (Firestein, 
2003). Extracellular enzymes with reported activities in RA include serine proteases, 
aggrecanases, and MMPs (Firestein, 2003). Bone collagen is primarily cleaved by MMPs 
(Cawston and Wilson, 2006). However, matrix-remodelling enzymes can regulate one 
another and appear to collectively affect bone and cartilage destruction. For example, 
MMPs can become further activated by serine proteases (Cawston and Wilson, 2006). 
Thus, increased serine protease activity in a disease state, such as RA, leads to feedback 
up-regulation of MMPs, resulting in further breakdown of matrix components. 
Aggrecanases are members of the A disintegrin and metalloprotease with 
thrombospondin motifs (ADAMTS) family. Cartilage components, such as proteoglycan 
aggrecan and cartilage oligomeric matrix protein (COMP), are degraded by multiple 
members of the ADAMTS and MMP families (Liu et al., 2006). MMPs and ADAMTS 
cleave aggrecan at distinct sites. Thus, different aggrecan fragments will be released in 
response to MMP activity versus those released by ADAMTS activity. Elevated levels of 
ADAMTS and MMPs are found in synovial and cartilage samples obtained from RA 
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patients (Vankemmelbeke et al., 2001, Liu et al., 2006). In addition, specific aggrecan 
fragments corresponding to MMP or ADAMTS activity are found in cartilage samples or 
synovial fluid from RA patients (Vankemmelbeke et al., 2001, Nagase and Kashiwagi, 
2003). Membrane-type MMPs are elevated in the synovial lining, synovial fibroblasts, 
macrophages, and multinucleated osteoclast-like cells of RA patients (Pap et al., 2000). 
Thus, multiple cell types and the potential interplay between these cell types may affect 
the expression and/or secretion of enzymes that promote bone and cartilage destruction in 
RA patients. Interestingly, serum concentrations of COMP are increased in patients with 
early RA who have evidence of bone destruction by magnetic resonance imaging, in 
contrast to patients without detectable bone erosion (Fujikawa et al., 2009). Furthermore, 
elevated COMP levels in patients with early RA and bone erosion are also associated 
with increased serum MMP-3 (Fujikawa et al., 2009). Conversely, various studies have 
debated which major aggrecanase or ADAMTS are involved in cartilage destruction. 
Among the ADAMTS family members, three have been investigated, including 
ADAMTS4, ADAMTS5, and ADAMTS17. Researchers have reported that ADAMTS4 
and 5 are expressed in joint tissue and may play pivotal roles in cartilage destruction. 
However, the exact roles and contributions of these two enzymes in cartilage destruction 
remain elusive. In murine models of arthritis, ADAMTS4 deletion did not provide any 
protective effect on cartilage erosion in ADAMTS4 knockout mice, whereas the 
protection of cartilage was significant in ADAMTS5 knockout mice (Glasson et al., 
2004, Glasson et al., 2005). However, Song et al. (Song et al., 2007) showed that both 
ADAMTS4 and 5 are effective in aggrecan degradation in human articular cartilage 
explants. Then again, ADAMTS17 has been associated with a significant increase in 
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synovial cells after the induction of TNF and hypoxia (Charbonneau et al., 2007). That 
study reported that the effect of TNF on ADAMTS17 induction was mediate through 
nuclear factor-kappa B (NF-κB), and the hypoxia effect was mediated via both hypoxia-
inducible factor (HIF)-1 and NF-κB pathways. 
Similar to MMPs, the cysteine proteases cathepsins B and L have shown a broad 
proteolytic activity on proteoglycans and type II, IX, and XI collagen under acidic 
conditions (Maciewicz et al., 1990). In the Maciewicz et al. study, cathepsins B and L 
degraded rat chondrosarcoma collagens at 20°C to 37°C and pH values of 3.5 to 7.0. 
Moreover, another study reported that TNF enhances the expression of cathepsin B in 
FLS (Lemaire et al., 1997). In addition, FLS invasiveness activity and cartilage 
destruction were reduced after cathepsin L cleavage by ribozymes in a severe combined 
immunodeficient mouse model (Pierer et al., 2003). Among cathepsins, cathepsin K plays 
a pivotal role in osteoclast-mediated degradation of bone matrix through its ability to 
degrade type I collagen (Garnero et al., 1998). Cathepsin K expression was reported 
higher in RA than in OA synovium (Hou et al., 2002). Previous studies demonstrated that 
IL-1B enhances the production of polysulphated glycosaminoglycans in FLS, which in 
turn boosts the expression and activity of cathepsin K (Akimoto et al., 2000, Li et al., 
2000). Cathepsin K knockout mice showed no signs of bone degradation as compared to 
wild-type mice (Stroup et al., 2001). In addition, the same study identified a selective 
cathepsin K inhibitor, SB-357114, that impaired human osteoclast activity in bovine 
cortical bone slices. Taken together, this evidence suggests the involvement of 
cathepsins, specifically cathepsin K, in bone degradation of the RA inflamed joint. These 
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findings support the pathological relevance of proteases in the erosion of articular 
cartilage and bone in RA.   
During the process of physical remodelling, the amount of bone that forms is usually 
equivalent to the amount that degenerated during bone resorption. Remodelling enables 
the skeleton to adapt to biomechanical changes. Bone formation and resorption are 
disturbed by inflammation. This imbalance is usually responsible for “articular bone 
losses” (Goldring, 2003). Numerous factors can act directly on osteoclasts to boost their 
resorbing activity, including TNF and receptor activator of nuclear factor kappa-B ligand 
(RANKL). RANKL has sparked interest because of its potent ability to regulate 
osteoclastogenesis. RANKL has been identified by many different laboratories, which 
have designated it as an osteoclast-distinguishing factor and a TNF ligand superfamily 
member, TNF-related activation-induced cytokine (Hofbauer et al., 2000). RANKL 
exerts its actions by binding to its associated receptor, receptor activator of nuclear factor 
kappa-B (RANK). RANKL activity is regulated by a naturally occurring inhibitor called 
osteoprotegerin (OPG). OPG is a soluble protein that works as a decoy receptor by 
binding to RANKL, preventing interaction between RANKL and RANK, thereby 
disrupting osteoclastogenesis (Simonet et al., 1997). 
Recently, various studies have provided additional evidence that osteoclasts are the main 
cell type mediating bone loss in inflammatory arthritis. These studies examined animal 
models in which osteoclast differentiation or activity was inhibited by the genetic 
knockout of factors that are essential for osteoclast creation or by RANKL inhibition 
(Pettit et al., 2001). The results showed minimal evidence of focal bone erosion. IL-1 and 
TNF have dual effects on osteoclastogenesis. These factors up-regulate RANKL in the 
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bone-lining and marrow stromal cells. Moreover, TNF and RANKL act synergistically to 
enhance osteoclast differentiation, whereas IL-1 primarily activates osteoclasts and 
delays osteoclast apoptosis (Romas et al., 2002). IL-1 and TNF contribute to bone loss in 
RA by inducing programmed cell death of osteoblasts and damaging bone development 
(Tsuboi et al., 1999). Unlike bone, cartilage has limited turnover. Hence, it cannot be 
continuously repaired. Synovial products that promote cartilage loss include TNF-α and 
IL-1. IL-1 causes chondrocytes to produce more MMPs and nitric oxide, which products 
that promote cartilage loss include TNF-α and IL-1. IL-1 causes chondrocytes to produce 
more MMPs and nitric oxide, which inhibits collagen and proteoglycan synthesis, 
enhances MMPs activity and induces chondrocytes apoptosis (Abramson et al., 2001). 
Moreover, IL-1 increases synthesis of peptidoglycans and collagens, which help degrade 
cartilage matrix (Goldring, 2003). Other researchers have reported that TNF has the same 
mechanism of action as IL-1. Therefore, TNF also contributes to cartilage destruction. In 
addition, cytokines also contribute to cartilage degeneration by decreasing proteoglycans 
and collagens that are essential to cartilage formation (Goldring, 2003). Cytokines and 
other mediators released from the synovium can also indirectly cause cartilage 
breakdown. 
The specific mechanisms by which TNF promotes cartilage and bone destruction include 
increased production of matrix-digesting proteases. TNF induces expression of MMPs 
(Burrage et al., 2006, Moelants et al., 2013) and ADAMTS (Moelants et al., 2013) in RA. 
Interestingly, these proteases cleave pro-TNF from the membrane and release active 
TNF, which promotes downstream signalling and further production of MMPs and 
ADAMTS (Moelants et al., 2013). MMPs and ADAMTS collectively degrade all 
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components of the extracellular matrix. Thus, production of MMPs and ADAMTS 
downstream of TNF promotes erosion of cartilage and bone. TNF antibody blockade with 
infliximab or treatment with etanercept, a recombinant TNF receptor-Fc fusion protein, 
suppresses the expression of MMPs in RA (Huang et al., 2013, Catrina et al., 2002). The 
major downstream signalling effectors activated by TNF are NF-κB, p38 mitogen-
activated protein kinase (MAPK), c-Jun N-terminal kinase (JNK), and extracellular-
regulated kinase (ERK) (Baud and Karin, 2001). Transgenic mice that over-express 
human TNF develop synovial inflammation and arthritis (Gortz et al., 2005). 
Interestingly, these mice demonstrate increased phosphorylation of p38 MAPK and ERK 
but not JNK in synovial inflammatory tissues (Gortz et al., 2005). TNF antibody 
blockade with infliximab suppresses phosphorylation of p38 MAPK and ERK in synovial 
tissues, confirming that these are major signalling pathways downstream of TNF in RA 
(Gortz et al., 2005). ERK phosphorylates c-Jun, a member of the activating protein-1 
(AP-1) family, which pairs with c-Fos to drive the expression of MMPs (Vincenti and 
Brinckerhoff, 2002). Further, p38 indirectly activates the expression of AP-1 genes, 
leading to MMP up-regulation (Vincenti and Brinckerhoff, 2002). In addition to 
contributions by MAPK signalling, TNF-mediated bone and cartilage degradation also 
appear to be partially dependent upon IL-1 expression. Human TNF transgenic mice that 
are IL-1-null have significantly reduced bone erosion and osteoclast formation and 
undetectable cartilage damage in association with lower expression levels of ADAMTS-5 
and MMP-3 (Zwerina et al., 2007). Thus, TNF contributes to loss of bone and cartilage in 
RA by inducing the expression of matrix-degrading proteases. These effects may be 
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further potentiated by increased expression of other cytokines, such as IL-1. This is 
illustrated in Figure 1.3. 
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Figure ‎1.3 Mechanism of TNF-mediated bone and cartilage erosion. 
TNF signalling in RA promotes increased production of matrix-digesting proteases. TNF 
binds to the TNF receptor and induces major signalling pathways, including p38 MAPK 
and Erk1/2. These signalling pathways induce the expression of MMPs and ADAMTS in 
part through the phosphorylation of transcription factors such as c-Jun. MMPs and 
ADAMTS digest major extracellular matrix proteins, resulting in erosion of cartilage and 
bone. TNF, tumour necrosis factor; TNFR, TNF receptor; p38, p38 mitogen-activated 
protein kinase; Erk, extracellular-regulated kinase; MMP, matrix metalloproteinase; 
ADAMTS, a disintegrin and metalloprotease with thrombospondin motifs. 
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1.5.4 Hypoxia  
Active synovium metabolically consumes more oxygen. Chronically inflamed joints with 
large effusions have increased pressure and, consequently, a reduced supply of blood 
(Ahn et al., 2008). The rheumatoid synovial microenvironment is normally hypoxic 
(Stevens et al., 1991). In a hypoxic environment, the vascular system starts to adapt its 
structure to facilitate blood flow to the tissues and cells of the inflamed joints. 
Macrophages and proliferating synovial cells produce cytokines and angiogenic factors, 
such as VEGF and FGF, which activate angiogenesis. A master regulator of the 
adaptation response to the change in oxygen supply is HIF. Activation of HIF signalling 
leads to extensive changes in gene expression, which allows cells and tissues to adapt to 
reduced oxygen levels. The changes that happen in response to HIF activation include 
enhanced glucose uptake, increased expression of glycolytic enzymes, and increased 
expression of angiogenic factors. However, the formation of new blood vessels is 
insufficient to cope with cellular proliferation. Thus, inadequate oxygen delivery creates a 
hypoxic environment (Stevens et al., 1991).   
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1.5.5 Acid and acid build-up 
Cells require an adequate supply of oxygenated blood to prevent possible disturbances in 
the cellular membrane and to generate energy. Synoviocytes start to adapt their metabolic 
pathways in hypoxic conditions by shifting the metabolic pathway from the aerobic 
pyruvate to the anaerobic glycolytic pathway. Thus, lactic acid accumulates inside the 
inflamed joint (Lund-Olesen, 1970, Treuhaft et al., 1971). 
 In 1970, oxygen tension (pO2) was measured in synovial fluid samples from 58 RA 
patients. The mean pO2 was 27 mmHg, which was significantly lower than the mean pO2 
of 43 mmHg reported for patients with OA. Similar to the Treuhaft and McCarty study, 
another study reported that the pO2 was less than 15–20 mmHg in 27% of synovial 
samples from 55 RA patients (Stevens et al., 1991). Moreover, various studies identified 
physiological alterations in synovial fluid from RA patients, including elevated pCO2, as 
high as 150 mmHg, high lactic acid (10 mmol/L), and low pH (as low as 6.6) (McCarty, 
1974, Falchuk et al., 1970). In addition, an acid-base analyser measured the H
+
 
concentration in synovial fluids from 130 patients with arthritis. Synovial fluid from 60 
RA patients showed a mean H
+ 
concentration of 64.4 nmol/L, with pH ranging from 7.41 
to 6.85. In contrast, the mean H
+
 concentration in OA synovial fluid was approximately 
44 nmol/L, and the pH ranged from 7.41 to 7.06 (Farr et al., 1985). The impact of 
extracellular acidification on bone and cartilage cells has been studied. Arnett and 
Dempster showed that acid stimulation of rat osteoclasts led to bone erosion (Arnett and 
Dempster, 1986). Moreover, recent studies suggest that acid-sensing proteins play critical 
roles in osteoclast (Jahr et al., 2005) and chondrocyte (Jahr et al., 2005, Yuan et al., 
2010c) activity. 
  
46 
 
1.6 Acid-sensing proteins  
Recently, three different types of acid-sensing proteins have been found in various tissues 
and synoviocytes. First, acid-sensing ion channels (ASICs) are highly expressed in 
central neurons and peripheral sensory neurons (Waldmann et al., 1997). ASICs are 
members of the epithelial sodium channel/degenerin family. Members of this family have 
two characteristic transmembrane areas: (i) a large cysteine-rich extracellular loop and 
(ii) short extracellular N- and C-termini (Krishtal, 2003, Waldmann, 2001). Six subunits 
have been cloned. ASIC1a, 2a, and 2b are found in central neurons (Alvarez de la Rosa et 
al., 2002). ASIC1a, 1b, 2a, and 3 are expressed in sensory neurons. Kolker et al. (2010) 
conducted an in-depth study of ASIC3 expression in FLS. ASIC3 plays a vital role in the 
regulation of hyaluronan release, as observed in FLS of ASIC3-/-
 
mice.  
Second, G-protein-coupled receptors (GPCRs or GPRs) play vital roles in intracellular 
calcium mobilization and generation of inositol phosphates in hypoxic conditions. A 
study by Christensen et al. (2005) identified GPCR activity in human synoviocytes. 
However, the molecular identity of the protein is unknown.  
Third, transient receptor potential cation channel subfamily V member 1 (TRPV1), also 
known as the vanilloid receptor 1, is expressed in synoviocytes of patients with OA and 
RA (Engler et al., 2007). These studies suggest that functional acid-sensing proteins are 
expressed in synoviocytes. However, the roles of specific acid-sensing proteins in 
modulating functional responses of synovial cells to acidic conditions remain unknown. 
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1.6.1 Acid-sensing ion channels (ASICs) 
Studies showed that external protons are responsible for the activation of sodium ion 
(Na
+
) channels, which are ASICs. These channels were duplicated according to their 
resemblance to a larger subfamily of channels called degenerin/epithelial Na
+
 channels 
(ENaCs).  
 
1.6.1.1 Structure 
ASICs open in response to reduced extracellular pH due to acidification (Krishtal, 2003, 
Waldmann, 2001). The degenerin ion channel superfamily includes ASICs that are 
ENaCs (Waldmann and Lazdunski, 1998, Kellenberger and Schild, 2002). These 
channels are specific for sodium ions and are inhibited by diuretic drugs, such as 
amiloride. They are membrane-spanning proteins that contain two transmembrane 
regions, each of which has a large extracellular loop, an intracellular amino group, and a 
terminal carboxyl group (Figure 1.4). Multiple ASIC subunits must assemble to form a 
functional ion channel (Waldmann, 2001). 
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Figure ‎1.4 Structure of an ASIC. 
The ASIC monomeric structure is composed of two transmembrane regions connected by 
an extracellular loop. An ASIC has an intracellular amino and terminal carboxyl group. 
Na
+
 enters the channel, and small concentrations of Ca
2+
 usually accompany the influx of 
sodium. Diuretics, such as amiloride, inhibit ASIC activity. PDZ-containing scaffolding 
proteins, such as PSD-95 and PIST, bind to ASICs. Scaffolding proteins form unique 
docking sites for additional signalling molecules, propagating downstream signalling 
diversity. For example, PIST interacts with Rho GTPase family members, whereas other 
signalling pathways may be activated by PSD-95 or another scaffolding protein. TM, 
transmembrane region; COOH, carboxyl group; NH2, amine group; ASIC, acid-sensing 
ion channel; Na
+
, sodium ion; Ca
2+
, calcium ion; PDZ, post-synaptic density, Drosophila 
discs large, and zonula occludens-1; PSD-95, post-synaptic density protein 95; PIST, 
PDZ domain protein interacting specifically with TC10; GTPase, hydrolase that acts on 
guanosine triphosphate. 
  
49 
 
ASICs exhibit all of the features and traits of ENaCs despite showing only approximately 
20%–25% similarity with the superfamily. Functional ASICs are either heterotetramers 
or homotetramers that have diverse functional properties. The functional ENaC is mainly 
composed of four subunits. Both ENaCs and ASICs are sensitive to low concentrations of 
amiloride (Krishtal, 2003).  
The six recognized proteins of the ASIC family are as follows. ASIC1a and ASIC1b are 
variants encoded by ASIC1. ASIC2b and ASIC2a are derived from ASIC2. The other two 
members are ASIC3 and ASIC4. Both ASIC4 and ASIC2b are inactive if expressed 
alone. ASIC4 cannot function as a proton-gated channel, whereas ASIC2b can alter the 
structures of ASIC3 and ASIC2 if they are co-expressed (Lingueglia et al., 2006). Both 
extracellular and intracellular aspects can effectively adjust the functions of an ASIC. For 
example, the neuropeptides FF (Phe-Leu-Phe-Gln-Pro-Arg-Phe amide) and FMRFamide 
(Phe-Met-Arg-Phe amide) transform the ASIC current by limiting or enhancing channel 
desensitisation following pH activation (Askwith et al., 2000). Moreover, protein kinase 
C (PKC) specifically targets ASIC1 and ASIC2 through its PDZ (post-synaptic density, 
Drosophila discs large, and zonula occludens-1) domain, whereas protein kinase A 
(PKA) effectively modulates ASIC1 (Bronstein-Sitton, 2004). Additionally, ASIC3 
interacts with channel-interacting PDZ protein primarily to adjust cell-surface expression 
of the channels.  
 
1.6.1.2 Mechanisms 
ASICs have various pathological and physiological roles due to their specific localisation 
and functional traits. Expression of ASICs in the central nervous system and peripheral 
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tissues plays a crucial role in various diseases, such as multiple sclerosis, anxiety, 
memory lapses, musculoskeletal pain, and learning disorders (Kolker et al., 2010). 
Studies in ASIC1-/- mice have implicated this particular channel in memory and learning 
(Bronstein-Sitton, 2004). Destruction of long-term potentiation (LTP) was observed in 
hippocampal neurons from these mice. Damaged LTP may cause memory and learning 
problems. In these knockout mice, ASIC flow shortages in the hippocampal neurons 
significantly reduced the movement of N-methyl-D-aspartate receptors. In addition, 
ASIC2a, which can create heterodimers with ASIC1, failed to form functional channels 
in ASIC1-/- mice (Bronstein-Sitton, 2004). In contrast, ASIC3-/- and ASIC2-/- mice had 
fewer defects. Nonetheless, both ASIC3-/- and ASIC2-/- mice had deficiencies in 
mechanosensation and light touch. 
Two major studies established the immunoreactivity of ASIC3 in sensory neurons. The 
first one showed that ASIC3 and ASIC2 are co-expressed in the dorsal root ganglion 
(DRG) and that these proteins are more commonly found in large neurons (Alvarez de la 
Rosa et al., 2002). However, co-expression of ASIC3 with a calcitonin gene-related 
peptide (CGRP) is found in large and small trigeminal ganglion neurons (Ichikawa and 
Sugimoto, 2002).  
In the central and peripheral nervous systems, ASIC1 and ASIC3, respectively, play key 
roles together with extracellular modulators and interacting proteins. ASIC3 activity is 
up-regulated by activators of the PKC pathway, which are released during peripheral 
inflammation. Inflammation leads to an elevation of ASIC3 mRNA transcription levels in 
the DRG and spinal cord. Protons released at either the pre- or post-synaptic membranes 
could activate ASIC3 (Molliver et al., 2005). 
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Interestingly, ASIC3 has been identified as the most sensitive ion channel. It is more 
widely distributed in human beings than in mice, which indicates its extensive role in 
human beings (Kolker et al., 2010). During episodes of cardiac ischemic pain, ASIC3 
senses changes in pH and mediates the sensation of pain. This is caused by large fluxes in 
current at the DRG of sensory neurons that supply nervous impulses to the heart (Benson 
et al., 1999, Sutherland et al., 2001), resulting in angina. In addition, ASIC3 detects and 
responds to small changes in the extracellular pH of muscles due to metabolic stress (pH 
7.4 to 7.0).  
The axon reflex caused by the peripheral release of CGRP occurs due to the activation of 
C fibres with subsequent vasodilation and extravasation (Willis, 1999, Sann and Pierau, 
1998). ASIC3, TRPV1, and CGRP are co-expressed on the afferent vessels of the arterial 
muscle. This suggests all three function as sensors and effectors of localised blood influx 
in response to elevated lactic acid levels and rising temperatures in muscle. This co-
expression assists cellular detection of a broad range of acid levels. 
Activation of ASICs by acidosis increases the influx of Na
+
 into cells (Zha, 2013). Small 
concentrations of calcium ions (Ca
2+
) accompany Na
2+
 through ASICs, which results in 
the activation of voltage-gated calcium channels and increased intracellular Ca
2+ 
concentrations (Figure 1.5). Thus, although the roles of ASICs in Ca
2+ 
influx are indirect, 
these ion channels contribute to the overall increase in Ca
2+ 
that occurs in response to 
acidosis. ASIC knockout mouse models accumulate reduced amounts of Ca
2+
 in 
synoviocytes under acidic conditions (Kolker et al., 2010). Further, ASIC inhibition 
reduces cellular Ca
2+
 levels and articular cartilage breakdown in rats (Yuan et al., 2010b). 
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These results are consistent with the notion that ASICs are important regulators of Ca
2+ 
accumulation and cartilage destruction in RA.  
Signalling molecules that interact with ASICs include components of the cytoskeleton, 
such as α-actinin (Zha, 2013). Scaffolding proteins bind ASICs through PDZ motifs and 
include protein interacting with C-kinase 1 (PICK1), PDZ domain protein interacting 
specifically with TC10 (PIST), A-kinase anchoring protein 150 (AKAP150), and post-
synaptic density protein 95 (PSD-95) (Zha, 2013). Interactions between ASICs and 
PICK1 depend upon PKA and PKC signalling and regulate trafficking of ASICs to the 
membrane (Zha, 2013). PIST interacts with ASICs and members of the Rho GTPase 
family (Neudauer et al., 2001). However, the specific functional consequences of ASIC 
interactions with PIST remain unknown. Disruption of AKAP150-ASIC binding reduces 
ASIC signalling, indicating that AKAPs may be involved in the activation or 
maintenance of ASIC function (Chu et al., 2011). Further, PSD-95 reduces cell-surface 
levels and signalling of ASICs (Zha, 2013). Thus, multiple binding partners and 
downstream signalling effectors modulate ASIC function and affect intracellular ion 
concentrations and cartilage destruction in response to altered cellular pH.  
ASIC function may be further enhanced by GPCR signalling, which induces intracellular 
Ca
2+
 accumulation and activation of PKA (Christensen et al., 2005) as discussed below. 
PKA increases surface levels and signalling from ASICs. Thus, GPCRs lead to increased 
activation of ASIC function. Signalling from ovarian cancer GPCR 1 (OGR1 or GPR68), 
a membrane receptor for protons and lipids, is associated with osteoclast differentiation 
(Yang et al., 2006), which leads to bone resorption. Thus, GPCR signalling in the 
synovial environment may contribute to bone destruction in RA. TRPV1 also becomes 
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activated during acidic conditions. ASICs are usually activated in the presence of mild 
acidosis, whereas TRPV1 activity occurs during severe acidosis (Bohlen and Julius, 
2012). TRPV1 is activated by GPCR signalling due to changes in phosphorylation or 
lipid status (Bohlen and Julius, 2012). Thus, cross-signalling from GPCRs appears to 
activate ASICs and TRPV1, two critical ion channel families, in response to acidic pH in 
the synovial environment in RA.   
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Figure ‎1.5 ASICs multimeric structure and function. 
 
Upon ASICs activation, there is Na
+
 and, to a lesser degree, Ca
2+
 influx into the cell, 
which depolarizes the cell membrane. The inward current activates other voltage-gated 
channels, such as VGCCs, VGSCs, and NMDARs; this will enhance the generation of 
dendritic spikes and action potentials. Moreover, Ca
2+
 influx activates CaMKII, which in 
turn influences other messenger pathways (Wemmie et al., 2013). Ca
2+
, calcium ion; Na
+
, 
sodium ion; CaMKII, Ca
2+
/calmodulin-dependent protein kinase II; VGSC, voltage-gated 
sodium channel; VGCC, voltage-gated calcium channel; NMDAR, N-methyl-D-aspartate 
receptor. 
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1.6.2 ASIC3 in inflammatory disorders and rheumatoid arthritis  
ASIC3 expression is increased in various inflammatory conditions. For example, a three-
fold increase in ASIC3 expression was found in inflamed intestinal tissue from a patient 
with Crohn’s disease (Yiangou et al., 2001). In addition, ASIC3 appears to be involved in 
the metabolic and inflammatory conditions associated with obesity and type 2 diabetes 
(Huang et al., 2008). ASIC3 knockout mice show reduced adiposity, increased insulin 
sensitivity, and improved performance in glucose tolerance tests compared with their 
wild-type counterparts (Huang et al., 2008). Furthermore, ASIC expression increases in 
sensory neurons in response to inflammation-associated pH reduction (Voilley et al., 
2001). However, NSAIDs suppress increased ASIC expression and reduce currents from 
ASICs (Voilley et al., 2001). These data indicate that the expression and function of 
ASICs are inhibited by anti-inflammatory drugs. Thus, inflammation is a major trigger 
for ASIC activity. These findings are consistent with our hypothesis that acid-sensing 
proteins play critical roles in the development and maintenance of the inflammatory 
environment found in RA. 
Acid build-up leads to pain and harms the joints. A correlation exists between the degree 
of pain and joint damage and the acidity of the synovial fluid present in arthritic joints 
(Revici et al., 1949, Geborek et al., 1989). A study by Kolker et al. (Kolker et al., 2010) 
showed that ASIC3 may be expressed in synoviocytes, type B FLS, and the epiphyseal 
plates of ASIC3+/+ mice. Immunostaining for ASIC3 was not detected in tissues from 
control ASIC3-/- mice. However, the role that ASIC3 plays in synoviocytes remains 
unclear (Waldburger et al., 2008). 
Activated ASIC3 is more permeable to Ca
2+
 and facilitates an increase in intracellular 
Ca
2+
 mobilization. Increased intracellular Ca
2+
 activates several signalling pathways, 
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leading to increased production of hyaluronan by type B synoviocytes (Kolker et al., 
2012). High levels of Ca
2+
 in the cell are also associated with Ca
2+
/calmodulin-dependent 
protein kinase II activation, which may further aggravate inflammation. Increased 
intracellular Ca
2+
 in FLS activates intracellular signalling pathways that enhance the 
inflammatory response. In turn, increased inflammation and destruction of cartilage 
aggravates disease. Studies show that GPCR and TRPV1 are also activated in FLS, 
resulting in increased intracellular Ca
2+
. Based on this, researchers have suggested that 
ASIC3 is not the only pH sensor in FLS (Hu et al., 2008, Christensen et al., 2005b).  
The roles of ASIC3 in sensing acidity, as well as in the modulation of hyaluronan 
expression and release, were evaluated at a pH of 5.5. However, in RA the prevailing pH 
is usually between 6.0 and 6.9 (Kolker et al., 2012). In addition, researchers have shown 
that responses to changes in acidity by ASICs are dependent on the level of acidity 
(Benson et al., 2002). Consequently, future studies should evaluate these parameters at a 
range of different acidic conditions. 
 
1.6.2.1 Transient receptor potential cation channel subfamily V member 1 
(TRPV1) 
Cloning of TRPV1 provided evidence that transient receptor potential (TRP) channels 
participate in the pain pathway. Research shows that TRPV1 is the most studied receptor 
in the TRP superfamily (Caterina and Julius, 2001). It is expressed in the 
trigeminal ganglia, DRG, and nodose ganglion neurons and works together with 
nociceptive fibres at an activation temperature of 43°C. Sensing of an acid or vanilloid 
compound is a clear indication of the significance of TRPV1 in mediating responses to 
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harmful stimuli (Caterina et al., 1997, Tominaga et al., 1998). TRPV1 is encoded by 
TRPV1 in humans. This group of ion channels detects and regulates body temperature 
and is involved in sensing heat and pain. Structurally, TRPV1 is 838 amino acids long, 
with a molecular weight of 95 kDa. It has six transmembrane domains, a C-terminal 
cytosolic region that is 132 amino acids long, and an N-terminal region that is 432 amino 
acids long (Figure 1.6).   
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The structure of TRPV1 consists of six transmembrane domains. There are amino-
terminal sequences that mediate CaM and PIP2 signalling. TRPV1 activators are shown 
above the structure. NGF, nerve growth factor; COOH, carboxyl group; TRP, transient 
receptor potential; NH4, amine group; CaM, calcium-modulated protein; PIP2, 
phosphatidylinositol 4,5-bisphosphonate; TRPV1, transient receptor potential cation 
channel subfamily V member 1. TRPV1 is widely distributed across many tissues and is 
activated in a polymodal manner by both chemical and physical stimuli. Different 
TRPV1 activators are shown in Table 1 below. 
 
 
  
Vanilloids, lipids, protons, cations, heat, voltage, NGF
 
Plasma membrane 
CaM 
PIP2 
TRP 
box 
NH4 
COOH 
    Figure ‎1.6 TRPV1 structure. 
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Table1 Physical and chemical activators of TRPV1 
Activator  Examples  
Vanilloids Capsaicin, olvanil, resiniferatoxin 
Lipids Anandamide, N-oleoyldopamine, endocannabinoid, N-arachidonoyl 
dopamine, 18–20 carbon N-acylethanolamines, 12-
hydroperoxyeicosatetraenoic acid 
Protons  H
+
 
Cations  K
+
, Rb
+
, Cs
+
, Na
+
, and Li
+
 ions 
Heat  
Voltage  
Source: (Devesa et al., 2011) 
 
1.6.2.1.1 Functionality  
TRPV1 is non-selective and can be stimulated by a wide range of endogenous and 
exogenous stimuli, such as acidic conditions; N-arachidonoyl dopamine; vanilloids like 
capsaicin; and heat, which leads to a painful and burning sensation. Located in the 
nociceptive neurons of the peripheral nervous system, TRPV1 receptors modulate pain 
sensation and play a role in the integration of diverse painful stimuli. TRPV1-/- mice 
were shown to lack effective responses to harmful heat stimuli or to the pungent 
vanilloids. Other studies note that gene knockdown or knockout is crucial for examining 
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the role that TRP channels play in detecting certain painful stimuli in nociceptive 
neurons. For example, TRPV3-/- mice do not exhibit sensitivities to noxious and 
innocuous heat (Moqrich et al., 2005). TRPV4-/- mice present with other characteristics, 
such as reduced sensitivity at the tail when pressure is exerted on it (Suzuki et al., 2003). 
The best description for TRPV1 function is as a mediator of hyperalgesia and allodynia. 
In fact, TRPV1-/- mice did not respond effectively to severe chemical or thermal stimuli 
and did not develop inflammatory hyperalgesia (Caterina et al., 2000, Davis et al., 2000).  
 
1.6.2.1.2 Sensitisation and desensitisation 
Prostaglandins and bradykinin are released as inflammatory mediators and lead to 
increased nociceptor sensitivity to noxious stimuli in the presence of tissue damage, 
injury, and inflammation. This manifests as an increased sensitivity to painful stimuli or 
to the increased sensation of pain in response to non-painful stimuli. The phospholipase C 
(PLC) pathway is activated by these pro-inflammatory agents, leading to phosphorylation 
of TRPV1 by PKC and sensitization. Cleavage of phosphatidylinositol 4,5-bisphosphate 
(PIP2) by PLC results in re-activation of TRPV1 and contributes to TRPV1 sensitivity to 
stimuli. However, desensitisation may occur with prolonged exposure to stimuli due to 
increased intracellular Ca
2+
 influx from the extracellular space, which leads to decreased 
TRPV1 activity. 
TRPV1 synthesis occurs in the DRG sensory neurons, and TRPV1 is transported along 
the central and peripheral axons to the spinal dorsal horn and to the skin and visceral 
organs, respectively (Guo et al., 1999, Tominaga et al., 1998). TRPV1 is critical to a 
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number of sensory issues in the skin, such as heat sensation, nociception, inflammatory 
hyperalgesia, allodynia, and neuropathic nociception (Hudson et al., 2001). 
Capsaicin, which is a treatment for arthritic pain, works by temporarily desensitising its 
only known receptor, TRPV1 (Holzer, 1991),(Szallasi, 2002) Capsaicin also reduces 
blood flow in capsaicin-sensitive afferents (Tang et al., 2004, Helyes et al., 2004) 
(Bolcskei et al., 2005), (Barton et al., 2006, Keeble et al., 2005, Szabo et al., 2005).  
Despite TRPV1’s role in arthritis, the exact mechanisms by which TRPV1 exerts its 
effects are not fully understood. Sensing acid stimulates the expression of immediate 
early genes in sensory neurons. The ERK pathway is part of the serine/threonine MAPK 
family. ERK signalling links nociception to altered gene expression by transducing 
extracellular stimuli through its signalling pathway to achieve an intracellular 
transcriptional and post-translational response. After activation by mediators of cellular 
stress, inflammation, growth factors, and mitogens, MAPK translocates into the nucleus 
and binds to transcription factors. Transcription of specific genes is regulated to achieve 
many types of cellular activities, such as proliferation and production of cytokines and 
other inflammatory response factors (Seger and Krebs, 1995, Lewis et al., 2000). MAPKs 
exist in numerous isoforms and are activated by kinases, resulting in the formation of a 
complex biochemical cascade that is critical for the overall regulation of the 
inflammatory process (Karin, 2004, Thiel et al., 2007). 
 
  
62 
 
1.6.2.1.3 Role of TRPV1 in inflammatory disorders and rheumatoid arthritis  
 
TRPV1 signalling is associated with numerous inflammatory conditions, including RA. 
Similar to RA, chronic pancreatitis is characterised by neurogenic inflammation 
(Schwartz et al., 2013). Increased expression of TRPV1 and its upstream regulator, nerve 
growth factor (NGF) is found in chronically inflamed rat pancreatic tissues (Zhu et al., 
2011). However, a blockade of NGF reduces TRPV1 expression and function in rat 
pancreatic sensory neurons (Zhu et al., 2011). Further, TRPV1 antagonists reduce 
inflammation and pain in a mouse model of chronic pancreatitis (Schwartz et al., 2013). 
Up-regulation of TRPV1 expression and activity is also found in acute pancreatitis in 
mice (Schwartz et al., 2011). Thus, expression and activation of TRPV1 in pancreatic 
sensory neurons are believed to be a major mechanism mediating pancreatic 
inflammation (Liddle, 2007). Consistent with these studies, TRPV1 also appears to be an 
important mediator of pancreatic inflammation in diabetes (Suri and Szallasi, 2008). In 
fact, loss of TRPV1 signalling in rats results in reduced age-related weight gain and 
improved glucose tolerance (Suri and Szallasi, 2008). These results implicate TRPV1 as a 
critical mediator and potential therapeutic target in obesity and diabetes, which are major 
inflammatory disorders. However, the role of TRPV1 in diabetes appears to include not 
only type 2 diabetes but also autoimmune type 1 diabetes (Suri and Szallasi, 2008), which 
is also characterised by pancreatic inflammation. TRPV1 activation is also associated 
with inflammatory bowel disease (Akbar et al., 2010). Thus, TRPV1 antagonism is a 
potentially beneficial approach for multiple pathological conditions characterised by 
chronic inflammation. These studies suggest a general link between TRPV1 activity and 
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inflammation, which is consistent with the concept that TRPV1 is an important mediator 
of inflammation in RA.     
Engler et al. (Engler et al., 2007) demonstrated that TRPV1 is expressed in FLS of OA 
and RA patients. Synoviocytes can be exposed to TRPV1 stimuli, especially thermal 
stress and acidic conditions, if there is chronic or acute inflammation (Kochukov et al., 
2006). Moreover, over-expression of TRPV1 has been identified in joint synovial fluids 
and contributes to the OA pathogenesis. TRPV1 and CGRP were expressed in a rat 
model of OA that was enhanced by complete Freund's adjuvant (CFA) or iodoacetate 
(Kochukov et al., 2006, Nilius et al., 2007). CFA decreased mechanonociceptive 
thresholds and allodynia, and increased arthritic changes at the tibiotarsal joints of wild-
type mice. CFA-induced swelling at the knee joint is significantly reduced in TRPV1-/- 
mice compared to wild-type mice (Kochukov et al., 2006). TRPV1 protein expression is 
abundant in synoviocytes. However, its role in pathological conditions, such as arthritic 
inflammation, remains under debate (Kochukov et al., 2006).  
The role of TRPV1 in inflammation is thought to be largely neuronal, although some 
evidence indicates that it may contribute to immune responses. These receptors are 
sensitized by neurons to generate the perception of pain. Sensitization occurs through an 
enhanced expression of TRPV1 and modification of the channel. Sensitized TRPV1 may 
also increase the release of substance P and CGRP from sensory neurons. These pro-
inflammatory mediators cause vasodilation and movement of pro-inflammatory 
mediators and immune cells to the injury site, contributing to swelling and plasma 
extravasation. In RA, the levels of neuropeptides in the synovial fluid are high. Even 
though the role of TRPV1 in RA has not been clearly elucidated, TRPV1 is widely 
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considered to play a critical role in the accumulation of neuropeptides and in the 
integration of different noxious stimuli (Fernandes et al., 2011). Protons affect TRPV1 
function by reducing the threshold for channel activation by agonists and heat and by 
promoting channel opening at a low pH (Tominaga and Tominaga, 2005). 
TNF-α enhances the expression of TRPV1, activates TRPV1 contributing to 
inflammation-related pain, enhances capsaicin-induced Ca
2+
 influx, and contributes to 
TRPV1 sensitization. Bradykinin, histamine, adenosine triphosphate, and prostaglandin 
E2 have also been shown to mediate the excitation and sensitization of TRPV1 (Devesa 
et al., 2011). 
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1.6.3 G-protein-coupled receptors (GPCRs) 
GPCRs have seven transmembrane domains (Figure 1.7). Members of this 
transmembrane receptor family recognize biomolecules in the extracellular space and 
initiate the activation of signal transduction pathways and appropriate cellular responses. 
 
 
Figure ‎1.7 Structure of GPCR 
A GPCR consists of an intracellular C-terminal domain, seven transmembrane domains, 
and an extracellular N-terminal domain. The G-α/β/γ subunits attach near the carboxyl 
terminus. GPCR, G-protein-coupled receptor. 
 
These receptors are activated when they bind their ligands, which are normally peptides 
of varying sizes. GPCRs have two main transduction pathways: the cyclic adenosine 
monophosphate (cAMP) and phosphatidylinositol signalling pathways (Figure 8) 
(Gilman et al., 1987). G-proteins are composed of three different subunits: G-alpha, G-
beta, and G-gamma. Once the ligand binds to the GPCR, guanine diphosphate is replaced 
by guanine triphosphate, inducing activation of the G-alpha protein subunit and 
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dissociation from the beta and gamma subunits. G-alpha has four different isoforms: G-
alpha o, G-alpha s, G-alpha i, and G-alpha 12/13. 
 The activity of phosphatidylinositol-specific phospholipases is controlled by the G-alpha 
o family. For example, PLC-beta hydrolyses PIP2 and generates the second messengers, 
diacylglycerol and inositol 1,4,5-trisphosphate. These messengers increase intracellular 
Ca
2+
 concentrations and activate proteins kinases, such as PKC (Ludwig et al., 2003). G-
alpha o can work directly or through PKC and regulates different phospholipase-D 
isoforms. G-alpha o induces the transcription factor NF-κB via proline-rich tyrosine 
kinase-2. Conversely, G-alpha s induces the adenylyl cyclase pathway, leading to cAMP 
accumulation in cells. cAMP binds to PKA and induces GPCR phosphorylation (Gilchrist 
et al., 2002). 
GPCRs have some acid-sensitive units, such as GPR4, GPR65, GPR68, and GPR132. 
These subunits are activated as ASICs if extracellular pH declines to between 6.4 and 6.8. 
These G-protein receptors were initially de-orphanised as receptors of lipid messengers. 
Recently, GPR4, GPR68 (OGR1), GPR65 (T-cell death-associated gene 8 [TDAG8]), 
and GPR132 (G2A) have been reported to be proton-sensing receptors that activate either 
the phosphoinositol or cAMP pathways. Expression of these proteins is observed in DRG 
and small neurons that are responsible for nociception. More than half of these proteins 
contribute to inflammation and neuropathic diseases. However, their functions in chronic 
inflammation, such as RA, remain unclear. Recently, researchers have found that OGR1 
and G2A respond to low pH by increasing inositol phosphatases (IPs). In contrast, GPR4 
and TDAG8 accumulate cAMP in response to extracellular acidification (Christensen et 
al., 2005a).   
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1.6.3.1 Role of GPCR in inflammatory disorders and rheumatoid arthritis  
Many inflammatory mediators activate GPCR signalling. In addition, chronic 
inflammatory conditions such as asthma demonstrate increased GPCR activity (Druey, 
2003). Allergens stimulate GPCR signalling in endothelial and respiratory smooth muscle 
cells (Druey, 2003). Activated GPCR signalling is a major therapeutic target for allergy 
medications (Druey, 2003), demonstrating the major role that GPCRs play in allergic 
conditions. Furthermore, down-regulation of G-protein-coupled receptor kinase 2, which 
results in increased GPCR signalling, is observed in multiple sclerosis, which is 
characterised by neuronal inflammation (Vroon et al., 2005). In addition to being 
associated with numerous inflammatory conditions, GPCR signalling is active during 
bone remodelling. Expression of OGR1 (GPR68) has been observed during osteoclast 
differentiation in a study of toothless osteoporotic rats. Colony stimulating factor-1 
injection and RANKL treatment were administered to restore the osteoclast population. 
In that study, over-expression of OGR1 (GPR68) was noticed after 2 days of injection. 
Moreover, mRNA expression increased after treatment with RANKL to induce osteoclast 
differentiation. Inhibition of OGR1 by anti-OGR antibody or by small inhibitory RNA 
inhibited RANKL-induced differentiation of mouse bone marrow mononuclear cells and 
raw cells in vitro (Gilchrist et al., 2002). That study indicated that OGR1 might play a 
critical role in the development of RA because of its role in early osteoclastogenesis and 
osteoclast differentiation. GPR4 has been reported as a receptor for 
sphingosylphosphorylcholine (SPC) and lysophosphatidylcholine (LPC). However, this 
observation has not been confirmed yet. Zhu et al. (Zhu et al., 2001) showed that SPC 
and LPC enhanced intracellular Ca
2+
 in GPR4-transfected cells. However, in another 
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study by Ludwig et al., SPC and LPC were not considered activators or ligands for 
GPR68 and GPR4 (Ludwig et al., 2003). Another experiment found that LPC had no 
effect on cytosolic Ca
2+
, whereas SPC activated intracellular Ca
2+
 release in synoviocytes 
(Christensen et al., 2005a). Because the function of GPR4 is not yet confirmed, whether 
GPR4 directly or indirectly mediates the effects of LPC and SPC remains unclear. 
Recently, various studies have shown that GPR4 senses extracellular acidification (Chen 
et al., 2011). Activation of GPR4 by acidic pH transduces downstream signals via cAMP 
and PLC. A new effector of cAMP has recently been identified and is referred to as an 
exchange protein directly activated by cAMP (Epac). Epac is involved in various cellular 
processes, including cell adhesion (Lorenowicz et al., 2007, Roscioni et al., 2008). 
Moreover, Epac signalling regulates PKA-independent processes, such as B2-adrenergic 
receptor-mediated ovarian carcinoma cell adhesion, chemotaxis, and monocyte adhesion. 
Activation of GPR4 at an acidic pH (6.4) enhanced human umbilical vein endothelial cell 
(HUVEC) adhesiveness and binding to U937 monocytes. These effects were decreased 
upon knockdown of GPR4 in HUVECs (Chen et al., 2011). 
GPCR expression has been found in synoviocytes. Two separate studies examined 
synoviocytes from two groups of patients. One group of patients had RA, and the other 
had psoriatic arthritis. The results showed a significant increase in intracellular Ca
2+
 at 
pH 6.7 in both groups. Moreover, IP production was examined to confirm the role of 
GPCR. A significant increase in IP was found in cultured synoviocytes (SW982) at pH 
6.7 (Christensen et al., 2005a). However, the identity of the GPCR detected in the 
previous study remains unknown. Further studies are needed to identify and characterise 
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the functions of these proteins in synoviocytes, including how they contribute to the 
pathology and progression of RA. 
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1.7 Hypothesis 
In this research project we test the hypothesis that human synoviocytes (FLS) express 
acid sensing proteins that regulate the functional responses to acidification and that 
blocking expression of acid sensing mechanism in synoviocytes reduces destructive 
responses in human synoviocytes. 
 
1.8 Aims and Objectives 
1- To determine the expression and localisation of acid sensing proteins in synovium 
from patients with RA. 
 
2- To determine the affect of acidic environment on acid sensing proteins and matrix 
metalloproteinase (MMP) expression in RA-FLS at both mRNA and protein level. 
 
3- To determine the effects of acid sensing proteins inhibition on functional responses to 
acid in synoviocytes.  
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2 Chapter 2: Materials and Methods 
2.1 List of materials 
2× qPCR mastermix (plus SYBR green plus ROX) 
Primerdesign, Southampton, 
UK 
3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium 
Bromide (MTT) 
Sigma Aldrich, MO, USA 
3,3'-Diaminobenzidine (DAB) peroxidase substrate 
Vector Laboratories, CA, 
USA 
Amersham western blotting detection reagent enhanced 
chemiluminescence (Thiel et al.) Plus 
GE Healthcare, Chalfont St. 
Giles, UK 
Aperio CS2 slidescanner Leica, Wetzlar, Germany 
Dharmafect 4 transfection reagent 
Dharmacon, Thermo Fisher 
Scientific Inc, MA, USA 
Dimethyl sulfoxide (DMSO) D8418 Sigma Aldrich, MO, USA 
Donkey anti-rabbit Alexa Fluor® 568 
Life Technologies, Thermo 
Fisher Scientific Inc, MA, 
USA 
Dulbecco's Modified Eagle's medium (DMEM)/F-12 
GlutaMAX™ Supplement 
Life Technologies, Thermo 
Fisher Scientific Inc, MA, 
USA 
Fetal Bovine Serum  
Biosera, East Sussex, UK, 
East Sussex, UK 
Goat anti-mouse horseradish peroxidase conjugated 
antibody 
Abcam, Cambridge, UK 
Goat anti-rabbit horseradish peroxidase conjugated 
antibody 
Abcam, Cambridge, UK 
Haematoxylin Sigma Aldrich, MO, USA 
HALT™ proteinase inhibitor cocktail EDTA-free 100x 
Thermo Fisher Scientific Inc, 
MA, USA 
iBlot® gel transfer stack, nitrocellulose Invitrogen, Paisley, UK 
L-Glutamine 200mM 
Lonza-Biowhittaker, 
Cologne, Germany 
Lipofectamine 2000 transfection reagent Invitrogen, Paisley, UK 
Mouse anti-human fibroblast antigen clone IB10 Abcam, Cambridge, UK 
Mouse anti-human β-Actin purified antibody Sigma Aldrich, MO, USA 
NTC ON TARGET plus SMART pool siRNA 
Dharmacon, Thermo Fisher 
Scientific Inc, MA, USA 
Oligofectamine transfection reagent Invitrogen, Paisley, UK 
Penicillin-Streptomycin (100x) 
Lonza-Biowhittaker, 
Cologne, Germany 
Precast 12% 12-well polyacrylamide mini PROTEAN 
TGX gels 
BIORAD, CA, USA 
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Precision Nanoscript Reverse Transcription Kit 
Primerdesign, Southampton, 
UK 
Prestained protein ladder broad range (10-230 kDa) 
New England Biolabs, MA, 
USA 
Rabbit anti-mouse Alexa Fluor® 488 
Life Technologies, Thermo 
Fisher Scientific Inc, MA, 
USA 
Recombinant human TNF-alpha PeproTech, NJ, USA 
RNeasy mini kit Qiagen, Dusseldorf, Germany 
Skimmed milk powder Sigma Aldrich, MO, USA 
Trypan blue 0.4% solution 
Lonza-Biowhittaker, 
Cologne, Germany 
Trypsin-Ethylenediaminetetraacetic acid (EDTA) (1X) 
liquid [0.05% Trypsin 0.53 mM EDTA•4Na] 
Fisher Scientific, Thermo 
Fisher Scientific Inc, MA, 
USA 
Vectastain universal elite avidin-biotin complex (ABC) 
kit 
Vector Laboratories, CA, 
USA 
Vectorshield mounting medium containing 4',6-
diamidino-2-phenylindole (DAPI) 
Vector Laboratories, CA, 
USA 
 
2.2 Clinical samples  
Biopsies of tissue synovium were collected from patients with RA and OA; some patients 
were undergoing surgery in theatre for knee replacements, the other patients were 
undergoing arthroscopy visual examinations. These samples were obtained by Professor 
A. Gerry Wilson, Dr. Mohammed Akil, and Professor J. Mark Wilkinson (Ethics were 
obtained – SSREC/03/106 and REC10/H0606/20). 
For vascularity of synovitis, the visual analogue scale (VAS) was used. All samples for 
RA biopsies were issued pathological severity scores, the tests carried out are based on 
100 mm, the scores were counted by a skilled arthroscopist, samples are marked on a 
physical 100-mm length scale and a ruler is used to take measurements starting left to 
right. Once the scores were obtained, the tissues were divided into two groups: A. Mild 
disease (score of <50 mm) and B. Severe disease (score >50 mm). 
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2.3 Isolation of RA and OA FLS 
The biopsy tissue was processed and added to 1× trypsin-EDTA for approximately 1 hour 
at 37°C. The tissue was then cut up again and treated with 10 ml collagenase per sample 
at 1 mg/ml (sterilised through a 0.22-μm PES express Millex-GV filter) for 24 hours at 
37°C, and the cell suspension was passed through a 70-μm nylon cell strainer. This was 
placed in a new T25 flask, the cells were incubated at 37°C, 5% CO2 and 20% O2. These 
cells were washed after approximately 24–48 hours with PBS. The complete culture 
medium was replaced every 2–3 days. 
 
2.4 Processing of synovial tissue for paraffin embedding 
Synovial tissue was placed in a labelled cassette of an appropriate size and dehydrated to 
displace the water through a series of graded alcohol baths (2 hours in each bath). The 
first 3 baths were 70% ethanol, the next 2 were 95% ethanol, and the last 2 were absolute 
ethanol and xylene. Then the cassette was incubated in two paraffin wax baths with a 
vacuum applied for 2 hours in each bath and then moved a warm place. The tissue was 
placed into a mould, surrounded with molten paraffin, and moved to a cold plate to allow 
the wax to set. The mould was then removed, and the block was inserted into a 
microtome to cut 5-µm sections. Synovial tissue sections were floated on the surface of a 
37ºC water bath, transferred onto the surface of clean glass slides, and then placed on a 
warm block to melt the wax and bond the tissue to the glass. 
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2.5 Immunohistochemistry of paraffin-embedded sections (IHC-P) 
Histochemical methods were used to study the expression of acid sensing proteins in 
arthroscopic biopsies from RA patients. Antibody optimization was performed prior to 
investigation of acid sensing proteins. The acid sensing proteins ASIC3, GPCR4, OGR1, 
and TRPV1 were evaluated with rabbit polyclonal primary antibodies purchased from 
Abcam. The detection of acid sensing proteins was optimized in sections of lung tissue, 
which expresses all four types of proteins and served as a positive control (Xu and Casey, 
1996, Su et al., 2006, Chen et al., 2011, Deering-Rice et al., 2012). Rabbit isotype-
specific IgG and lung tissues with no primary antibodies were used as negative controls.  
Paraffin-embedded sections of human synovial tissue were deparaffinised (de-waxed) by 
placing the slides on a carrier and performing the following incubations for 3 min each: 
xylene, xylene with 100% ethanol (1:1), 100% ethanol, 70% ethanol, and 50% ethanol. 
Finally, the slides were washed under running tap water. Then, antigen retrieval was 
performed by incubating the slides in tri-sodium citrate (2.94 g in 1000 ml distilled water, 
pH 6.0), followed by microwaving at 98°C. After the solution reached the boiling point, 
20 min was counted. This antigen retrieval procedure was performed to break the 
methylene bonds that cross-link proteins and mask antigen binding sites. Slides were 
removed from the microwave and washed under running tap water for 10 min. The slides 
were then washed twice in Tris-buffered saline (TBS) with 0.025% Triton X100, blocked 
in 10% goat serum with 1% BSA for 2 hours at room temperature, and washed twice 
prior to addition of the primary antibodies. Primary antibodies were diluted in TBS with 
1% BSA as follows: ASIC3 (AB49333; 1:50), GPCR4 (AB75330; 1:100), GPCR68 
(AB61420; 1:50), and TRPV1 (AB63083; 1:100). Synovial tissue sections were 
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incubated with primary antibodies for 24 hours at 4°C. On day 2, the slides were rinsed in 
TBS with 0.025% Triton X100 and incubated in 3% hydrogen peroxide (H2O2) in TBS 
for 15 min to quench endogenous peroxidases and reduce background staining. The 
secondary antibody (universal biotinylated anti-mouse/rabbit IgG secondary antibody) 
provided by Vector Laboratories was diluted at 1µl:50µl of TBS with 1% BSA, and 
slides were incubated at room temperature (25°C) for 1 hr. Sections were rinsed in TBS-
Tween (TBST), and then avidin-biotin complex (ABC) solution was applied for 1 hr. 
ABC is a method of antigen detection that exploits the binding affinity between avidin 
and biotin using a secondary antibody conjugated to biotin to amplify the signal from the 
primary antibody (Figure 2.2). Horseradish peroxidase is conjugated to a large avidin-
biotin complex, which is then added to the sample to enzymatically label each complex 
and further amplify the signal. Synovial tissue sections were washed twice with TBST. 
DAB stain (Vector Kit, DAB substrate kit for peroxidase), which was used to visualize 
the protein expression, was prepared by adding two drops of hydrogen peroxide solution, 
two drops of buffer stock solution, and four drops of DAB stock solution (each drop = 50 
µl) to 5 ml distilled water and mixing well. DAB solution was added to the slides for 2–
10 min, avoiding light exposure as much as possible. The colour development was 
checked under a microscope. Then, the sections were washed with TBST, counter-stained 
with haematoxylin for 30 sec, and washed in Scott’s water to reduce the background 
staining. Sections were rehydrated in 50% ethanol, 70% ethanol, 100% ethanol, xylene 
with 100% ethanol, and xylene for 50 sec each. Sections were mounted and viewed. 
Aprio software was used to scan and analyse IHC slides (Figure 2.1). 
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Figure ‎2.1 A screenshot for a scanned slide of synovial tissue using Aprio software. 
All slides were scanned by Aprio software. Donor details (upper left corner), 
magnification of a specific area (lower right corner) and an overview of whole slide can 
be investigated. 
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Figure ‎2.2 AB complex (ABC). 
Avidin and biotinylated enzyme are mixed together in a specified ratio to prevent avidin 
saturation and incubated for about 15 min at room temperature to form the complex. 
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2.6 Frozen tissue sectioning 
Synovial tissue was snap-frozen in liquid nitrogen and then stored in at -80°C. Before 
sectioning, the cryostat chamber and chuck temperature were set to -20°C. The frozen 
tissue was placed in the chamber and allowed to warm up, and the tissue or block was 
then frozen to a chuck using Cryoembed. Once the tissue was securely frozen in place, it 
was fixed into the holder and trimmed to achieve a full-face section. Sections were then 
taken at 7 μm and fixed to a slide using electrostatic charge. Cut sections were stored at -
80°C until needed. 
 
2.7 Immunofluorescence (IF) 
 Frozen synovial tissue sections were used to identify and co-localise the expression of 
acid-sensing proteins in RA FLS. RA synovial tissue was defrosted for one hour at room 
temperature, rinsed with PBS with 0.025% Tween 20 (PBST), and then fixed in ice-cold 
4% paraformaldehyde for 10–15 min. After fixation, tissue was rinsed with PBST twice 
and blocked with 5% normal goat serum in PBS for 1 hr at room temperature followed by 
two more rinses with PBST. Rabbit anti-ASIC3 (AB49333; 1:50), GPR4 (AB75330; 
1:100), GPR68 /OGR1 (AB61420; 1:50), TRPV1 (AB63083; 1:100), and mouse 
monoclonal to fibroblast surface protein (Anti-Fibroblast Surface Protein antibody 1B10, 
Abcam ab11333) were used for immunostaining. Synovial tissue was incubated with 
primary antibodies overnight at 4°C. Donkey anti-mouse Alexa Fluor® 488 conjugate 
and goat anti-rabbit IgG (H+L) Alexa Fluor® 594 conjugate were used as secondary 
antibodies. Samples were rinsed with PBST, and then secondary antibodies were applied 
(1:1000) in PBST with 1% BSA for 2 hr at room temperature in dark. Slides were washed 
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three times for 5 min, followed by adding one drop of mounting medium with DAPI 
(VECTASHIELD HardSet), which hardens after the coverslip is placed. Sections with no 
primary antibodies and sections treated with iso-IgG (Rabbit polyclonal IgG, ab27472) 
served as negative controls. All slides were examined using an inverted widefield 
fluorescence microscope (Leica DMI4000B) and LAS AF Lite software (Figure 2.3). 
Sections were investigated at 10× for whole section visualization and at 40× for specific 
area details.  
During image collection, three different channels were used to detect acid-sensing protein 
expression in RA synovial tissue. Each channel is specific for a wavelength (Channel 0 to 
detect Alexa Fluor® 488 (green), Channel 1 for Alexa Fluor® 594 (red), and Channel 2 
for DAPI stain (blue) and the exposure time was set at 6100 ms, 5072 ms, and 364 ms, 
with gain 6.2, 6.1, and 5.5 respectively. All sections were investigated at 10× for a whole 
section vision, and 40× for a specific area details. All three channels were used to detect 
acid-sensing proteins (red), FLS (green), and nucleus (glue) separately, and then all three 
channels were merged in one image as shown below.    
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Figure ‎2.3 IF images 
This figure illustrates the inverted widefield fluorescence microscope software LAS AF 
Lite and the three different channels for RA-FLS (green), acid sensing proteins interest 
(red), nucleus (blue), and the merged of all three channels for an RA synovial tissue 
section.  
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2.8 RA Fibroblast-like synoviocyte (RAFLS) culture 
Dulbecco's modified Eagle's medium (DMEM)/F-12 Gluta-Max medium (Gibco, UK) 
was prepared by adding 5–10% foetal bovine serum (FBS), 100 U/ml penicillin, and 100 
μg/ml streptomycin (P/S), mixing well, and storing at 4°C. Upon receipt of the RA FLS 
cell lines, complete DMEM culture medium was warmed up at room temperature for 1 
hour and then cells were counted with a haemocytometer (Figure 2.4). RAFLS were 
initially cultured at a density of 5 × 10
4 
cells in five T-25 flasks and were incubated at 
37°C in 5% CO2. The complete culture medium was changed every 3 days, and the cells 
were harvested after 14 days (80%–90% confluent) by adding trypsin/EDTA (2 ml for a 
T-75 flask and 500 µl for a T-25 flask). (DMEM)/F-12 GlutaMAX medium contains 
calcium and magnesium ions, and foetal bovine serum contains proteins that are trypsin 
inhibitors. Both Mg
2+
 and Ca
2+
 inhibit trypsin. Therefore, we used PBS without 
Ca
2+
/Mg
2+
 to wash the cells prior to trypsinisation to reduce the concentration of divalent 
cations and proteins that inhibit trypsin. EDTA is a calcium chelator, which will "mop" 
up the remaining divalent cations. If trypsin is allowed to stay in contact with the cells for 
too long, cell viability will be reduced. So, flasks were incubated with trypsin/EDTA at 
37°C in 5% CO2 for maximum 5 min, and then cells were checked to see if they were 
detached. Once detached, 4 ml of complete DMEM medium was added to inhibit the 
trypsinisation. The suspension was transferred to a universal tube, and flasks were 
checked for any remaining attached cells before discarding the flask. The tube was 
centrifuged at 500×g, the supernatant was discarded, and the pellet was collected and 
washed twice with PBS and then resuspended in 1 ml complete DMEM prior to counting 
and subculturing the cells. 
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Contamination tests were performed for every new DMEM bottle by incubating DMEM 
plus 5% FBS and 1× P/S at 37°C in 5% CO2 for 24 hr and examining the medium with 
light microscopy at 40X for microbe growth. Moreover, incubator cleaning and 
mycoplasma testing were performed monthly.  
 
2.9  RA FLS counting 
 A 10-µl aliquot of the cell suspension (described in section 2.8) was transferred into a 
new microtube, and 10 µl trypan blue was added to the suspension and mixed well with a 
pipette. The haemocytometer was prepared, the cover slip was cleaned and fixed on its 
correct position, and 10 µl of the trypan blue/cell mixture was dispensed under the cover 
slip until it covered the counting area completely. The chamber counter was inspected 
under the microscope at 40×. For cell counting, the following equation was used (average 
of cells × dilution factor × 10
4
). The dilution factor in this case was 2 (1:1 diluted with 
trypan blue), and 10
4
 is the conversion factor to ml (Figure 2.4). 
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Figure ‎2.4 Cell counting by using Haemocytometer. 
Cells in red were excluded from counting, cells in blue represent dead cells, and 
translucent cells represent live cells. 
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2.10 RA-FLS subculture 
After re-suspending the pellet as described in the previous section (2.8), an equal volume 
(1 ml) of medium as the cell suspension was dispensed into four new T-25 flasks and 6-
well plates, and cells were incubated at 37°C in 5% CO2. Cells reached 90% confluence 
in 10–14 days, and the medium was changed every 3–4 days. 
 
2.11 Culture medium pH optimization 
DMEM medium was adjusted by using 1 M HCL (pH 7.4, 7.0, 6.5, 6.0), transferred into 
T-25 flasks, and then incubated at 37°C in 5% CO2 for 24 hr. on day 2, acidified medium 
were collected in sealed tube and pH was measured by using pH meter from METTLER 
TOLEDO. The pH measurements for all acidified medium ranged between 7.10 and 7.50, 
which reflects that the buffering system (NaHCO3) was effectively changing the acidity 
of the medium to neutral pH or pH≈7.4. So, DMEM culture medium with no NaHCO3 
was used. However, inside the incubator CO2 dissolves in water and forms carbonic acid 
(H2CO3), which dissociates and form a proton H
+
 and bicarbonate HCO3
-
, and that will 
acidify the medium to an extremely low pH in the absence of a buffering system. 
 
CO2 + H2O ↔ H2CO3 ↔ H+ + HCO3 
 
The presence of sodium bicarbonate as a buffering system in the culture medium will 
maintain medium condition at neutral pH under maintained CO2 tension. 
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NaHCO3 + H2O ↔ Na+ + HCO3- + H2O ↔ Na+ + H2CO3 + OH- ↔ Na+ + H2O +OH- 
+ [CO2(aq) ↔ CO2(g)] 
The amount of dissolved CO2 in the culture medium is dependent on the amount of 
environmental CO2 and the temperature of the incubator. Inside the incubator CO2 tension 
is maintained, but when CO2 escapes, the reaction is driven to the right and sodium 
carbonate is produced, which will increase pH and turn the medium more alkaline.  
HEPES has a superior buffering capacity and does not require a controlled gaseous 
atmosphere (Shipman, 1969). However, HEPES is relatively expensive and toxic at 
higher concentrations for some cell types. HEPES also greatly increases the sensitivity of 
media to phototoxic effects induced by exposure to fluorescent light (Zigler et al., 1985). 
In addition, our RAF-FLS cells were optimized to grow under a controlled gaseous 
atmosphere with 5% CO2. Moreover, most incubators were in use by other researchers, 
and it was difficult to find an available incubator without a controlled gaseous 
atmosphere. The concentration of HEPES when used in a CO2 environment must be more 
than double the amount of bicarbonate for adequate buffering, and that may be toxic to 
RA-FLS. Incubation of HEPES buffer without bicarbonate in a CO2 atmosphere will turn 
the medium extremely acidic. Thus, the complexity of using HEPES as pH monitor 
prevented its use. 
So the pH of MEM culture medium should be adjusted by changing CO2 tension or the 
buffering system (HCO3) concentration, not only by addition of HCl or lactic acid 
(C3H6O3) as illustrated in the equations below. 
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NaHCO3 + HCL NaCL + H2O+ CO2 
NaHCO3 + C3H6O3                 CO2 + H2O + NaC3H5O 
 
NaHCO3 concentration in DMEM culture medium is 3.7 g/L, which will maintain a pH 
of 7.4 in a 5% CO2 environment. The concentration of NaHCO3 was manipulated to 
achieve desired acidic condition.  
The 10× MEM with no buffering system (sodium bicarbonate) was diluted to 1× 
(pH=2.10–2.31) with sterile filtered distilled water, then 5% FBS, 1% penicillin 
streptomycin, and 1% L-Glutamine were added. The pH of the medium was measured 
and adjusted to be maintained at desired acidic condition by using 7.5% NaHCO3 (75 g 
NaHCO3 per litre of distilled water) (Table 1). Then all acidified medium were adjusted 
to pH 7.4 using 1 M NaOH and stored at 4°C. Different volumes of 1 M lactic acid were 
used to acidify culture medium at pH 7.4, 7.0, 6.5, and 6.0. Acidified medium was 
transferred into flasks with and without RA-FLS and incubated at 37°C in 5% CO2 for 24 
hr to evaluate the acidic condition and pH stability  
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1X MEM Volume Components (Control) pH 7.4 pH 7.0 pH 6.5 pH 6.0 
 
 
 
20ML 
7.5% NaHCO3 850 µl 575 µl 310 µl 160 µl 
1M NaOH -  30 µl 65 µl 92 µl 
1M LA  -  32 µl 90 µl 100 µl 
7.5% NaHCO3 1000 µl 550 µl 270 µl 155 µl 
NaOH -  35 µl 65 µl 100 µl 
LA -  45 µl 75 µl 115 µl 
 
 
 
25ML 
7.5% NaHCO3 1150 µl 750 µl 450 µl 300 µl 
NaOH -  40 µl 75 µl 90 µl 
LA -  55 µl 110 µl 140 µl 
7.5% NaHCO3 850 µl 630 µl 400 µl 225 µl 
NaOH -  35 µl 70 µl 97 µl 
LA -  40 µl 90 µl 100 µl 
 
 
 
 
 
 
30ML 
7.5% NaHCO3 970 µl 580 µl 285 µl 200 µl 
NaOH -  35 µl 70 µl 95 µl 
LA -  42 µl 60 µl 42 µl 
7.5% NaHCO3 1050 µl 735 µl 420 µl 270 µl 
NaOH -  60 µl 100 µl 130 µl 
LA -  40 µl 120 µl 140 µl 
7.5% NaHCO3 820 µl 590 µl 390 µl 270 µl 
NaOH -  30 µl 60 µl 100 µl 
LA -  60 µl 90 µl 120 µl 
7.5% NaHCO3 765 µl 550 µl 440 µl 255 µl 
NaOH -  35 µl 85 µl 115 µl 
LA -  13µl 40µl 100 µl 
 
80ML 
7.5% NaHCO3 3410 µl 2220 µl 1160 µl 600 µl 
NaOH -  180 µl 260 µl 320 µl 
LA -  180 µl 310 µl 370 µl 
 
Table 2 shows different volumes of culture 1x MEM (20, 25, 30 and 80ml) and the amount of 
NaHCO3, NaOH and lactic acid needed to adjust the pH to (7.4, 7.0, 6.5, and 6.0). The 
amount of all components depends on the initial pH of the sterile distilled water used to 
prepare 1X culture medium. 
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Medium pH  pH Before incubation pH After incubation 
7.0 7.07 6.98 
6.51 6.55 6.50 
6.0 6.0 5.94 
7.0 7.17 7.04 
6.50 6.50 6.47 
6.07 6.10 6.0 
7.0 7.11 7.08 
 
 
 
Medium pH  pH Before incubation with 
RAFLS 
pH After incubation with 
RAFLS 
7.10 7.15 6.87 
6.50 6.51 6.45 
6.0 6.0 5.90 
7.0 7.17 6.99 
6.52 6.50 6.42 
5.99 6.0 6.1 
7.0 7.05 7.01 
 
 
 
 
 
Table 3 1X MEM pH reading before and after 24 hr incubation in T-25 
flasks with no cells at 37oC in 5% CO2  
Table 4 1X MEM pH reading before and after 24 hr incubation in T-25 flasks 
with RA FLS cells at 37oC in 5% CO2  
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2.12 RA FLS treatment with TNF   
Equal numbers (30,000 cells) of RAFLS cells were seeded in six T-25 flasks and 
incubated at 37°C in 5% CO2. Once they reached confluence (80%–90%), the complete 
DMEM was removed, and cells were washed with phosphate-buffered saline (PBS). 
Cells were serum starved by adding DMEM without FBS and incubating the flasks for 24 
hr at 37°C in 5% CO2. On day 2, starvation medium was removed and replaced with 1× 
DMEM containing 5% FBS and 10 ng/ml TNF. Cells were treated for different times: 0, 
30 minutes, 2 hours, 4 hours, and 24 hours with TNF. Each time point with TNF 
treatment had its own control (four controls for four treated FLS cultures). FLS cells were 
then harvested with trypsin/EDTA, and total RNA was extracted using the Qiagen spin 
column method (RNeasy Mini Kit). Then qPCR was performed using β-actin as a 
reference gene. 
 
2.13 RAFLS treatment with acidified medium 
RA-FLS (1.5–2.0×105/ml) were seeded into T-25 flasks using complete DMEM medium 
and incubated at 37°C in 5% CO2. When the cells reached 80%–90% confluency, the 
complete culture medium was replaced with serum starvation medium (1% PS, 1% LG, 
1% FBS), and the cells were incubated for 24 hr. On day 2, the serum starvation medium 
was discarded, and the cells were washed twice with PBS. The cells were then treated 
with acidified culture medium at pH 7.4, 7.0, 6.5, and 6.0 (prepared as described in 
section 2.11) and incubated for another 24 hrs at 37°C in 5% CO2. After incubation, the 
acidified culture medium was discarded, and the RA-FLS were washed twice with PBS 
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and harvested by using trypsin/EDTA. The cell pellets were collected in Falcon 15-mL 
conical centrifuge tubes to extract total RNA. 
 
2.14 Total RNA extraction 
Cell pellets were washed twice in PBS prior to RNA extraction by using a spin column. 
All reagents and columns were purchased from Qiagen (RNeasy Mini Kit, Qiagen). For 
RNA extraction, buffer RLT (lysis buffer) and 70% ethanol (600 μl each) were added to 
the cell pellet and mixed well by pipetting. Then up to 700 μl of the suspension was 
transferred to an RNeasy Mini spin column placed in a 2-ml collection tube, which was 
centrifuged for 15 seconds at ≈ 8000×g. The flow-through was discarded, and then 700 μl 
buffer RW1 was added to the RNeasy spin column, which was centrifuged again for 15 
seconds at ≈ 8000×g. The flow-through discarded again, followed by addition of 500 μl 
buffer RPE to the spin column, which was centrifuged. The flow-through was discarded 
(this step was repeated once again), and then the collection tube was replaced by new 
one, and 50 μl RNase free water was added to the spin column, which was centrifuged for 
2 min at 8000×g. Precision DNase (Primerdesign Ltd.) was used to eliminate gDNA 
contamination of the RNA prior to reverse transcription/real-time PCR. The 10× 
Precision DNase reaction buffer (5 l) was added directly to 50 l RNA, and then 1 l 
Precision DNase enzyme was added. The reaction mixture was incubated for 10 minutes 
at 30C for DNase treatment, followed by 5 minutes at 55C for DNase inactivation. All 
extracted total RNA was quantified by using the NanoDrop spectrophotometer before the 
first-strand synthesis step. After quantification, all total mRNA samples were diluted at a 
single concentration (10 ng/µl) by following the equation below. 
91 
 
 
 
 
 
[(Desired Concentration (10 ng)) / (total mRNA concentration)] * (Desired volume) = X 
X - Desired volume=Y 
Whereas: 
X is the amount of sample that needed to be diluted 
Y is the diluent volume to be added to x 
 
 
 
 
2.15 First-strand synthesis 
First-strand synthesis (cDNA) was done using the Primer Design Ltd. Precision 
Nanoscript Reverse Transcriptase kit. In a microtube, 1 μl each of oligo-dt, which is 
single-stranded sequence of deoxythymine (dT), was used for priming reactions catalysed 
by reverse transcriptase. The transcript was primed in the poly (A) tail of mRNA 
molecules, and random nonamer primers were added to 10 ng RNA template. RNAse-
/DNase-free water was added to a final volume of 10 μl. The reaction was heated to 65°C 
for 5 min in a hot block (T100™ Thermal Cycler, Bio-Rad), and samples were then 
transferred directly to ice. Then, 10 μl of a mixture of nanoScript 10× Buffer, RNAse-
DNase-free water, 1.0μl of 10 mM of nucleotide triphosphates mix (dNTP), and Nano-
Script enzyme (reverse transcriptase enzyme) were added to the samples, which were 
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briefly vortexed, spun down quickly, and incubated at 25°C (room temperature) for 5 
min, 55°C for 20 min, and 75°C for 15 min to inactivate the reaction then stored at -20°C.   
 
 
 
 
 
 
 
 
Figure ‎2.5 Flow chart of cDNA synthesis. 
Shows tables of reagents concentration and incubation period and temperature 
 
 
Component Volume 
for 1 
reaction  
RNA 
template 
5.0μl 
(50ng) 
Oligo-dT 
primer 
1.0μl 
Random 
nonamer 
primer 
1.0μl 
RNase/DNase 
free water 
3.0μl 
Final volume 10μl 
Component  Volume for 1 
reaction 
nanoScript2 4X 
Buffer 
5.0μl 
dNTP mix 
10mM 
1.0μl 
RNase/DNase 
free water 
3.0μl 
nanoScript2 
enzyme 
1.0μl 
Final volume 10μl 
Heat to 65°C for 5 minutes then 
immediately cool the tubes in an 
ice water bath.   
55°C for 20 
minutes 
Heat inactivate the 
reaction by incubation at 
75°C for 10-15 minutes 
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2.16 Quantitative polymerase chain reaction (qPCR) 
RA-FLS mRNA was evaluated for expression of the acid sensing proteins, ASIC3, 
GPR4, OGR1, and TRPV1. Total mRNA from each sample was reverse transcribed into 
cDNA using the precision nanoscript reverse transcriptase kit (Primer Design Ltd., UK) 
as described above. Relative gene expression levels were determined with semi-
quantitative real-time PCR using 10 μl MasterMix with SYBR Green and Rox using 
primers purchased from Primer Design Ltd. According to Primerdesign Ltd., all primers 
were designed without regards to intron-exon boundaries, as this is restrictive, and the 
most efficient location for the primers may not be on an exon-exon junction. However, to 
prevent gDNA contamination, the mRNA samples were treated with precision DNase, as 
described in section 2.14.  A 348-well plate was used in which the final volume in each 
well was 20 μl and contained 10 μl MasterMix, 1 μl specific primers purchased from 
Primerdesign ltd , 4 μl RNase-/DNase-free water, and 5 μl cDNA. All reactions were run 
in duplicate. 
 
Component Volume 
MasterMix 10 μl 
RNase/DNase free H2O 4 μl 
Specific Primers 1 μl 
cDNA 5 μl 
Final volume 20 μl 
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All real-time PCR assays were run on the ABI Prism 7900HT Sequence Detection 
System (Applied Biosystems SDS). PCR amplifications were performed in duplicate 
wells using universal temperature cycles: 10 min at 95°C, followed by 40 two-
temperature cycles (15 sec at 95°C and 1 min at 60°C). 
 
Figure ‎2.6 Real-time PCR standard cycles parameters. 
Thermal cycles start with incubation at 50°C for 2 minutes prior to raise the temperature 
to initial denaturation (stage 2) at 95°C for 10 minutes followed by 40 cycles of 
denaturation, annealing and extension at 95°C and 60°C for 15 seconds and 1 minute, 
respectively (stage 3). 
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2.17 qPCR raw data collection and analysis  
After each qPCR run, Applied Biosystems SDS2.4 software was used to collect raw data 
and analyse it using the comparative CT method (ΔΔCT method), where CT is the point in 
which SYBR Green florescence exceeds the detection threshold, and the curve starts to 
take off (Figure 2.7). Each gene target and endogenous controls were run in duplicate and 
CT values were accepted only if they were within 0.5 CT of each other. The mRNA levels 
of all samples were normalized to levels of glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH), B2M, and β-actin, as screening of all samples determined no variability in 
GAPDH, B2M, and β-actin expression. ΔCT was calculated by subtraction the average 
endogenous control CT value from the average of target CT value  
 
 
ΔCT = CT target – CT endogenous 
 
Then ΔΔCT was calculated by subtraction ΔCT of the untreated (control) from the ΔCT of 
treated  
 
ΔΔCT = ΔCT test sample – ΔCT control/untreated sample 
 
Then fold difference to the control was calculated as 2
^ - (ΔΔC
T
).
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Figure ‎2.7 qPCR amplification phases. 
CT refers to threshold cycles when fluorescent rises above the baseline, the Exponential 
phase starts when the target yields reached the detection threshold. During the 
amplification the amount of template increases while the concentration of DNA 
polymerase reduces, which in turn reduces the reaction rate, and this is called Linear 
phase. Once there are insufficient enzymes to continue amplification, the Plateau phase 
starts. 
 
 
 
Amplification plot
CT
Δ
R
n
Cycles 0-40
Threshold 
Exponential phase
Linear phase
Plateau phase
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2.18 Western Blotting (WB) 
RA-FLS (2×10
5
) were washed with PBS and harvested by trypsin/EDTA. The cell 
suspension was centrifuged at 500×g for 7 minutes. The cell pellet was collected and 
washed with PBS twice then lysed by 200–400 μl Radio-Immunoprecipitation Assay 
(RIPA) buffer to extract total protein, and 1 µl protease inhibitor (Halt™ Protease 
Inhibitor Cocktail, Thermo Fisher Scientific) was added per 100 μl lysis buffer. RA-FLS 
lysate was incubated for 30 minutes on ice with a vortex and pipetting every 10 minutes, 
and then the mixture was clarified by spinning for 10 minutes at approximately 500×g at 
4°C. Supernatants were collected and protein concentration was measured by NanoDrop 
quantification. Protein concentrations were normalised to the sample with the lowest 
concentration, by dilution in DNase/RNase-Free water. To denature, loading buffer with 
the anionic denaturing detergent sodium dodecyl sulfate (SDS) was used, and mixed with 
the cell lysate at ratio 1:1 then boiled at 95°C –100°C for 5–10 minutes before loading 
onto a 12% polyacrylamide gel (12% Mini-PROTEAN® TGX™ precast gels, Bio-Rad). 
Protein was loaded onto the gel (24 µg/well), and electrophoresis was performed at 120 
volts for 60 minutes. Nitrocellulose membrane blotting was done by using iBlot® Gel 
Transfer Device for 7 minutes and then washing with TBST three times 10 minutes each. 
Skim milk (5%) was prepared and used as blocker. The nitrocellulose membrane was 
blocked by skim milk for 1 hr at room temperature. Primary mouse monoclonal antibody 
for β-actin (1:1000) and rabbit polyclonal antibodies for MMP-1 & MMP-9 (1:1000) 
diluted with the blocking solution were applied to the nitrocellulose membrane overnight 
at 4°C, followed by washing with TBST twice for 20 minutes, and then incubation with 
secondary goat anti-rabbit HRP conjugated antibodies (Abcam, ab7090; 1:1000) for 2 
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hours at room temperature. Then membrane was washed twice, and ECL (Amersham 
ECL Prime Western Blotting Detection Reagent. GE Healthcare) was added for 5 
minutes in a dark place. The ECL removed by using tissue and membrane was sealed by 
plastic cling. Results were collected and imaged by ChemiDoc XRS+ imaging system 
and Bio-Rad Image-Lab software. This imaging system consists of a dark hood with a 
charge-coupled device (CCD) camera, which offers sensitive chemiluminescence 
detection. The ChemiDoc XRS+ imaging system has a signal accumulation mode (SAM) 
that takes a series of exposures in a set period of time to choose an image with optimal 
signals. Once the membrane is placed inside the hood of the device, the following steps 
were performed using Bio-Rad Image-Lab software: 
 
 
 
Figure ‎2.8 Flowchart of programming WB membrane run using Bio-Rad Image-
Lab software. 
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Figure ‎2.9 Arrangement of Western Blot transfer stack 
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2.19 Migration assay 24 Trans-well plate 
RA FLS were harvested using trypsin/EDTA. Cells were re-suspended and cells were 
added to each of four tubes, pelleted, washed twice with PBS, and re-suspended in 
serum-starved acidified 1× MEM medium at pH 7.4, 7.0, 6.5, or 6.0. In 24-well plates, 
700 µl of acidic MEM with 10% FBS, pH 7.4, 7.0, 6.5, or 6.0, was added to the wells, 
and then cell culture inserts with pore size of 8.0 µm (Falcon, 353097) were applied. Two 
hundred microliters of acidified serum-starved MEM containing 2.5×10
4
 RA FLS cells 
were added into inserts. Cells in MEM at pH 7.4 were used as a control. 
The plates were incubated for 24 hr in a humidified tissue culture incubator at 37°C in 
5% CO2, then inserts were removed from the chamber and washed twice with PBS. Cells 
were fixed by submerging the insert in 4% paraformaldehyde for 10 min, washed twice 
by PBS, and permeabilised with 100% methanol for 20 min at room temperature, 
followed by two more PBS washes. Cell inserts were stained with haematoxylin or 
Giemsa stain for 30 min, and then washed several times with distilled water to remove 
excess stain. Removal of non-invading cells was done by inserting a cotton tipped swab 
and gently scrubbing the upper surface of the membrane quickly to avoid drying the cells 
adhered to the bottom surface of the membrane. Another scrubbing was done with a 
second cotton swab moistened with medium or PBS. Migrated cells were counted under 
60× magnification. Five to 10 high power fields (HPFs) were counted to determine the 
average cell number migrated per HPF. 
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Figure ‎2.10  RA-FLS migration in Transwell membrane. 
RAF-FLS cells were seeded in cell culture inserts with acidified serum starved medium 
in the upper compartment and complete acidified medium in the lower compartments 
followed by 24 hrs incubation at 37°C and 5% CO2 
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2.20 Migration in Oris 96 wells 
Oris 96-well plates (Platypus Technologies, LLC) were used to monitor the migration 
activity of RA-FLS (Figure 2.11). These plates are populated with stoppers that serve as 
barriers to create a cell-free detection zone in the centre of each well (Figure 2.11). RA-
FLS migration was tracked by using CellTracker™ Green CMFDA (5-
chloromethylfluorescein diacetate), a green fluorescent dye that freely passes through cell 
membranes into the cells, where it is transformed into cell membrane-impermeant 
reaction products. The CellTracker solution was prepared by dissolving 50 µg in 10.75 µl 
DMSO. Then 25 µl of the CellTracker solution was added to 10 ml 1X conditioned MEM 
with no FBS, and the mixture was warmed at 37°C for 5 minutes before the experiment 
started. Approximately 20,000 RA-FLS were seeded per well and incubated in DMEM 
(1% PS, 1% LG, 1% FBS) at 37˚C/5% CO2 for 24 hours. Stoppers were gently removed, 
and the medium was discarded. The cells were washed twice with PBS, and then 100 µl 
cell tracker mixture (prepared as mentioned above) was added per well and incubated at 
37°C/5% CO2 for 30 minutes. The medium with CellTracker solution was then removed 
and replaced with acidified medium (1% PS, 1% LG, 1% FBS) with or without APETX2 
and AMG 517, as shown in Figure 2.10. The day 1 image was taken, and then the plates 
were re-incubated. On day 2, images were taken, then the medium of day 1 was removed 
and replaced with new filtered acidified medium (1% PS, 1% LG, 1% FBS) with/without 
inhibitor, and then the plate was incubated again at 37°C/5% CO2 for another 24 hours. 
On day 3, the image was taken, and the medium was replaced with fresh medium, and the 
plates were re-incubated again for day 4. The same procedure was followed for day 4 
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images. Multimode plate reader (Ensight,PerkinElmer) and Kaleido 1.3 software were 
used to capture the images as illustrated in Figure 2.11 .  
 
  
Figure ‎2.11 Kaleido 1.3 software 
Shows the steps and settings of well imaging to analyse RA-FLS migration using Oris 96 well 
plate and multimode plate reader (Ensight,PerkinElmer). 
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Figure ‎2.12 96 well plate design for RA-FLS migration experiment in Oris 96 well 
plate 
 
 
Figure ‎2.13 RA-FLS migration activity in Oris 96 well plate 
Cells were seeded
Stopper
Day1 Stoppers were 
removed and cell 
tracker was added
Day2 Day3 Day4
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2.21 ASIC3 inhibition with APETX2 
APETX2 from SMARTOX BIOTECHNOLOGY (Product code: 07APE002-00500) was 
used to block ASIC3 activity. APETX2 was provided as white lyophilized solid. A stock 
concentration of 350 nM was prepared by dissolving 0.5 mg APETX2 in 313 ml 
sterilised distal water, as recommended by the supplier. The suspension was mixed well 
by vortexing and pipetting and then stored at -20°C. IC50 value of 175 nM was indicated 
for homomeric human ASIC3 channels inhibition (Diochot et al., 2004). 
To prepare a 175 nM APETX2 solution, 0.5 ml MEM (10×) was transferred to a 25-ml 
Falcon tube, and then 2.5 ml of 350 nM APETX2 (dissolved in sterilised distilled water) 
was added. The total volume was increased to 5 mL, and the pH was adjusted (pH 7.4, 
7.0, 6.5, and 6.0).  
For RA-FLS treatment with 175 nM APETX2, cells were grown to 80%–90% 
confluency, and the complete culture medium was replaced with serum starvation 
medium (1% PS, 1% LG, 1% FBS). The cells were incubated for 24 hr prior to treatment 
with APTEX2. On day 2, the culture medium was replaced with acidified medium (pH 
7.4, 7.0, 6.5, or 6.0). At the same time, T-25 flasks with RA-FLS from the same donors 
were treated with acidified medium only (no inhibitor), as illustrated in Figure 2.12, and 
incubated at 37°C with 5% CO2 for 24 hrs. On day 3 the cells were harvested by 
trypsin/EDTA and centrifuged at 500×g for 7 min. The cell pellet was washed twice with 
PBS, and then total RNA was extracted and converted to cDNA. Real-time PCR was 
performed to determine the expression of acid sensing proteins and MMPs in RAFLS 
after treatment with APETX2. Cell viability was analysed before and after treatment. 
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2.22 TRPV1 inhibition with AMG517 
 A 5.0 mg potential selective TRPV1 inhibitor (AMG517) purchased from MedChem 
Express. A 1 mM stock solution of AMG517 was prepared by dissolving 5.0 mg 
AMG517 in 11.6171 ml DMSO (as recommended by the supplier) and stored at -80°C. A 
250 nM solution was prepared (as a second stock solution) by adding 12.5 µl of the 1 
mM AMG517 solution to 50 ml 1× MEM culture medium. It has been detected that 
AMG 517 inhibited acid-induced Ca
2+
 uptake into human cells expressing TRPV1 with 
IC50 values of ≈ 0.75 nM (Gavva et al., 2007), 
Figure ‎2.14 treated and untreated RA-FLS in T-25 flasks 
pH 7.4 + APETx2 pH 7.0 + APETx2 pH 6.5 + APETx2 pH 6.0 + APETx2 
pH 7.4 
Control 
pH 7.0 pH 6.5 pH 6.0 
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 For the 0.75 nM AMG517 solution, 15 µl of the 250 nm stock solution was added to 5 
ml acidified medium (pH (7.4, 7.0, 6.5, and 6.0). The RA-FLS were treated with 
AMG517 using the same procedure described above for APETX2 treatment.  
 
2.23 RA-FLS Viability assay 
RA-FLS cells were harvested after the treatment with APETx2, AMG517, and acidified 
medium as described in section 2.8. The cell suspension (20 µl) was mixed with 20 µl 
0.4% trypan blue dye in a microtube, and 10 µl of this mixture was uploaded into 
counting slid insert that has chambers in both sides (each with 10 µl). Counting slide was 
inserted into TC20 automated cell counter; samples of each condition were run in 
duplicate. 
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3 Chapter 3: Expression and localisation of acid-sensing proteins in synovium 
from patients with RA 
 
3.1 Introduction 
Recent studies have identified the expression of different acid-sensing molecules in the 
nervous system e.g., identification of ASIC expression in the central nervous system 
(Waldmann et al., 1997), expression of TRPV1 in pain sensing neurons (Caterina et al., 
1997). The expression of these proteins is not restricted to neurons; other studies have 
shown their expression in immune cells. Tong and colleagues (Tong et al., 2011) showed 
that all ASICs were expressed in dendritic cells. Similarly, ASIC1 and ASIC3 were 
detected in bone marrow-derived macrophages (BMMs) (Kong et al., 2013). Various 
studies of the vanilloid receptors have described the expression of TRPV1 in 
macrophages and dendritic cells (Linscheid et al., 2004, Toth et al., 2009, Zhao et al., 
2013). In addition to these channels, G-protein coupled receptors (GPCRs), including 
GPR4, GPR65 (TDAG8), GPR68 (OGR1), and GPR132 (G2A), have been investigated 
for their involvement in cancer cell proliferation, apoptosis, metastasis, angiogenesis, 
immune cell function, and inflammation (Ludwig et al., 2003, Singh et al., 2007, Yang et 
al., 2007, Mogi et al., 2009, Castellone et al., 2011, Chen et al., 2011, He et al., 2011, 
Ren and Zhang, 2011, Dong et al., 2013). 
 
RA pathogenesis is complex, and various types of immune cells are involved in the 
development of the disease. Such immune cells include macrophages, mast cells, plasma 
cells, dendritic cells, B-cells, and T-cells (Smolen and Steiner, 2003). FLS play a vital 
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role in the pathogenesis of RA by producing cytokines and developing an aggressive 
phenotype that enhances extracellular matrix invasion and joint damage (Bartok and 
Firestein, 2010). Because rheumatoid joints are characterised by the acidic 
microenvironment, the detection of acid-sensing protein expression in RA synovium and 
RA-FLS is essential to investigating the role of these molecules, including their response 
to acid and their contribution to the development of RA. 
 
Different methods and techniques have been used to study the expression of acid-sensing 
proteins in fibroblast-like synoviocytes. For example, TRPV1 was identified by qPCR in 
synovium of RA and OA patients (Engler et al., 2007), while ASIC3 expression was 
demonstrated by immunohistochemistry and immunolocalisation in murine FLS (Kolker 
et al., 2010). GPCR sensitivity to H
+
 in synoviocytes was confirmed by measuring 
inositol phosphate (IP) production using ion exchange chromatography (Christensen et 
al., 2005a); however, the molecular identity of this channel is unknown. Despite this 
progress, it is still not clear how these acid-sensing proteins are differentially expressed in 
RA- and OA-FLS. In this study, several different methods were used to examine the 
expression of the acid-sensing molecules ASIC3, GPCR4, OGR1, and TRPV1 in the FLS 
of RA patients at protein and mRNA levels.  
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3.2 Hypothesis 
In this study, we formulated the following hypotheses: 
A- Acid-sensing proteins ASIC3, GPCR4, OGR1, and TRPV1 are differentially 
expressed at the protein level in RA synovium. 
B- Acid-sensing proteins ASIC3, GPCR4, OGR1, and TRPV1 are differentially 
expressed at the mRNA level in RA-FLS and OA-FLS. 
 
3.3 Methods 
3.3.1 Histochemical methods 
Immunohistochemistry (IHC-P) is one of the most powerful techniques to study the 
expression and localisation of proteins in complex tissue, such as synovium. In IHC-P, 
the antigen-antibody interaction can be visualized by means of colour signal through light 
microscopy, so different colours can be used to detect the expression and localisation of 
different antigens. In this study, IHC-P was used to identify and evaluate the expression 
of acid-sensing proteins in arthroscopic biopsies from RA patients while 
immunofluorescence microscopy (IF) was used to localise the expression of these acid-
sensing molecules in RA-FLS. 
To confirm the specificity of the primary antibodies in IHC-P, positive and negative 
controls were used for every experiment. The positive control was lung tissue, which is 
known to express all antigens of interest. The negative controls were lung tissue with no 
primary antibodies and lung tissue stained with non-specific rabbit iso-IgG. 
Paraffin-embedded RA synovium specimens (thickness = 5 μm) were run as described in 
section (2.5). 
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3.3.2 H-SCORE and statistical analysis 
Immunohistochemical scoring (H-SCORE) is a valuable semi-quantitative method used 
to study protein expression in a complex tissue. The results of IHC-P can be evaluated for 
staining intensity and percentage of stained cells. Staining intensity is categorised as 
follows: 0 for “no staining,” 1+ for “weak staining,” 2+ for “intermediate staining,” and 
3+ for “strong or dark staining.” The percentage of stained cells can be calculated as the 
number of cells at different staining intensities divided by total number of cells, 
multiplied by 100. The H-SCORE can then be calculated by multiplying staining 
intensity by the percentage of cells showing that staining intensity using the following 
equation: 1×(% of 1+ cells) + 2×(% of 2+ cells) + 3×(% of 3+ cells). The IHC H-score 
scale ranges from 0 to 300 based on the percentage of cells at different staining 
intensities. The H-SCORE was originally developed during a study of breast and 
endometrial carcinoma in 1986 by McCarty et al. (1986). This method combines stain 
distribution and stain. There are two different methods for IHC scoring. The first method 
is a manual procedure to count positive cells and evaluate the intensity of the stain using 
light microscopy. The second method is automated and is based on digital scan of IHC 
slides and software analysis to calculate the number of stained cells and intensities. To 
evaluate the expression of each acid-sensing protein of interest, manual method was used 
and confirmed by the automated method.  
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3.3.2.1 Manual H-SCORE 
The expression of each acid-sensing protein was evaluated in synovial tissue of four 
different patients. Positive and negative synovium cells were counted using light 
microscopy (at 60×) and computer monitor for scanned slides. Five viewing fields in each 
slide were examined and the average was calculated. The intensity of DAB-stained cells 
was evaluated and divided into four categories: negative, weak positive, positive, and 
strong positive, with scores of 0, 1+, 2+ and 3+, respectively (Figure 3.1).  
 
 
 
The H-SCORE was calculated as follows: 
 
H-SCORE= [(Nwp/Ntotal)×(1)]x100 + [(Np/Ntotal)×(2)]x100 + 
[(Nsp/Ntotal)×(Bingham)]x100 
 
Where Nwp = Number of weakly positive; Np = Number of moderately positive; Nsp = 
Number of strongly positive; Ntotal = Total number negative + positive cells. 
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Figure ‎3.1 Manual evaluation of staining intensity. 
The intensity of cells was evaluated as follows: 0 score or negative, (wp) = weak positive, 
with a score of 1+; (p) = positive, with a score of 2+; and (sp) = strong positive, with a 
score of 3+.  
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3.3.2.2 Automated H-SCORE 
The manual method depends on visual evaluation of intensity, which may affected by 
perception bias due to the counter stain (Varghese et al., 2014). In contrast, the automated 
method is based on software analysis, which may give more accurate calculations and 
avoid visual perception bias. This method applies positive pixel counts and intensity 
algorithms to the digital image. Automated method was used to confirm the outputs of 
the manual method. 
The IHC-P slides of lung and synovial sections were scanned using the Aperio CS2 slide 
scanner. The scanned slides (saved as digital images) were evaluated on the computer 
monitor using Aperio ImageScope to evaluate staining intensity and count the number of 
stained cells. The section of interest was opened as illustrated in Figure 3.2.  
 
Figure ‎3.2 Digital scanned picture of lung tissue inspected by using Aperio 
ImageScope software. 
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Five random areas of the section were chosen at 8× magnification (300 µm), as shown 
below. 
 
 
Figure ‎3.3 Slide analysis using ImageScope Software. 
The first image shows the selected five areas to be analysed, and the second image shows 
an area at 8× magnification. 
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From the tool bar (under View), Analysis was chosen, and from the window on the right 
side, the region of analysis was chosen (Current Screen), and the analysis was run. Once 
the run was completed, Annotations was chosen to show the results of the analysed area, 
as illustrated in Figure 3.4. The H-SCORE we calculated using the following equation: 
1×(% of 1+ cells) + 2×(% of 2 + cells) + 3×(% of 3+ cells). 
 
 
Figure ‎3.4 Illustrates the steps of analysis to retrieve the number of stained cells and 
intensities.  
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Figure ‎3.5 Image analysis at 40× using the Aperio system. 
The different pixel colours correlate with the intensity of DAB and haematoxylin stain. 
Panels A & B illustrate one area of interest in lung tissue before (A) and after (B) the 
software analysis.  
A B 
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Nwp: number of weak positive 36189 
Np: number of positive 203073 
Nsp: number of strong positive 56055 
Iwp: intensity of weak positive 7075260 
IP: intensity of positive 26659123 
Isp: intensity of strong positive 4979904 
Nn: number of negative 377240 
In: intensity of negative 50665482 
 
Figure ‎3.6 Sample of the annotation result calculations. 
A screen shot of the automated calculations. Yellow = number and intensity of weak 
positive cells (wp); red = number and intensity of positive cells (p); brown = number and 
intensity of strong positive (sp); blue = negative cells. 
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3.3.3 Dual immunofluorescence (IF) 
The IHC-P results showed the expression of acid sensing proteins in the synovium 
without specifying cell type. Therefore, dual IF was performed to localise the expression 
of acid sensing proteins in RA-FLS. FLS and the protein of interest were targeted in the 
synovial tissue using two primary antibodies of differing species and two secondary 
antibodies labelled with different fluorescent dyes. Frozen tissue section were stained 
with polyclonal primary antibodies to ASIC3, GPR4, OGR1, TRPV1 (rabbit), or FLS 
(mouse) surface protein for 24 h at 4°C followed by incubation with Alexa Fluor-
conjugated secondary antibodies and nuclear DAPI stain as described in material and 
methods section. 
 
3.3.4 RA-FLS treatment with TNF 
The 80%–90% confluent RA-FLS cells were incubated with a serum starved medium 
(1% FBS) for 24 hr. Starvation medium was replaced by a complete culture medium with 
10 ng/ml TNF and re-incubated at different time points as described in section 2.12. RA-
FLS cells were harvested as described in material and methods section prior to run real 
time PCR. RA-FLS without TNF treatment was used as control. 
 
3.3.5 Polymerase chain reaction (PCR) 
RA-FLS cells from different RA patients were used to measure the expression of mRNA 
of acid-sensing protein. RA-FLS cell cultures were treated with 10 ng/ml TNF at varying 
acidic pH conditions (7.0, 6.5, and 6.0). Treated RA-FLS cell cultures were compared to 
untreated RA-FLS pH 7.4 in this study. Quantitative real-time PCR (qPCR) was used to 
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determine the mRNA expression levels of acid-sensing proteins in RA-FLS under 
standard growth culture conditions with respect to the housekeeping genes GAPDH, 
B2M, and β-actin. The expression stability of these housekeeping genes was evaluated in 
RA-FLS by qPCR before examining the genes of interest. A master mix containing 
SYBR Green was used to measure cDNA amplification. The following primers were 
used to amplify cDNA of acid-sensing proteins: 
 
Gene  Forward Reverse 
ASIC3 CTCCCTGCCTTAACCTT AAGAAGCGAGAGAGAGTCAGT 
GPR4 TCCACAGACCGAGCCTTTTA CCAGAAAGCAACAGAGATAAGTAAC 
GPR68/OGR1 GTGCGGCATCCTCCTGTAC AACTGGTGGAAGCGGAACG 
TRPV1 CTGGACCAACATGCTCTACTAC AAACCCGAACAAGAAGACGAT 
 
The reaction mixture of SYBR Green, cDNA, primers, and RNase-free water were 
prepared in duplicate for each sample in 384-well plates. The plate was briefly 
centrifuged and loaded onto to ABI 7900HT device to quantify gene of interest. SDS 2.4 
software was used to set up 40 cycles of qPCR run and data collection. 
 
3.3.5.1 SYBR Green assessment 
SYBR Green is a non-specific fluorescent dye that will bind to any double-stranded DNA 
in the mixture of the reaction. It will detect primer dimers, genomic DNA, and PCR 
products that result from misannealed primers, which will interfere with the accuracy of 
the final result (King, 2010). To evaluate and assess the specificity of the primers and 
SYBR Green after each run of qPCR, two different methods are used. The first method is 
to analyse the PCR products by agarose gel electrophoresis. The presence of multiple 
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bands indicates contamination, while a single band that matches the predicted protein of 
interest size reflects a specific PCR reaction. The second, more precise method of 
contamination detection is a melt-curve analysis described by (Kochan et al., 2008). In 
this method, a high temperature 95°C is applied for one minute to denature the DNA 
strands and release the SYBR Green, decreasing the fluorescent signal. Then the 
temperature is dropped to 55°C and increased by 0.5 every 30 seconds from 55–95°C. 
During this process, SYBR Green will bind to any annealed DNA, and the resulting 
fluorescent signals are detected. A single peak reflects one product, while multiple peaks 
usually indicate multiple products. 
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3.4 Results 
3.4.1 Acid-sensing proteins are expressed in human RA synovial tissues 
The negative control (lung tissue treated with non-specific rabbit polyclonal iso-IgG) 
showed no staining indicative of the proteins of interest, while the positive control (lung 
tissue treated with specific, rabbit, polyclonal antibodies) displayed staining specific to 
all acid-sensing proteins (Figure 3.7). Immunohistochemistry (IHC-P) using ASIC3-, 
GPR4-, OGR1-, and TRPV1-specific primary antibodies showed expression of these 
proteins in different patterns in RA synovial tissue. All four acid-sensing proteins are 
distributed across the tissue and around the blood vessels, concentrated in the tissue 
lining as shown in Figures 3.8–3.11. 
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Figure ‎3.7 IHC-P positive and negative controls. 
Lung tissue sections were used as positive controls for all four acid-sensing molecules. 
Lung tissues treated with Iso-IgG only were used as negative controls. DAB stain was 
used to indicate the expression of acid-sensing proteins (brown colour), while 
haematoxylin is for the nuclear staining (purple colour). 
 
ASIC3 
GPR4 
OGR1 
TRPV1 
Positive controls 
ASIC3 OGR1 
GPR4 TRPV1 
Negative controls 
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Figure ‎3.8 Acid-sensing ion channel 3 expression in synovial tissue. 
ASIC3 was expressed around the blood vessels (arrows), close to the tissue lining. Within 
the tissue, ASIC3 expression was high in the fibrous regions, with clear areas around the 
vessels. ASIC3 was distributed over the entire tissue section, image (A). ASIC3 was 
expressed in tissue lining (4–6 cells thick) and concentrated in the inner and outer tissue 
lining, with moderate expression in the middle layer, image (B). These images are 
representative of four biological replicates (600 μm and 200 μm). 
  
ASIC3/SYNOVIAL TISSUE 
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Figure ‎3.9 G-protein coupled receptor 4 expression in synovial tissue. 
IHC-P showed high expression of GPCR4 in the outer issue lining layer, image (A). 
GPR4 was expressed throughout the synovium (A). Moreover, GPR4 expression 
concentrated around the blood vessels and distributed within the fibrous tissue between 
the vessels, image (B). These images are representative of four biological replicates (600 
μm and 100 μm). 
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Figure ‎3.10 G-protein coupled receptor 68 (OGR1) expressions in synovial tissue. 
GPR68 was expressed predominantly in the inner and outer layers of the synovium, with 
moderate to high expression in the middle layer (B).  Within fibrous tissues, GPR68 was 
expressed in the entire arthroscopic section (A) and around the blood vessels at different 
concentrations (B). Weak expression was visible around some blood vessels and high 
expression in the outer layer of tissue lining (B). These images are representative of four 
biological replicates (600 μm and 200 μm). 
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Figure ‎3.11 The vanilloid receptor 1 expressions in synovial tissue. 
TRPV1 is expressed around the blood vessels with a clear area (1–2 cells thick) between 
the vessels, and highly expressed in the outer and inner tissue lining layers, image. 
TRPV1 expression was distributed within the fibrous tissue and around some blood 
vessels (arrows), concentrated in the lining (A). TRPV1 expression was concentrated in 
the outer and inner edges of tissue lining, with low to moderate expression in the middle 
layer (B). These images are representative of four biological replicates (600 μm and 100 
μm).  
TRPV1/SYNOVIAL TISSUE 
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3.5 H-score of acid sensing proteins in lung tissue and RA synovial tissue 
GPR4 showed the highest expression in RA synovial tissue with a score of (211) and 
recorded 41% higher than its expression in lung tissue (H-score =149.5), followed by 
TRPV1 which is expressed 30% higher in lung tissue than in RA synovium with a score 
of (129). ASIC3 scored (91) in RA synovium, while the lung tissue showed 34% higher 
expression of ASIC3 than in synovium with score of (139). OGR1 showed lowest 
expression in RA synovial tissue with a score of (75) and (153) in the lung tissue, which 
reflects that OGR1 is expressed 50% higher in lung tissue than in RA synovial tissue. The 
results of acid sensing protein expression in lung and RA synovium tissue are not 
statistically significant. Data was calculated and analysed by GraphPad Prism 6 using 
two-tailed unpaired t-test. 
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Figure ‎3.12 H-score of Acid sensing protein (ASIC3) in lung and tissue and RA 
synovial tissue. 
 
ASIC3 is expressed 34% higher in lung tissue than in RA synovium. ASIC3 was 
distributed within the lung tissue including bronchioles and alveoli (arrows). The H-
SCORE method assigned a value of 0–300 to each protein, based on the percentage of 
cells stained at different intensities using automated method by Aperio system slide 
scanner and analysis of five random fields (n=4). 
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Figure ‎3.13 H-score of GPR4 in lung and tissue and RA synovial tissue. 
 
GPR4 showed about 41% higher expression in lung compared to the expression in RA 
synovial. GPR4 was expressed within the lung epithelial tissue and around alveoli, while 
it concentrated in the lining of the synovial tissue with mild to expression around the 
blood vessels (n=4). 
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 Figure ‎3.14 H-score of OGR1 in lung and tissue and RA synovial tissue. 
 
OGR1 is expressed more in lung tissue than in RA synovium. OGR1 distributed within 
the lung tissue and around bronchioles and alveoli. While in RA synovium it is indicated 
in the tissue lining layers with low expression around the blood vessels (n=4). 
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Figure ‎3.15 H-score of OGR1 in lung and tissue and RA synovial tissue 
 
TRPV1 shows higher H-score in lung tissue compared to RA synovial tissue. TRPV1 
expression is highly expressed within the epithelial tissue, around bronchioles and 
alveoli. TRPV1 in RA synovium is mildly distributed within the tissue and around the 
blood vessels while highly expressed in the tissue lining layers (n=4). 
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3.5.1 Acid-sensing proteins are expressed in RA-FLS, which reside in the synovial 
tissue lining 
IHC-P data showed the expression of acid-sensing proteins in the synovium; however, 
the identity of the cells that expressed these proteins remains unknown. IF was used to 
determine the tissue localisation of acid-sensing proteins in synovium. These data showed 
that FLS reside in synovial tissue lining (Figure 3.16) A&B, with low localisation within 
the tissue shown in green (Alexa Fluor 488) (B). In addition, acid-sensing proteins, red 
(Alexa Fluor 594) co-localised with the FLS in the RA synovium. ASIC3 was expressed 
mainly on the cell membrane and the cytoplasm (represented by yellow colour) (Figure 
3.17). GPR4 (Figure 3.18), OGR1 (Figure 3.19), and TRPV1 (Figure 3.20) were highly 
expressed in the nucleus (pink colour), with moderate to high expression on the cell 
surface and in the cytoplasm. Other types of unknown immune cells that expressed acid-
sensing proteins were detected in RA synovium as illustrated by the arrow in figures 
(3.18-3.20).  
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Figure ‎3.16 Detection of FLS in the RA synovium. 
Synovial tissue was treated with nuclear DAPI stain and Alexa Fluor 488 to target the 
FLS surface protein, 1B10. FLS were distributed over the entire synovial tissue section 
(A). The FLS surface protein was highly expressed in the tissue lining, where FLS reside 
(B). These images are representative of four biological replicates. 
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Figure ‎3.17 Co-localisation of the FLS surface marker 1B10 and ASIC3. 
ASIC3 is highly expressed in the FLS of the RA synovial tissue. ASIC3 and FLS surface 
proteins are concentrated in the synovial tissue lining (yellow colour in merged image). 
These images are representative of four biological replicates. 
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Figure ‎3.18 Co-localisation of the FLS surface marker 1B10 and GPR4 in RA 
synovial tissue. 
GPR4 was expressed in the tissue lining where FLS were found, the expression is nuclear 
(pink colour) and surficial (yellow). Additionally, other types of cells were expressing 
GPR4 in the synovium . These images are representative of four biological replicates. 
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Figure ‎3.19 Co-localisation of the FLS surface marker 1B10 and OGR1 in RA 
synovium. 
OGR1 (red) is predominantly expressed in the synovial tissue lining with mild expression 
within the synovium. OGR1 expression was detected in RA-FLS and other types of cells 
in the synovium as illustrated by the arrow. Co-localisation is depicted by yellow colour. 
These images are representative of four biological replicates. 
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Figure ‎3.20 Localisation of FLS marker surface protein (1B10) and TRPV1 in 
synovial tissue. 
TRPV1 was expressed in the tissue lining, with mild to low expression within the nuclear 
(pink) and surface (yellow, in the merged image) regions of RA-FLS. TRPV1 was 
detected in other immune cells than RA FLS in the synovium. These images are 
representative of four biological replicates. 
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3.5.2 Validation of primers for acid-sensing proteins and housekeeping genes 
expression by using RT-PCR reaction 
According to MIQUE guidelines, qPCR efficiency is highly dependent on the validity of 
the primers used in the reaction (Bustin et al., 2009). To test primer efficiencies for this 
study, standard curves were constructed from 10-fold serial dilutions of known copy 
numbers of the genes of interest (Figure 3.21). The qPCR reaction efficiency was 
calculated with the equation: (Efficiency = -1 + 10
(-1/slope)
). ASIC3 primer efficiency was 
94.06%, with a calculated slope of -3.473. GPR4 primer efficiency was 94.25%, with a 
calculate slope of -3.468. The OGR1 and TRPV1 primer sets has efficiencies of 103.94% 
and 95.07%, respectively. Their respective slopes were -3.231 and -3.446. The 
efficiencies of the two housekeeping gene primer sets (for GAPDH and B2M) were 
103.67% and 104.98%, respectively. Their respective slopes were -3.237 and -3.208. 
Acceptable amplification efficiencies range from 90% to 110% (D'Haene et al., 2010). 
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Figure ‎3.21 Standard curves for primer efficiency 
Curves were constructed from a known copy number of genes of interest and two 
housekeeping genes, GAPDH and B2M. Ten-fold serial dilutions of target genes 
templates were assayed using real-time PCR and SYBR Green. 
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3.5.3 SYBR Green assessment after qPCR runs 
Melt-curve analysis following qPCR shows a single peak for each amplicon (denoting the 
target gene). This result reflects the specificity of the primers and excludes interference 
from genomic DNA or primer dimers. 
 
 
 
 
Figure ‎3.22 Disassociation curve results following qPCR reaction. 
Each qPCR reaction was evaluated by melt curve analysis to determine SYBR Green 
specificity and identify any contamination with genomic DNA or primer dimers. 
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3.5.4 Expression of ASIC3, GPR4, OGR1 and TRPV1 in OA- and RA-FLS 
All acid-sensing proteins of interest were expressed at the mRNA level in both OA- and 
RA-FLS. The gene with the highest expression was OGR1, with ΔCT (-10,-12) in OA and 
(-5,-7) in RA FLS (Figures 3.23 and 3.24). TRPV1 was reported to have the lowest 
expression at mRNA in both OA and RA FLS, with ΔCT (-15,-19) and (-11,-14), 
respectively (Figures 3.23 and 3.24). The ΔCT values were calculated relatively to 
GAPDH. Data were collected and analysed by SDS 2.2 and GraphPad Prism 6 software. 
 
 
Figure ‎3.23 Expression of acid-sensing proteins in OA-FLS. 
Total RNA was extracted from OA-FLS under normal cell culture conditions. RNA was 
reverse-transcribed, and cDNA for acid-sensing proteins ASIC3, GPR4, OGR1, and 
TRPV1 were measured using qPCR. All four acid-sensing proteins were detected at the 
mRNA level. Expression data are reported relative to the housekeeping gene, GAPDH 
(n=3). 
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Figure ‎3.24 Expression of acid-sensing proteins in RA-FLS. 
Total RNA was extracted from synovial FLS under maintenance cell culture conditions 
(described in the materials and methods section). RNA was reverse-transcribed, and 
cDNA for acid-sensing proteins ASIC3, GPR4, OGR1, and TRPV1 were measured using 
qPCR. All four acid-sensing proteins were detected at the mRNA level. Expression data 
are reported relative to the housekeeping gene, GAPDH (n=5). 
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3.5.5 Variation of acid-sensing protein expression mRNA in RA and OA 
Results of qPCR showed that the expression of acid-sensing mRNA molecules was 
significantly higher in RA-FLS (n=3) than in OA-FLS (n=3) with P ≤ 0.0001 (Figure 
3.25). The mRNA was extracted from OA- and RA-FLS and converted to cDNA at a 
final concentration of 10 ng. This cDNA library was used for qPCR analysis. Averages of 
ΔCT were calculated and analysed by GraphPad Prism 6 using two-way analysis of 
variance (two-way ANOVA) and the Sidak's multiple comparisons test.  
 
 
Figure ‎3.25 Expression of acid-sensing proteins at mRNA level in OA and RA-FLS. 
The data above demonstrates the variation in the expression of ASIC3, GPR4, OGR1 and 
TRPV1 at mRNA level in OA and RA-FLS. Data was analysed using two-way ANOVA, 
P ≤ 0.0001 for all acid-sensing proteins. Data are presented as mean ± SEM. OA, n=3; 
RA, n=3. 
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3.5.6 TNF has no effect on acid-sensing proteins expression in RA-FLS 
The qPCR data shows no significant alteration for ASIC3 and OGR1. GPR4 showed a 
slight but not significant increase after the incubation RA-FLS with 10ng/ml TNF for 24 
hours. TRPV1 was insignificantly increased after 30 min of TNF and gradually reduced 
with the time up to 24 hrs. Data was calculated and analysed by GraphPad Prism 6 using 
two-tailed paired t-test. 
 
 
Figure ‎3.26 Acid-sensing protein expression in RA-FLS after treatment with TNF at 
different time points 
The qPCR data analysis shows insignificant upregulation of acid sensing proteins (GPR4 
and TRPV1) expression at mRNA level in RA-FLS treated with 10 ng/ml TNF as 
compared to untreated RA-FLS. Data are presented as mean ± SEM (n=4). 
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3.6 Discussion 
From biopsies we have examined, our data suggest that at least four independent 
mechanisms for sensing acid exist in the RA synovium at the protein level. ASIC3, 
GPR4, OGR1, and TRPV1 were detected at the mRNA and protein levels in synovial 
biopsies and in RA-FLS. All four of the proteins were present in the synovial lining layer, 
which is where the FLS reside. However, the expression levels are varied between the 
proteins. GPR4 and TRPV1 were present in the majority of cells, whereas OGR1 and 
ASIC3 were detected in approximately one-third of cells. Moreover, ASIC3 expression in 
lung tissue was also detected in a previous study, which concluded that cystic fibrosis 
transmembrane conductance regulator (CFTR) and ASIC3 down-regulate each other and 
contribute to sodium reabsorption in cystic fibrosis epithelia (Su et al., 2006). Another 
study reported that TRPV1 activation by endogenous agonists may contribute to the 
induction of lung cell death (Thomas et al., 2007). Furthermore, the expression and 
involvement of OGR1 and GPR4 in lung were detected, and these proteins were 
described as inflammatory proton-sensing receptors (Tsurumaki et al., 2015). In our study 
we also detected the expression of these acid sensing proteins in lung tissue. The 
expression of these proteins (other than GPR4) was higher in the lung than in RA 
synovium. Specifically, H-SCORE analysis showed that ASIC3 expression was 34% 
higher in the lung than in the RA synovium, OGR1 expression was 50% higher in the 
lung, and TRPV1 expression was 30% higher in the lung. In contrast, GPR4 was the only 
ion channel among the proteins of interest with higher expression in RA synovial tissues 
(41% higher than in lung tissue).   
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Synovial tissue is complex and composed of different types of immune cells such as FLS, 
macrophages, and dendritic cells. The IF analysis shows that FLS cells are highly 
concentrated in RA-synovial tissue lining (Figure 3.16), where all four acid-sensing 
proteins are presented. Localisation of acid-sensing proteins in synoviocytes is varied. 
ASIC3 is expressed mainly on the surface and in the cytoplasm of RA-FLS, with low 
nuclear expression. GPR4 expression was high on the cell surface and in the cytoplasm 
with medium expression in the nucleus. In contrast, OGR1 and TRPV1 are expressed 
moderately on the cell surface and in the nucleus. Interestingly, our data showed that 
ASIC3, GPR4, OGR1 and TRPV1 were also expressed by other types of cells of the 
synovium. However, the identity of these cell types remains unknown. Previous studies 
have reported the expression of these acid-sensing proteins in other immune cells, such as 
dendritic cells (Tong et al., 2011). While TRPV1 is expressed in both macrophages and 
dendritic cells (Linscheid et al., 2004, Toth et al., 2009). Although this study focussed on 
fibroblasts like synoviocytes, the identity of these other cells expressing acid-sensing 
proteins in the synovium is an important future research direction. Our qPCR results 
show the expression of these proteins at the mRNA level in OA- and RA-FLS. All acid-
sensing proteins were detected at the mRNA level; however, the abundance of these 
transcripts varied. For both OA- and RA-FLS, OGR1 mRNA expression was highest. 
GPR4 and ASIC3 mRNAs are expressed in similar abundance, followed by TRPV1, with 
the lowest level of expression in both OA- and RA-FLS. It has been reported that TNF 
induces glucose uptake and lactate production in different types of cells such as Sertoli 
cells, muscle cells, and adipocytes (Nehar et al., 1997, Boussouar et al., 1999, Porter et 
al., 2002, Remels et al., 2015). Although acidification is enhanced by TNF, our data 
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showed that TNF slightly altered the expression of GPR4 and TRPV1 at the mRNA level 
in RA-FLS; however, this effect was not significant. The expression of ASIC3 and OGR1 
was not changed after TNF treatment. 
By comparing IHC-P data with the expression at mRNA by qPCR, we can conclude that 
the expression of acid-sensing proteins is inconsistent between the protein mRNA levels. 
It is possible that this inconsistency is due to different types of cells that express acid-
sensing proteins in the synovium, such as macrophages and dendritic cells. At the mRNA 
level, the expression of these proteins was investigated in only RA-FLS. Moreover, dual 
immunofluorescence staining of acid-sensing proteins and FLS in RA synovium showed 
that other, unknown cell types expressed acid-sensing proteins. Finally, synovial tissue 
and RA-FLS samples were collected from different patients, which may explain the 
observed inconsistencies. 
The raw qPCR data show variation in the expression of acid-sensing proteins at mRNA 
level between OA- and RA-FLS. Our data indicate that the expression of ASIC3, OGR1, 
GPR4, and TRPV1 is higher in RA-FLS than in OA-FLS. Interestingly, the expression 
variation between OGR1, GPR4, and TRPV1 in OA-FLS is similar to the expression 
variation among these proteins in RA-FLS. 
In conclusion, this histological study demonstrates that ASIC3, GPR4, OGR1, and 
TRPV1 are differentially expressed in the RA synovium. These acid-sensing molecules 
are expressed by FLS and other types of cells in the synovium. qPCR data demonstrate 
that the expression of acid-sensing proteins ASIC3, GPR4, OGR1, and TRPV1 is greater 
in RA-FLS than in OA-FLS. Thus, consistent with our hypothesis, our results show that 
acid-sensing proteins are expressed in RA synovial biopsies, and the genes are expressed 
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at the mRNA level in RA-FLS patients. Moreover, mRNA levels of these proteins are 
higher in RA-FLS than in OA-FLS.  
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4 Chapter 4: Effect of acidification on the expression of acid-sensing proteins and 
MMPs in RA-FLS 
 
4.1 Introduction 
The pH of tissue and blood is maintained at 7.4 under normal physiological conditions. 
However, various studies have shown that acidosis correlates with injuries and various 
diseases. For example, cerebral ischemia can drop extracellular pH to 6.3 and below 
(Siesjo et al., 1996), while in severe cardiac ischemia, the extracellular pH drops to 6.7 
(Cobbe and Poole-Wilson, 1980, Cobbe et al., 1982). Moreover, pH 7.2 was reported in 
other kinds of systemic acidosis, although these examples did not have accompanying 
pain sensation (Sutherland et al., 2001). Finally, tumour microenvironment was described 
as an acidic space with pH range 5.5 to 7.0 (Vaupel et al., 1989, Gatenby and Gillies, 
2004, Yan et al., 2014). 
 
In all of above studies, lactic acid was described as the primary metabolite produced in 
response to low oxygen, which reduces the physiological pH of the extracellular 
microenvironment and enhances acidosis. The molecular identity of different acid sensors 
has been described in correlation with acidosis. In rat cardiac sensory neurons, ASIC3 
has high sensitivity to acid pH 7.0 with a very steep activation curve when pH dropped to 
6.7 (Sutherland et al., 2001). With regards GPCRs, sphingosylphosphorylcholine (SPC), 
lysophosphatidylcholine (LPC), and psychosine were described as agonists for GPR4 and 
OGR1 (Zhu et al., 2001); however, this finding has been challenged by Seuwen and 
colleagues, who showed that GPR4 and OGR1 are unaffected by SPC or LPC 
concentration (Seuwen et al., 2006). For the vanilloid receptor, research suggests that H
+
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is a major participant that induces TRPV1 activity. One study has described that 
extracellular pH 6.7 can activate the TRPV1 channel at body temperature (37.4°C) (Jordt 
et al., 2000), while further acidification to pH <6.0 is needed to activate the channel at 
room temperature (Tominaga et al., 1998). 
 
As mentioned in the introduction, poor blood perfusion and hypoxia lead to H
+
 export 
and lactic acid production, which creates an acidic microenvironment in RA 
inflammatory joints. Recently, the effect of low pH on acid-sensing proteins activity was 
described. ASIC3 is permeable to Ca
++
 and activated under pH 5.5. Furthermore, the 
intracellular Ca
++
 concentration in FLS from ASIC3
+/+
 mice was greater than in FLS from 
ASIC3
-/-
 mice at pH 5.5 (Kolker et al., 2010). On the other hand, a second study has 
shown that the intracellular Ca
++
 was significantly higher in human FLS treated with IL-
1B at pH 6.0 compared to FLS incubated at pH 6.0 alone (Gong et al., 2014). TRPV1 
activation by capsaicin showed a significant increase in cytosolic Ca
++
 concentration in 
human synoviocytes at pH 7.0‒7.2 (Kochukov et al., 2006). GPCRs responded to H+ by 
increasing intracellular calcium mobilization at various pH conditions and induction of IP 
production in cultured SW982 synoviocytes, with maximum production at pH 6.8 
(Christensen et al., 2005a, Kochukov et al., 2006). 
 
The previous studies of acid-sensing molecules have been focussed primarily on 
identifying these molecules in RA-FLS and investigating the activities of these proteins 
under low pH. However, it is possible that acid-sensing protein expression may vary 
under different acidic conditions, in addition to the activity. 
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 Bartok and Firestein have described FLS as potential cellular players in the pathogenesis 
of RA by contributing to the local production of inflammatory modulators, cytokines, and 
proteolytic enzymes that induce bone resorption (Bartok and Firestein, 2010). In addition, 
cathepsins K&L expression can be induced by cytokines, such as TNF and IL-1 (Bartok 
and Firestein, 2010). Another study in a severe combined immunodeficiency mouse 
model (SCID) has identified that reduction in mRNA expression for either cathepsin K or 
L in FLS reduces cartilage destruction and invasion (Pierer et al., 2003). Matrix 
metalloproteases were described as effective players in bone degradation. A study in 
2002 investigated the expression of MMPs 1–14, 17, 19 in RA and OA patients and 
concluded that expression of MMP-1, MMP-3, MMP-9, and MMP-10 in FLS enhances 
the invasiveness of the cells (Tolboom et al., 2002). Additionally, MMP-1 and MMP-9 
are expressed in both RA and OA; however, the expression of these two enzymes was 
significantly higher in RA-FLS than in OA-FLS (Tolboom et al., 2002). This same study 
concluded that MMP-3 and MMP-10 expression does not correlate significantly with RA. 
MMP-1, MMP-3, and MMP-13 expression has been reported in the lining layer cells, 
where FLS and macrophages reside (Firestein et al., 1991, Lindy et al., 1997). In addition 
to MMPs, a group of metallopeptidases related to ADAMs, ADAMTS-4 and ADAMTS-
4, were identified at mRNA level in bovine synovium and human OA synovium (Kaushal 
and Shah, 2000, Vankemmelbeke et al., 2001). ADAMTS-5 proteinases may contribute 
in cartilage destruction in the synovium; however, the process of this breakdown is 
unknown (Vankemmelbeke et al., 2001). As described in main introduction, RANK and 
RANKL upregulation is induced by proinflammatory cytokines, such as interleukins and 
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TNF. These cytokines enhance osteoclast differentiation and increase rate of bone 
degradation rate in RA as described in the main introduction. The involvement of 
RANK/RANKL in bone destruction was reduced when IL-1, TNF, and IL-17 were 
inhibited (Page and Miossec, 2005). Despite these important finding, it is not known 
whether extracellular acidosis influences the expression of acid-sensing proteins or other 
bone or cartilage destruction modulators in RA-FLS. 
 
4.2 Hypothesis 
Based on the data above, we hypothesized that the acidified milieu of the RA joint alters 
the expression of acid-sensing proteins MMP-1, -3, -9, and -14, cathepsin K, ADAMTS-
5, and RANKL at the mRNA level in RA-FLS. 
 
4.3 Methods 
4.3.1 RA-FLS viability after the treatment MEM acidified by lactic acid at pH 7.4, 
7.0, 6.5, and 6.0 
1.5 × 10
5
 RA-FLS were seeded in T-25 flasks using DMEM GlutaMAX with 10% FBS, 
1% penicillin and streptomycin, and then they were incubated in 5% CO2 at 37°C. At 
80‒90% confluency, the cells were washing with PBS and placed in serum-free medium, 
then incubated under normal culture conditions for 24 h. Serum-starved medium was 
replaced with MEM acidified with lactic acid buffered to at pH 7.4, 6.5, or pH 6.0 with 
10% FBS, 1% penicillin, 1% streptomycin, and 1% glutamine, and then cells were 
incubated in 5% CO2 at 37°C for 24 h. After incubation, RA-FLS were harvested and 
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counted with a haemocytometer using trypan blue as described in material and methods 
section. 
4.3.2 Validation of primers for MMP -1, -3, and -9, CathK, RANKL, and 
ADAMTS-5 genes expression by using RT-PCR reaction 
Primers of bone modulator genes described in the table below were purchased from 
Primerdesign Ltd. The primers were designed without regards to intron-exon boundaries, 
as this is restrictive, and the most efficient location for the primers may not be on an 
exon-exon junction. However, to prevent gDNA contamination, the mRNA samples were 
treated with precision DNase, as described in the Material and Methods section. 
Gene Forward Reverse 
MMP-1 GCACTGGAGAAAGAAGACAAAGG CTAAGTCCACATCTTGTCTTG 
MMP-3 ATGAACAATGGACAAAGGATAC AGTGTTGGCTGAGTGAAAGAG 
MMP-9 CTTCCAGTACCGAGAGAAAGC CAGGATGTCATAGGTCACGTAG 
MMP-14 TCGCAGTCAGTCAAGTTCCT CCCATCCAAGGCTAACATTCG 
Cath K ACTGCCTCCTTCCCTCCTC GGGTGCTAGATTTATTCCATCGG 
RANKL AAAGATGTATATAGGTGTGTGAGACT CTCCCACTGGCTGTAAATACG 
ADAMTS-5 GCAGCACCAACACAACCAG CCAGGGTGTCACATGAATGATG 
 
Table forward and reverse primers of bone modulator genes (MMP-1, MMP-3, MMP-9, 
MMP-14, CathK, RANKL, ADAMTS-5) that were used for the qPCR assay.  
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4.3.3 Detection of acid-sensing proteins MMP1, MMP-3, MMP-9, MMP-14 and 
bone degradation modulators cathepsin K, RANKL and ADAMTS-5 
expression at mRNA in RA-FLS by real-time PCR 
RA-FLS exposed to different acidic conditions were harvested, and mRNA was 
extracted, and cDNA was synthesized as described in section 2.12. Samples were 
prepared in 384-well plate using MasterMix with SYBR Green with primers for each 
gene of interest. Each sample was run in duplicate using ABI Prism 7900HT Sequence 
Detection System (Applied Biosystems SDS). Data were collected and analysed using 
SDS 2.2 and GraphPad Prism software. Dissociation curve analysis was used after each 
qPCR run to check for any genomic DNA or primer dimers in the samples. 
 
4.3.4 Migration of RA-FLS under low pH conditions using Oris 96-well plates with 
stoppers 
RA-FLS (2×104) were seeded in Oris 96-well plates, and the migration assay was 
performed as described in section 2.20. Migrated cells were counted and Graph Pad 
Prism was used to analyse the data collected. 
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4.4 Results 
4.4.1 Evaluation of primers efficiency by using RT-PCR reaction 
All evaluated primers showed efficiency within the acceptable rage (90%–110%: MMP-1 
(slope = -3.543 with 91.53% efficiency), MMP-3 (slope = -3.182 with 106.9% 
efficiency), MMP-9 (slope = -3.027 with 113.97% efficiency), RANKL (slope = -3.531 
with 91.96% efficiency), CathK (slope = -3.412 with 96.37 %), and ADAMTS-5 (slope = 
-3.159 with 107.29% efficiency).    
 
 
Figure ‎4.1 Standard curves for primer efficiency. 
Curves were constructed from a known copy number of MMP-1, MMP-3, MMP-9, 
RANKL, CathK, and ADAMTS-5 genes. Ten-fold serial dilutions of target gene templates 
were assayed using real-time PCR and SYBR Green.  
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4.4.2 Expression of acid-sensing proteins, MMPs, Cathepsin K, RANKL and 
ADAMTS-5 in RA-FLS after the treatment with different acidic conditions 
for 24 hours 
The mRNA expression of acid-sensing proteins in RA-FLS was not significantly 
increased at pH <7.4 compared to physiological pH 7.4 (Figure 4.2). However, MMP-1 
expression increased by 3.6- (P ≤ 0.01), 1.8- (P ≤ 0.05), and 2.2-fold (P ≤ 0.01) at pH 7.0, 
6.5, and 6.0, respectively (Figure 4.3). MMP-3 expression increased by 2.3-fold at pH 7.0 
and 1.7-fold at pH 6.5 with P value ≤ 0.05, but no significant increase was found at pH 
6.0 (Figure 4.3). MMP-9 was increased by 4.9-fold at pH 7.0 (P ≤ 0.01), 3.2-fold at pH 
6.5 (P ≤ 0.01), and 1.7-fold at pH 6.0 with P value ≤ 0.05. MMP-14 and the other bone 
and cartilage modulators, Cathepsin K, RANKL, ADAMTS-5 was not significantly 
altered in RA-FLS treated with acidified medium for 24 hours (Figure 4.4). Western blot 
analysis showed an increase in MMP-9 expression in culture medium at pH 7.0 and pH 
6.5, while in cell lysates, the increase was observed at pH 7.0 compared with the control 
(Figure 4.3). GraphPad Prism and SDS 2.4 software was used to collect and analyse data 
using a non-parametric paired two-tailed t-test. 
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Figure ‎4.2 Expression of acid-sensing proteins. 
Real-time PCR data showed the expression of four different acid-sensing molecules 
ASIC3, GPR4, OGR1, and TRPV1 in RA-FLS treated with acidified medium at pH 7.0, 
6.5, and 6.0 for 24 hours. The expression levels were measured relative to the 
housekeeping gene GAPDH and compared to control RA-FLS treated at pH 7.4. The 
qPCR data analysis showed no significant increase in acid-sensing protein expression in 
RA-FLS after the treatment with acidified medium. The two-tailed paired t-test was used 
and data are presented as mean ± SEM. n = 15, ns = P > 0.05. 
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Figure ‎4.3 Expression of matrix metalloproteases in RA-FLS after the induction of 
acidic condition. 
Data of qPCR showed a significant increase in MMP-1 and MMP-9 expression at low 
pH, while MMP-3 expression was not significantly altered at pH 6.0. MMP-14 showed a 
non-significant increase after treatment with acidified medium. WB showed an increase 
in MMP-9 in the culture medium at pH 7.0 and 6.5 respectively and at pH 7.0 in the cell 
lysate. Data were analysed using two-tailed t-test and presented as mean ± SEM. n = 10, 
ns = P > 0.05, * = P ≤ 0.05, and ** = P ≤ 0.01.  
160 
 
 
 
 
Figure ‎4.4 Expression of bone and cartilage modulators at the mRNA level in RA-
FLS under low pH. 
The expression of cathepsin K, RANKL, and ADAMTS-5 in RA-FLS was evaluated 
after incubation in acidified culture medium (pH 7.4, 7.0, 6.5, and 6.0) for 24 hours. The 
mRNA was extracted, reverse-transcribed to cDNA, and analysed by qPCR relative to 
GAPDH expression. None of the tested bone modulators was altered at the mRNA level 
at low pH. Results were analysed using SDS 2.4 and GraphPad Prism. Two-tailed paired 
t-test was used, and data are presented mean ± SEM (n = 10, ns = P > 0.05). 
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Figure ‎4.5 ΔCT variation in the expression of MMP-1 and MMP-9 in OA- and RA-
FLS. 
Real-time PCR showed a significant increase in the expression of MMP-1 and MMP-9 in 
RA-FLS compared to the expression of these proteases in OA-FLS with P ≤ 0.05 and P ≤ 
0.01 respectively. Expression data were analysed relative to the housekeeping gene, 
B2M. Data were collected and analysed with GraphPad Prism by two-way ANOVA. 
Data are presented as mean ± SEM. n=3. 
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4.4.3 Migration of RA-FLS under different acidic conditions 
In Oris 96-well plates, RA-FLS migration after 24 h incubation showed a gradual 
reduction at pH 7.0, pH 6.5, and pH 6.0 compared to cells incubated at pH 7.4 (Figure 4.6 
and 4.7). Average number of cells migrated at neutral pH was 153, while it was 143 at pH 
7.0. Migration was significantly reduced at pH 6.5 and 6.0 with 105 and 55 migrated cells 
and P value > 0.05 & 0.001, respectively as shown in (Figure 4.7). RA-FLS from three 
different donors were tested. Data was collected and analysed by GraphPad Prism using 
one-way ANOVA. 
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 RA-FLS Day 1 RA-FLS Day 4 
 
Control 
pH 7.4 
 
  
 
pH 7.0 
  
 
pH 6.5 
  
 
pH 6.0 
  
 
Figure ‎4.6 RA-FLS migration under acidic conditions. 
RA-FLS were seeded (2.5 × 10
4
 to 3.0 × 10
4
) and allowed to adhere. Stoppers were 
removed and different acidic conditions were induced for 24 h. CellTracker™ Green 
CMFDA (5-chloromethylfluorescein diacetate) was used to monitor RA-FLS migration 
after four days (n = 3). 
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Figure ‎4.7 Average number of migrated RA-FLS in Oris 96-well plate. 
The average number of migrated cells was calculated after incubation in acidified 
medium for 24 h, and then the data were analysed by GraphPad Prism using one-way 
ANOVA. Results are presented as mean ± SEM, where * = P ≤ 0.05 and *** = P ≤ 0.001 
(n =3). 
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4.5 Discussion 
The qPCR data revealed an insignificant increase in the expression of acid-sensing 
proteins in RA-FLS exposed to conditioned medium at pH 7.0, 6.5, and 6.0. OGR1 
expression increased gradually, up to 2-fold, (Figure 4.1) compared to the expression in 
control RA-FLS maintained at pH 7.4. MMP-1 and MMP-9 exhibited a significant 
increase in cells from RA patients compared to OA patients, and that observation 
coincides with our findings (Figure 4.2). After treatment in acidified medium, cultured 
RA-FLS increased expression of MMP-1 at pH 7.0, 6.5, and 6.0. The maximum 
expression for MMP-9 was at pH 7.0; however, this increase gradually diminished by 
two-fold as the pH continued to decrease (Figure 4.2). A previous stud has shown no 
significant increase in MMP-3 expression in RA patients (Tolboom et al., 2002); 
however, our qPCR data suggest that MMP-3 expression increased in RA-FLS at pH 7.0 
and pH 6.5, but not at pH 6.0. A recent study on the role of ASIC3 showed that MMP-3 
and MMP-13 expression did not increase significantly in FLS incubated at pH 6.0 
compared to those incubated at pH 7.4, even after IL-1B induction (Gong et al., 2014). 
Our results of MMP-3 expression were consistent with that finding. Previously, ASIC3 
was shown to suppress MMP-3 and MMP-13 mRNA expression in FLS at pH 6.0 (Sluka 
et al., 2013), and our result with MMP-3 has shown no significant increase. However, we 
report a slight, albeit significant, increase in MMP-3 expression at pH 7.0 and 6.5 
compared to the expression at physiological pH. ASIC3 is the most sensitive among 
ASICs at pH ≈ 6.7 (Sutherland et al., 2001), and that sensitivity may contribute to the 
reduced expression we observed at pH 6.5. MMP-14 expression was unaltered in RA-
FLS under acidic conditions. As mentioned in the introduction, Cathepsin K, RANKL, 
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and ADAMTS 5 are expressed in the synovium and play a pivotal role in the involvement 
of bone and cartilage destruction. Our data show that there was no significant increase in 
the expression of any of these molecules in RA-FLS. 
A recent investigation of human FLS migration showed a significant increase of MMP-1, 
MMP-2, and MMP-13 expression in FLS after the induction of a canonical Wnt 
antagonist, Dickkopf-1 (DKK-1). This study concluded that DKK-1 enhances FLS 
migration, as well as MMP-1 and -13 expression, via JNK phosphorylation and JNK-2 
signalling process. However, MMP-9 and MMP-3 expression was decreased under the 
same conditions. A second study reported that the inhibition of PI3K/AKT activity via 
sphingosine kinase 1 (SPHK1) knockdown in RA-FLS reduces MMP-9 and MMP-2 
expression and inhibits the migration and invasion of human RA-FLS (Yuan et al., 
2014b). Our results show a significant reduction of RA-FLS migration at pH 6.5 and pH 
6.0, but no significant changes in migration at pH 7.0 compared to pH 7.4 (Figure 4.5 & 
4.6). Altogether, these data suggest that the acidic environment hinders RA-FLS 
migration and enhances the production of MMP1, MMP-3, and MMP-9 in RA-FLS 
independently of the hypoxia. 
Previous studies investigated the invasiveness of RA-FLS via MMP activity and 
suggested that MMPs play a role in the invasive growth of FLS and may contribute to 
bone and cartilage degradation in RA (Tolboom et al., 2002, Zhu et al., 2006). However, 
in our study we investigated the roles of specific members of the MMP family (MMP-1, -
3, -9, and -14). Because MMPs have poor substrate sequence specificity, it is difficult to 
use a peptide substrate alone to differentiate the activity of a specific MMP from other 
MMPs. Therefore, we used a plate pre-coated with antibodies targeting a particular 
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MMP. AnaSpec provides assay kits designed to detect the activity of a specific MMP. A 
monoclonal human MMP antibody is used to pull down both pro and active MMP forms 
from the sample, and proteolytic activity is detected by using a 5-FAM/QXL™ 520 
FRET peptide. However, for this assay medium without phenol red and sodium 
bicarbonate is needed. Because RA-FLS are optimized to grow in DMEM and MEM 
medium, which contain phenol red, we could not perform MMP activity assays. 
Moreover, the quantities of primary RA-FLS were limited, so we used the available cells 
to perform other experiments such as qPCR, western blot, and migration assays under 
various acidic conditions. 
At pH 5.5, a rapid increase of intracellular calcium was observed in cultured FLS from 
ASIC3
+/+
 mice compared to those from ASIC3
-/-
 mice. The expression of MMP-3 and 
MMP-13 in ASIC3 knockdown FLS was significantly higher at pH 6.0 (Kolker et al., 
2010, Sluka et al., 2013). TRPV1 also alters expression of MMP-1 in human 
keratinocytes, and an influx of Ca
2+
 and involvement of PKC signal transduction may 
contribute in this process (Lee et al., 2008). The combination of low pH (7.1‒7.2) and 
capsaicin showed a potential increase in cytosolic calcium in synoviocytes via activity of 
TRPV1 (Kochukov et al., 2006). Another contribution of GPCRs in response to 
extracellular acidification and increase intracellular Ca
2+ 
mobilization in synoviocytes 
was reported by (Christensen et al., 2005a). This study suggested a modest and high 
intracellular Ca
2+ 
mobilization at pH 6.8 and pH 6.4 respectively with high generation of 
IP. Moreover, It has been found that activation of GPCRs by homocysteine induced 
PTKs, Ca
2+
-dependent PKC, and oxidative stress signal transduction process which 
induce ERK1/2 signalling pathway and regulate MMP-9 activity in microvascular 
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endothelial cells (Moshal et al., 2006). Taken together, these data suggest that 
intracellular calcium influx via acid-sensing protein activity modulates various 
intercellular signalling pathways and enhances the production of MMPs in RA-FLS in an 
acidic microenvironment. In our study, we reported increases in MMP-1, MMP-3, and 
MMP-9 and reduction of RA-FLS migration under acidic conditions. Moreover, we 
reported no significant increase of acid-sensing protein expression that would suggest the 
enhancement of MMP expression is mediated by the activity of acid-sensing molecules 
under acidic conditions. 
The findings reported in this section show acidification alters the migration of RA-FLS. 
However, it is unclear which types of acid-sensing proteins are most involved in this 
process. In order to answer this question, we used selective ASIC3 and TRPV1 
pharmacological inhibitors to test the expression of MMPs and investigate the RA-FLS 
migration rate. 
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5 Chapter 5: Use of pharmacological inhibitors APETX2 and AMG517 to 
investigate the roles of ASIC3 and TRPV1 in MMP modulation under acidic 
conditions 
 
5.1 Introduction 
The involvement of acid-sensing proteins in bone resorption and cartilage destruction of 
the RA joint remains unknown. There is accumulating evidence that ASIC3 is involved in 
the pathogenesis of RA. In a murine model of arthritis, ASIC3 was described as a 
protective molecule that enhances FLS death in RA joints and prevents excessive 
inflammation (Sluka et al., 2013). Additionally, ASIC3 was described as the most 
sensitive of the ASICs to acidic pH (6.7) in sensory neurons, and it has been reported that 
responsiveness to pain simulation was reduced in ASIC3
-/-
 mice compared to wild type 
(Sutherland et al., 2001, Sluka et al., 2013). The sensitivity of this channel to pH is 
attributed to residues Phe20 and Thr25 in the intracellular pre-TM1 domain and Gly430 
in the extracellular pre-TM2 domain (Yuan et al., 2010a).  
On the other hand, under acute inflammatory conditions, hyperalgesia to noxious heat 
produced by carrageenan induction was significantly inhibited in TRPV1-/- mice relative 
to the wild type (Davis et al., 2000). In contrast, the role of TRPV1 under chronic 
inflammatory conditions was studied in a murine model of arthritis using CFA. Paw 
enlargement and oedema were reported in wild type mice, while TRPV1-/- mice did not 
exhibit these responses. Moreover, synovial pannus expansion, as well as bone and 
cartilage destruction, were reported in wild type mice, but these responses were minimal 
in TRPV1-/- mice (Szabo et al., 2005). To elucidate the possible mechanism for this 
observation, the capability of proton concentration to modulate TRPV1 was investigated. 
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Specific TRPV1 extracellular amino acids residues at the E600 site were described as the 
site of proton interaction, which modulates the channel’s activity (Jordt et al., 2000). 
Heat-evoked currents at pH ranging from 6 to 8 were greater in TRPV1-expressing cells 
than in cells with a mutated E600 site in TRPV-1 (Jordt et al., 2000). Recent studies have 
shown that GPCRs contribute to the acid sensing at the site of ischemia and inflammation 
(Lardner, 2001, Tomura et al., 2005). 
 Extracellular acidification may activate OGR1 and enhances the production of COX-2 
and prostaglandin PGE2 through the OGR1/Gq/11/PLC/PKC signalling pathway in human 
osteoblasts (Tomura et al., 2008). In addition, activation OGR1/Gq/11 in human airway 
smooth muscle cells (ASMCs) enhances intracellular Ca
2+ 
mobilization and production of 
IL-6 via phosphorylation of ERK and p38MAPK (Ichimonji et al., 2010). On the other 
hand, GPR4 responds to acidosis through the GS/cAMP pathway and induces the 
production of adhesion molecules VCAM-1 and ICAM-1 in human umbilical vein 
endothelial cells (HUVECs) (Chen et al., 2011). Another study reported an expression of 
chemokines, cytokines, and other various inflammatory genes, including stress response 
genes and the NF-κB pathway genes, when GPR4 was activated by acid (Dong et al., 
2013). 
5.1.1 ASICs Inhibitors 
ASICs inhibitors can be categorized into specific, nonspecific, and non-discriminative 
molecules. A potassium-sparing diuretic or amiloride was the first ASICs blocker 
described (Waldmann et al., 1996). It has been reported that this molecule was able to 
increase the rate of sodium excretion in deoxycorticosterone acetate-induced 
hypertensive rats, while maintaining potassium levels. Moreover, amiloride was 
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described as safe compound for long-term treatment of hypertension, as it reduced the 
risk of hypokalemia (Qadri et al., 2010). However, amiloride and its derivatives such as 
benzamil and ethylisopropyl amiloride (EIPA) were indicated as non-discriminative 
molecules and poor reversible blockers of ASICs (Deval et al., 2010). Moreover, non-
steroid anti-inflammatory drugs (NSAIDs) can also inhibit the activity of ASICs with 
relatively low affinity (IC50 ranging from 92 to 249 μM) as described by (Voilley et al., 
2001). This study showed that both flurbiprofen and ibuprofen blocked the activity of 
ASIC1a, while ASIC3 is de-activated by salicylic acid, aspirin and diclofenac. Four 
organic compounds known as anti-protozoal diarylamidines  (DAPI, diminazene, HSB 
and pentamidine) were described as a potent ASIC inhibitors in primary cultures of 
hippocampal neurons with apparent affinities ranging from 300 nM to 38 μM (Chen et 
al., 2010). In addition to organic compounds, Bi- and trivalent cations were also defined 
as ASICs inhibitor. For instance, gadolinium (Gd
3+
) inhibited both ASIC2a (IC50 ≥1 mM) 
and ASIC2a-ASIC3 heteromers at higher potency (IC50 ∼40 μM) as (Babinski et al., 
2000) described. Moreover, CU
2+ 
was described as an inhibitor of ASICs in hypothalamic 
neurons with IC50=46.8 μM (Wang et al., 2007). However, none of these molecules is 
absolutely specific for ASIC channels (Diochot et al., 2004). 
 Two peptide toxins isolated from the venoms of the spider Psalmopoeus cambridgei 
(PcTx1) and the sea anemone Anthopleura elegantissima (APETx2) were described as 
selective blockers for ASIC1a and ASIC3 channels, respectively (Diochot et al., 2004). It 
has been reported that PcTx1 toxin inhibited the activity of ASIC1a channel in animal 
models of acute and chronic pain when injected intrathecally or intracerebroventricularly 
(Duan et al., 2007, Mazzuca et al., 2007). It has been described that the binding site of 
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PcTx1 is on the extracellular loop of ASIC1a, a site close to the H
+
 sensing site (which 
involves in pH sensing) at the interface between two subunits in the trimeric channel, and 
stabilizes it (Qadri et al., 2009). On the other hand, it has been reported that ASIC3-like 
currents were expressed by ∼60% of rat cutaneous sensory neurons (Deval et al., 2008). 
This study showed that after the induction of moderate cutaneous acidifications (at pH 
6.9–6.6) the skin C-fibres firing was totally inhibited after the treatment with ASIC3-
specific toxin APETx2 in rat models (Deval et al., 2008). Moreover, heat hyperalgesia 
was inhibited when APETx2 is co-injected with CFA in the hind paw, whereas PcTx1 
has no significant effect. This finding was also confirmed when pain behaviour 
experiments was performed by using an ASIC3 knockdown model, and the results 
showed no signs of heat hyperalgesia (Deval et al., 2008). APETX2 directly inhibits the 
ASIC3 channel by acting at its external side, and it does not modify the channel unitary 
conductance. This peptide is composed of 24 amino acids, linked together by three 
disulfide bridges, and reversibly inhibits ASIC3 peak current in both rat and human cell 
culture with an IC50 =63 nM and 175 nM, respectively, without any effect on ASIC1a, 
ASIC1b, or ASIC2a (Diochot et al., 2004). Also, it has been reported that the heteromeric 
ASIC2b-ASIC3 channel was inhibited by APETx2 with an IC50 of 117 nM and 
heteromeric ASIC1a-ASIC3 and ASIC1b-ASIC3 channels with lower affinities (IC50=2 
and 0.9 μM, respectively).  APETx2 was tested on various heterologously expressed Kv 
channels. None of Kv channels subtypes (Kv1.4, HERG, Kv2.2, Kv3.1, Kv4.1, Kv4.2, 
Kv4.3) was significantly inhibited by APETx2. Only a partial inhibition of Kv3.4 current 
was reported when much higher concentrations (3 μM) of APETx2 applied (Diochot et 
al., 2004).   
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5.1.2 TRPV1 inhibitors 
TRPV1 channel can be blocked by two different methods. One method is by targeting 
TRPV1 using agonists to activate and desensitize the receptor (such as Capsaicin). 
Capsaicin desensitized TRPV1 and has been described as an effective treatment for pain 
produced by RA, OA and peripheral neuropathy (Brito et al., 2014). The other method is 
by using antagonists that able to inhibit all TPRV1 receptor activation modes. Several 
TRPV1 antagonists have been developed and tested. Capsazepine was the first described 
antagonist that blocks the capsaicin-binding site on TRPV1 and inhibits channel 
activation in rat DRG (Bevan et al., 1992). However, due to its low metabolic stability 
and non-selectivity, it has been not considered as a candidate for clinical trials (Broad et 
al., 2008, Pal et al., 2009, Vriens et al., 2009, Wong and Gavva, 2009). in contrast, 
selective TRPV1 inhibitors A-425619 and SB-705498 were tested in rats and humans and 
demonstrated effective reduction of hyperalgesia and allodynia, as well as increased heat 
pain tolerance (Jara-Oseguera et al., 2008). Another chemical compound (AMG517) was 
described as a potent selective inhibitor for TRPV1. It has been reported that capsaicin, 
pH 5, and heat-induced Ca
2+
 uptake and inward currents were inhibited in human 
TRPV1-expressing CHO cells when after the treatment with AMG517 at IC50 values of  
0.76 nM, 0.62 nM and 1.3 nM, respectively (Gavva et al., 2007). In addition, as measured 
by Ca
2+
 uptake into TRPV1-expressing cells it has been reported that AMG 517 did not 
activate TRPV1 at concentrations up to 40 µM.  Among the recombinant TRP family 
members it has been found that AMG517 selective for TRPV1 as the IC50 value for 
AMG 517 was >20 µM against 2-APB-activated TRPV2 and TRPV3, 4-PDD-activated 
TRPV4, allyl isothiocyanate-activated TRPA1, and icilin-activated TRPM8 (Gavva et al., 
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2007). Moreover, capsaicin-activated TRPV1 was inhibited by AMG517 in rat dorsal 
root ganglion neurons with an IC50 value of 0.68 nM (Gavva et al., 2007). 
 
5.1.3 GPCRs inhibitors 
Different GPCRs inhibitors, such as CU
++
 for OGR1 (Yuan et al., 2014a) and 2-Ethyl-3-
{4-[(E)-3-(4-isopropyl-piperazin-1-yl)-propenyl]-benzyl}-5,7-dimethyl-3H-imidazo[4,5-
b] pyridine (EIDIP) for GPR4 have been used previously (Dong et al., 2013); however, 
no specificity data were provided. Therefore, the selectivity of these compounds cannot 
be inferred.  
All above data illustrate the critical role of acid-sensing proteins in proton sensing and 
regulation of multiple intracellular signalling pathways. However, no study in RA-FLS 
has compared the contribution of each of these acid sensors in the development of RA. 
As we reported previously, MMPs (1, 3, and 9) were increased and the migration rate was 
reduced in RA-FLS under low pH conditions. To investigate the involvement of acid-
sensing proteins in MMP modulation and cellular migration, two potent selective 
inhibitors, APETX and AMG517, were used. Expression of MMPs and bone resorption 
modulators, as well as RA-FLS migration rate, were investigated after exposure to these 
specific inhibitors. 
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5.2 Hypothesis 
ASIC3 and TRPV1 modulate the expression of MMPs and bone destruction modulators 
in RA-FLS under acidic conditions. 
5.3 Methods 
5.3.1 RA-FLS treatment with ASIC3 (APETX2) and TRPV1 (AMG517) selective 
inhibitors 
1.5 × 10
4 
RA-FLS were seeded in T-25 flasks and allowed to grow to 80-90% confluence. 
Culture medium was replaced with serum-free medium for 24 h in 5% CO2 at 37°C. 
APETX2 (0.5 mg), provided by Smartox Biotechnology (Product code: 07APE002-
00500), was prepared at 175 nM as described in section 2.21. Meanwhile, 5 mg AMG517 
(SelleckChem) was prepared at 0.75 nM as described in section 2.22. Serum-free medium 
was replaced with acidified MEM and APETX2 or AMG517 (separate treatments) and 
incubated for 24 h at 37°C in 5% CO2. Culture medium and cell pellet were collected for 
western bolt, qPCR and RA-FLS migration assays. T-25 flasks with RA-FLS treated with 
only acidified MEM were run in parallel with T-25 RA-FLS treated with acidified 
medium and selected antagonist. 
 
5.3.2 RA-FLS viability assay after APETX2 and AMG 517 induction 
To monitor RA-FLS viability, cells were stained with trypan blue. A haemocytometer 
was used, as described in section 2.23, to count cells before and after exposure to 
APETX2 or AMG517.  
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5.3.3 Western blot (WB) 
RA-FLS lysates were analysed to measure the expression of MMP-1 and MMP-9. Rabbit 
polyclonal antibodies targeting MMP-1, MMP-9, and mouse monoclonal β-actin was 
used as loading control then WB was performed as described in section 2.18. 
5.3.4 Real-time PCR 
RA-FLS mRNA was extracted and converted to cDNA (section 2.15) to analyse the 
expression of acid-sensing proteins, MMPs, Cathepsin K, RANKL, and AMADTS5 
before and after exposure to APETX2 or AMG 517. SYBR Green chemistry was used as 
a cDNA amplification indicator, followed by disassociation curve analysis as described 
previously. 
 
5.3.5 RA-FLS migration assay using 96-well Oris plate  
20,000 RA-FLS cells were seeded in a 96-well Oris plate and incubated in a serum 
starved medium (1% FBS) for 24 hr. Starvation medium was removed and cell tracker 
was applied for 30 minutes then replaced by acidified medium with and without 175 nM 
APETX2 and 0.75 nM AMG 517 and incubated for 24 hr. Images was collected as 
described in section 2.20. 
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5.4 Results 
5.4.1 Viability of RA-FLS after the induction of APETX2 and AMG517 
RA-FLS showed a slight reduction in viability after exposure to acidic conditions and 
ASIC3 and TRPV1 antagonists. We observed a 2.5%–4.0% reduction in viability when 
cells were treated with acidified medium only. In contrast, viability was reduced between 
1.33%–7.0 % when cells were exposed to acidified medium and 175 nM APETX2, while 
exposure to acidified medium and 0.75 nM AMG517 reduced viability between 2.0% and 
8.3%. 
 
Figure ‎5.1 Viability of RA-FLS after 24 h incubation in different acidic conditions, 
with or without 175 nM ASIC3 and 0.75 nM TRPV1 inhibitors. 
RA-FLS were grown in T-25 flasks to 90% confluence. The culture medium replaced 
with acidified medium with or without APETX2 and AMG517. No significant changes in 
cell viability were observed. The two-tailed paired t-test was used, and results are 
presented as proportional change of three separate experiments.   
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5.4.2 Expression of MMPs -1, -3, -9, and acid-sensing proteins after treatment with 
APETX2 
RA-FLS treated with 175 nM APTEX2 exhibited no significant change in mRNA 
expression of acid-sensing proteins compared to cells treated with acidified medium only 
(Figure 5.2). However, real-time PCR data showed a significant reduction of 1.7-fold in 
MMP-1 expression (P ≤ 0.001), and 1.2-fold of MMP-9 expression at pH 7.0 after 24 h 
exposure to 175 nM APETX2 (P ≤ 0.0001) (Figure 5.3). No significant changes were 
reported in the expression of MMP-3 (Figure 5.3) or the tested bone destruction 
modulators after exposure to 175 nM ASIC3 selective antagonist (APETX2) (Figure 5.4).  
179 
 
 
Figure ‎5.2 mRNA quantification of acid sensing proteins in RA-FLS after the 
treatment with APETX2 
No significant changes in ASIC3, GPR4, OGR1 and TRPV1 expression were observed at 
mRNA level after exposure to APETX2. Results were calculated using two-tailed paired 
t-test. Data are presented as mean ± SEM, n=4. 
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Figure ‎5.3 Quantification of transcript levels for MMPs -1, -3, and -9 with real-time 
PCR after the inhibition of ASIC3 with 175 nM APETX2. 
MMP-1 and MMP-9 exhibited significant reductions in expression at pH 7.0 after 
exposure to APETX2. No significant changes in MMP-3 expression were observed. 
Results were calculated using two-tailed paired t-test. Data are presented as mean ± SEM. 
*** = P ≤ 0.001 and **** = P ≤ 0.0001 (n = 7). 
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 Figure ‎5.4 CathK, RANKL, and ADAMTS5 expression at the mRNA level in RA-
FLS after APETX2 induction. 
No significant alterations were indicated at mRNA level of these proteins in RA-FLS 
after exposure to APETX2. Results were calculated using two-tailed paired t-test. Data 
are presented as mean ± SEM, n=4.  
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5.4.3 The effect of TRPV1 inhibition on the expression of MMP-1, -3, 9, acid-
sensing proteins, and bone resorption modulators 
RA-FLS treated with the TRPV1 selective inhibitor, AMG 517 (0.75 nM), showed no 
significant alteration in ASIC3, GPR4, OGR1, or TRPV1 expression at the mRNA level 
(Figure 5.5). On the other hand, a significant reduction of MMP-1 expression of about 
one-fold at pH 7.0 (P ≤ 0.05). MMP-9 expression was reduced at pH 7.0 by 
approximately 2.5-fold reduction and pH 6.5 of about 1.5-fold (P ≤ 0.05) (Figure 5.6). No 
significant changes in MMP-3 and bone resorption modulators (CathK, RANKL and 
ADAMTS5) expression were observed in any of the tested conditions (Figure 5.7). The 
expression of these genes in RA-FLS treated with AMG517 was compared to the 
expression in RA-FLS exposed only to acidified medium. Data were collected and 
analysed by GraphPad Prism using the two-tailed paired t-test.  
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Figure ‎5.5 mRNA expression of acid sensing proteins in RA-FLS after the treatment 
with TRPV1 antagonist 
No significant alterations in ASIC3, GPR4, OGR1 and TRPV1 expression were indicated 
at mRNA level after exposure to AMG517. Results were calculated using two-tailed 
paired t-test. Data are presented as mean ± SEM, n=4.  
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Figure ‎5.6 Expression of MMPs under various acidic conditions and after exposure 
to 175 nM AMG517. 
MMP-1 showed a significant reduction in expression at pH 7.0, while MMP-9 expression 
was reduced at both pH 7.0 and 6.5. No significant changes in MMP-3 expression were 
observed after exposure to AMG517 relative to acidified medium only controls. Results 
are presented as mean ± SEM. * = P ≤ 0.05, n=7.  
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 Figure ‎5.7 mRNA expression of bone formation modulators in RA-FLS after the 
treatment with TRPV1 antagonist 
CathK, RANKL, and ADAMTS5 showed no significant alteration at mRNA level in RA-
FLS after exposure to AMG517. Results were calculated using two-tailed paired t-test. 
Data are presented as mean ± SEM, n=4.  
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5.4.4 Pro-MMP-9 Expression was reduced in RA-FLS after the induction of 
AMG517 
Western blot results showed a reduction in the expression of pro-MMP-9 (~92 kDa) in 
RA-FLS at pH 7.0, 6.5, and 6.0 after treatment with 0.75 AMG517, compared to 
expression in untreated RA-FLS. No protein bands were observed for MMP-1 or MMP-3, 
even after treatment with the ASIC3 and TRPV1 inhibitors. Protein quantification was 
analysed by using ImageJ software and calculated relative to the control (untreated cells 
at pH 7.4). 
 
Figure ‎5.8 MMP-9 expression at the protein level before and after treatment with 
AMG517 
Western blot analysis of MMP-9 showed lower expression at pH 7.0, 6.5, and 6.0 after 
TRPV1 inhibition compared to untreated cells cultured under acidic conditions  (n=2).  
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5.4.5 RA-FLS migration after the induction of APETX2 and AMG517  
No significant change in migration was reported after treatment with APETX2 and/or 
AMG517 compared to untreated cells cultured under various pH conditions (Figures 5.9-
5.10). RA-FLS migration was reported as the average of three separate experiments. 
Treatment groups were compared using the two-tailed unpaired t-test, and data were 
analysed using GraphPad Prism. 
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Figure ‎5.9 RA-FLS migration after exposure to of 0.75 nM AMG517 and 175nM 
APETX2  
Approximately 2.5 × 10
4–3.0 × 104 RA-FLS were seeded and allowed to adhere for 24 h 
in Oris 96-well plates with stoppers. Stoppers were removed and cell migration was 
imaged at day 1 and day 4 after AMG517 and APETX2 were applied. This experiment 
was completed in triplicate.  
189 
 
 
Figure ‎5.10 Alteration in RA-FLS migration rate under acidic conditions and after 
exposure to ASIC3 and TRPV1 specific inhibitors. 
RA-FLS migratory activity was evaluated before and after exposure to ASIC3- and 
TRPV1-specific inhibitors. No significant migration was indicated when treated RA-FLS 
compared to untreated. Unpaired t-test was used to analyse each condition. Results are 
presented as mean ± SEM. This experiment was conducted in triplicate. 
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5.5 Discussion 
The cell viability assay showed a slight non-significant reduction in RA-FLS viability 
after exposure to acidified medium and either 175 nM APETX2 or 0.75 nM AMG517 / 
24 h. pH 6.0, in combination with IL-1B, has been shown to enhance death in FLS from 
ASIC3-/- mice compared to those from wild type mice exposed to a solution pH 6.0 only 
(Sluka et al., 2013). Other studies have reported no significant reduction in viability of 
cells such as monocytes and macrophages after exposure to lactic acid-modified medium 
(Mogi et al., 2009, Dietl et al., 2010). These data agree with our observations that 
extracellular acidification has no significant effect on cell viability, enhances the 
expression of MMP-1 and MMP-9 and reduces the migration rate of RA-FLS. 
We hypothesized that acid-sensing proteins contribute to the modulation of MMPs and 
RA-FLS migration. To determine whether acid-sensing proteins affect expression of 
MMPs or bone destruction modulators, we inhibited the activity of ASIC3 and TRPV1 
using two selective inhibitors: APETX2 and AMG517. However, to investigate the 
electrophysiological properties of these acid-sensing proteins and the inhibition 
efficiency of the inhibitors, we needed to use the patch-clamp technique (Diochot et al., 
2004). This technique requires a large amount of time to identify the IC50 and extensive 
optimization of the inhibitor concentrations. Thus, we followed the recommended 
concentrations acquired from the providers and previous studies on human cells (Diochot 
et al., 2004, Gavva et al., 2007). With 175 nM APETX2 induction, qPCR data showed no 
change in expression of acid-sensing proteins and modulators of bone degradation in RA-
FLS. Furthermore, at the mRNA level, we observed a significant reduction in MMP-1 
and MMP-9 at pH 7.0 after treatment with APETX2. MMP-3 was reportedly increased in 
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a ASIC3
-/-
 arthritis mouse model relative to wild type (Sluka et al., 2013). In contrast, our 
data suggest a gradual increase in MMP-3 expression in RA-FLS after ASIC3 is 
inhibited; however, this increase is not statistically significant.  
Studies have suggested that MMP-1 stimulates cellular migration in myoblasts, epithelial 
cells, and fibroblasts (Wang et al., 2009, Herrera et al., 2013). In addition, MMP-9 
overexpression enhanced migratory activity in vascular smooth muscle cells (VSMCs) 
both in vitro and in vivo (Galis et al., 2002, Herrera et al., 2013). However, our data show 
no significant change in RA-FLS migration despite the down-regulation of MMP-1 and 
MMP-9 with APETX2 compared to untreated RA-FLS. Conversely, TRPV1 inhibition 
had no effect on expression of acid-sensing proteins or bone destruction modulators in 
RA-FLS. However, our qPCR data reported a reduction in MMP-1 expression at pH 7.0 
and MMP-9 at both pH 7.0 and pH 6.5. In addition, WB results showed a reduction in 
MMP-9 expression at the protein level at pH 7.0, 6.5 and 6.0 after treatment with 
AMG517. Despite the reduction in MMP-1 and MMP-9 expression upon AMG517 
treatment, our data indicate that RA-FLS exhibited no significant changes in migratory 
activity when compared to RA-FLS treated with acidified medium. Our results suggest 
that, under extracellular acidification, ASIC3 and TRPV1 modulate the expression of 
MMP-1 and MMP-9 in RA-FLS, implicating a new role for these two acid-sensing 
proteins in RA-FLS migratory activity. Moreover, extracellular acidification impaired 
RA-FLS migration despite overexpression or down-regulation of MMP-1 and MMP-9. 
MMP-1 and MMP-9 enhance cellular migration rate and various factors are thought to be 
cell migration enhancers, including TNF, IL-1B and IL-6. TNF/IL-1B were reported to 
enhance the production of IL-6 in dermal fibroblasts, which in turn induces MMP-9 
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production and enhances cellular migration (Saalbach et al., 2010). Another study 
reported that two migration markers, N-cadherin, and β-catenin, were upregulated by 
MMP-1 and myoblast migration was enhanced (Wang et al., 2009). Migration toward 
fibrinogen coincides with active integrin αVβ3 and the production of mature MMP-9 in 
breast cancer cells (Rolli et al., 2003). Furthermore, expression of IL-6, MMP-3, and 
MMP-13 were significantly increased in ASIC3
-/-
 mice relative to wild type after 
exposure to CAIA. Altogether, the data suggest vital roles for proinflammatory cytokines 
TNF, IL-1B and IL-6 in MMP expression, and thus in migration activity.  
We have reported that ASIC3 and TRPV1 modulate the expression of MMP-1 at mRNA 
level, and MMP-9 at both mRNA and protein levels in RA-FLS after treatment with 
acidified medium with lactic acid. Similarly, RA-FLS migratory activity was impaired 
gradually with pH reduction. The role of acidification via lactic acid in TNF and IL-6 
inhibition has been reported in monocytes and macrophages (Mogi et al., 2009, Dietl et 
al., 2010). It has been reported by Dietl et al., 2010 that low concentration of lactic acid 
(10 mM) inhibits TNF expression in monocytes, while inhibition of IL-6 requires a 
higher concentration (20 mM). This study identified that acidification of the medium to 
pH 7.1 has a minimal inhibition effect on TNF secretion, while a decrease in pH to 6.6 
had stronger effect on TNF production. Our data showed that pH 7.0 has no significant 
effect on RA-FLS migration rate, but media acidified to pH 6.5 and 6.0 decreased 
migration significantly. Moreover, the highest expression of MMP-1 and MMP-9 was 
observed at pH 7.0. 
Taken together, our data suggest that extracellular acidification enhances the activity of 
ASIC3 and TRPV1, which in turn increases the production of MMP-1 and -9 in RA-FLS. 
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Acidification seems to be a dominant factor that affects the production of 
proinflammatory cytokines TNF and IL-6 and inhibits RA-FLS migration. Moreover, 
ASIC3 and TRPV1 inhibition reduces MMP-1(mRNA) and MMP-9 expression and has 
no effect on RA-FLS migration rate.  
Because there are no selective inhibitors for OGR1 and GPR4, we have attempted OGR1 
knockdown in RA-FLS. However, the expression of OGR1 mRNA in RA-FLS was very 
low when 6-well plates were used. Thus, future studies of OGR1 will require 
optimization using T-75 flasks, which would generate a greater quantity of OGR1 
mRNA. RA-FLS invasion assay was planned; however, due to the limitation of samples 
(primary RA-FLS), we used the migration assay. The invasion assay usually uses 12- or 
24-well plates, which require large numbers of cells, whereas the migration assay can 
evaluate three different treatments and/or subjects in a single 96-well plate. We plan to 
carry out the invasion assay in the future when primary cells are available.   
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6 Chapter 6: Final Discussion 
Acid-sensing protein expression and localisation were investigated previously in different 
cells. However, to our knowledge, no study has investigated the expression of four 
different acid-sensing molecules in RA-FLS. In chapter 3 of this research project, we 
indicated the expression and localisation of ASIC3, OGR1, GPR4 and TRPV1 in RA-
FLS at both the mRNA and protein levels and in OA-FLS at the mRNA level. IHC-P 
reported that all four acid-sensing molecules were expressed in the synovial tissue of RA 
patients. Acid-sensing proteins were expressed in different patterns within fibrous tissue 
and around blood vessels; however, all were concentrated in the tissue lining in which 
FLS resides. In addition, we have detected acid-sensing protein expression in other 
immune cells of the synovial tissue. Furthermore, we have indicated that the expression 
of these molecules was higher in RA than in OA at the mRNA level. TNF is considered 
one of the main cytokines that promotes bone and cartilage destruction in the RA joint. 
TNF enhances downstream signalling pathways and promotes the production of bone and 
cartilage erosion modulators such as MMPs and ADAMTs (Moelants et al., 2013). Thus, 
we investigated whether TNF affects acid-sensing protein expression by treating RA-FLS 
with 10 ng of TNF. All four acid-sensing molecules were increased; however, the 
difference was insignificant possibly due to the small number of samples examined. A 
large number of samples may be needed to indicate the actual effect of TNF on acid-
sensing protein expression because signs of increase were reported in a small number of 
RA patient samples. rheumatoid joint characterised by an acidic microenvironment with 
pH as low as (6.6) (Falchuk et al., 1970), we investigated the expression of acid-sensing 
proteins in RA-FLS under different acidic conditions (pH 7.4-6.0). The expression of 
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these acid sensors was indicated in human RA-FLS with a slight but not significant 
alteration at low pH compared with that at pH 7.4. Bone and cartilage destruction are a 
major complication of RA, and this process is modulated by multiple enzymes such as 
serine proteases, aggrecanases, and MMPs. Few studies have focussed on the effect of an 
acidic microenvironment on the expression of such modulators in RA-FLS, while no 
study has shown how the expression of these proteins may be altered by a change in pH. 
In the current study, we investigated the effect of extracellular acidification on the 
expression of bone and cartilage modulators, including MMP-1, -3, -9, and -14, 
Cathepsin K, RANKL and ADAMTS-5, in human RA-FLS. MMP-1, -3 and -9 were 
upregulated under acidic conditions at pH 7.0-6.0 compared with the control at pH 7.4. 
MMP-9 expression in RA-FLS was dramatically upregulated at pH 7.0 compared with 
that in the control. Furthermore, we reported that MMP-1 and -9 were highly expressed in 
RA-FLS compared with that in OA-FLS. It has been known that MMP-1 and -9 play 
important roles in cell migration as reported in myoblasts, epithelial cells, and vascular 
smooth muscle cells (VSMCs) (Galis et al., 2002, Wang et al., 2009, Herrera et al., 2013) 
.Thus, we tested the migratory activity of RA-FLS under different acidic environments. 
Our data reported a reduction in the RA-FLS migration rate under low pH. Taken 
together, our data suggest that the acidic microenvironment of the RA joint enhances the 
activity of acid-sensing proteins that, in turn, promote the production of MMP-1, -3, and -
9. Furthermore, TNF/IL-1B and IL-6 were reported to be key players that enhance MMP-
9 expression, which then enhances the migratory activity of dermal fibroblasts (Saalbach 
et al., 2010). However, under acidified conditions created by lactic acid, the production of 
TNF and IL-6 are down-regulated as reported previously (Mogi et al., 2009, Dietl et al., 
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2010). Our data reflect that acid (lactic acid build up) is a key factor that enhances MMP-
1 and -9 expression and impairs RA-FLS migration activity. It would be interesting to 
study the expression of MMPs in RA-FLS under the effect of a combination of both TNF 
and an acidified medium. 
It has been reported that ASIC3 modulates the expression of MMP-3 and MMP-9 in 
ASIC3-/- mice (Sluka et al., 2013), and TRPV1 activation enhances the expression of 
MMP-1 in human keratinocytes (Lee et al., 2008). However, there is a lack of knowledge 
concerning the roles of these two acid-sensing proteins in RA. To understand the role of 
acid-sensing proteins in RA-FLS migration and MMP expression, ASIC3 and TRPV1 
were targeted by specific and potent inhibitors (APETx2 and AMG517). We reported that 
these two acid-sensor molecule alterations modulate the expression MMP-1 and -9 in 
RA-FLS but has no effect on the migration rate of RA-FLS under low pH. Our data 
suggest that both ASIC3 and TRPV1 activity may promote the expression of MMP-1 and 
-9, while the migration of RA-FLS could be modulated by other acid-sensing proteins 
such as OGR1 and/or GPR4. Moreover, ASIC3 and TRPV1 could be considered potential 
therapeutic targets that may reduce bone and cartilage erosion in RA. In vivo studies 
would provide interesting knowledge regarding the role of these two molecules in the 
development of RA. Understanding the intracellular signalling pathways underlying the 
activation of ASIC3 and TRPV1 would provide a wide range of therapeutic targets that 
may help to suppress RA complication. Different studies have investigated ASIC3 and 
TRPV1 signalling pathways for their activation in different inflammatory disorders. 
Active ASIC3 enhances Ca
2+ 
influx, which, in turn, increases intracellular calcium 
mobilisation and activates several signalling pathways. Increased Ca
2+
 in the cell is also 
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associated with Ca
2+
/calmodulin-dependent protein kinase II activation, further 
aggravating inflammation. Additionally, TRPV1 activation is associated with different 
inflammatory conditions such as RA. It has been described that TRPV1 activation 
mediates numerous signalling pathways, including the activation of PKC and PKA. 
To our knowledge, we are the first to report the expression of OGR1 and GPR4 in RA-
FLS and synovial tissue. However, the role of these two proteins in the development of 
RA remains elusive. In vitro and in vivo studies have reported that OGR1 was strongly 
upregulated during the activation of osteoclastogenesis (Yang et al., 2006). Another study 
demonstrated that OGR1 responds to extracellular acidification and enhances osteoclast 
viability through an NFAT-independent, protein kinase C-dependent pathway, while the 
inhibition of this channel by Cu
2+
 or siRNA suppressed the survival of osteoclasts under 
acidified conditions (Pereverzev et al., 2008). These findings suggest that OGR1 
expressed in RA-FLS may also be involved in bone degradation and cartilage destruction 
in the RA joint. Interestingly, different studies have described OGR1 as a cell migration 
suppressor; it has been found that OGR1, but not GPR4, inhibits both breast and prostate 
cancer cell migration and metastasis via the increased expression of Gαi1 (Singh et al., 
2007) and the Gα12/13-Rho-Rac1 pathway (Li et al., 2013). By contrast, another in vivo 
study demonstrated the role of GPR4 in melanoma and prostate cancer cells under an 
acidic environment. It has been reported that GPR4 activation at pH 6.4-6.9 enhances the 
production of active RhoA and actin stress fibre formation, which, in turn, reduces cell 
migration activity (Castellone et al., 2011). Our study reported a reduction in the RA-FLS 
migration rate under low pH and may reflect the involvement of OGR1 and GPR4 in RA-
FLS migration activity despite the increase in MMP-1, -3 and -9. In conclusion, our study 
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demonstrated that at least four mediating factors exist for sensing acid are expressed in 
the RA synovium at the mRNA and protein levels. To our knowledge, we are the first to 
indicate the expression of OGR1 and GPR4 in RA-FLS. Moreover, we reported that an 
acidified microenvironment has no effect on acid-sensing protein expression; however, 
the activity needs further investigation by using the patch clamp technique. Acidic 
conditions upregulate the expression of MMP-1, -3 and -9 in RA-FLS. Furthermore, our 
study indicated that ASIC3 and TRPV1 inhibition down regulate the expression of MMP-
1 and -9 under low pH. Additionally, the migration activity of RA-FLS was gradually 
reduced with the reduction in pH despite the inhibition of ASIC3 and TRPV1 activity. 
Taken together, these findings suggest that an acidic microenvironment within the 
rheumatoid joint promotes the activities of ASIC3 and TRPV1, which, in turn, increase 
the production of MMP-1, -3 and -9. In addition, OGR1 and GPR4 may be activated and 
halt the migration activity of RA-FLS, thus aggravating RA complication through bone 
erosion and cartilage destruction. Targeting acid-sensing receptors may represent a novel 
means to inhibit bone invasion and cartilage destruction in response to 
microenvironmental acidosis in RA. 
 
7 FUTURE WORK: 
As we reported the expression of acid-sensing proteins by immune cells other than FLS, 
identifying the identities of these cells will provide valuable knowledge concerning how 
these cells may be involved in RA development. We will also investigate the activity of 
the acid-sensing proteins ASIC3, OGR1, GPR4 and TRPV1 under different acidic 
conditions and how they might contribute to the expression of MMPs. It is crucial to 
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explore the intracellular signalling pathways induced by acid-sensing protein activity 
after RA-FLS exposure to an acidic environment. To better understand the exact role of 
OGR1 and GPR4 in RA-FLS migration and invasion, we will use small interfering RNA 
(siRNA) targeting these two molecules. An in vivo study using a murine model of RA 
and an acid-sensing protein knock-out model will provide interesting knowledge 
concerning the role of these molecules in the development of RA.  
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Appendices 
List of extra equipment  
7900HT AbiPrism sequence detection system 
Applied Biosystems, CA, 
USA 
Aperio CS2 slidescanner Leica, Wetzlar, Germany 
ChemiDoc™ XRS+ System BIORAD, CA,USA 
Inverted wide-field fluorescent microscope under 
mercury lamp DM1400B 
Leica, Wetzlar, Germany 
Microscope DM500 brightfield Leica, Wetzlar, Germany 
Nanodrop Spectrophotometer ND 1000 
Thermo Fisher Scientific Inc, 
MA, USA 
Original iBlot®  gel transfer device Invitrogen, Paisley, UK 
Thermo cycler T100 
Bio-Rad Laboratories, CA, 
USA 
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Figure, RA-FLS migration in transwell 24 well plate; Figure shows insignificant 
reduction in RA-FLS migration at low pH. 
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Manual H-score in lung and RA-synovium 
ASIC3 score ≈ 164 in lung and 139 in synovial tissue. GPR4 is expressed higher in lung 
than in RA synovium  with H-score 149 and 192, respectively. OGR1 H-score is lower in 
RA synoivum than in lung with H-score of 113 and 140 respectively. The average scores 
of TRPV1 ≈124 in RA synovium and 150 in lung tissue. No significant change was 
indicated. Unpaired t-test was used to analyze data. Results are presented as mean ± SEM 
 
Figure;‎H-score of Acid sensing protein (ASIC3) in lung and tissue and RA synovial 
tissue. 
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SYBR Green assessment after qPCR runs 
Melt-curve analysis following qPCR shows a single peak for each amplicon of bone and 
cartilage destruction modulators  
 
 
Figure ‎Disassociation curve results following qPCR reaction. 
Each qPCR reaction was evaluated by melt curve analysis to determine SYBR Green 
specificity and identify any contamination with genomic DNA or primer dimers. 
